Document_And_Entity_Informatio
Document And Entity Information (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Mar. 30, 2015 | Jun. 30, 2014 | |
Document and Entity Information [Abstract] | |||
Entity Registrant Name | OMNICOMM SYSTEMS INC | ||
Document Type | 10-K | ||
Current Fiscal Year End Date | -19 | ||
Entity Common Stock, Shares Outstanding | 92,234,302 | ||
Entity Public Float | $11,918,560 | ||
Amendment Flag | FALSE | ||
Entity Central Index Key | 1034592 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Well-known Seasoned Issuer | No | ||
Document Period End Date | 31-Dec-14 | ||
Document Fiscal Year Focus | 2014 | ||
Document Fiscal Period Focus | FY |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
ASSETS | ||
Cash | $522,914 | $1,160,720 |
Accounts receivable, net of allowance for doubtful accounts of $186,085 and $65,341, respectively | 3,416,151 | 1,599,568 |
Prepaid expenses | 228,082 | 146,907 |
Prepaid stock compensation, current portion | 153,500 | 0 |
Other current assets | 18,305 | 0 |
Total current assets | 4,338,952 | 2,907,195 |
Property and equipment, net | 468,136 | 607,433 |
Intangible assets, net | 203,921 | 270,242 |
Goodwill | 596,620 | 675,710 |
Prepaid stock compensation | 146,653 | 169,375 |
Other assets | 49,092 | 82,501 |
TOTAL ASSETS | 5,803,374 | 4,712,456 |
CURRENT LIABILITIES | ||
Accounts payable and accrued expenses | 1,894,185 | 2,540,956 |
Notes payable, current portion | 0 | 37,500 |
Deferred revenue, current portion | 5,840,875 | 2,866,356 |
Line of credit | 4,000,000 | 3,500,000 |
Convertible notes payable, current portion, net of discount of $-0- and $-0-, respectively | 75,000 | 75,000 |
Patent settlement liability, current portion | 962,500 | 962,500 |
Total current liabilities | 22,412,022 | 19,052,495 |
LONG TERM LIABILITIES | ||
Notes payable, related parties, long term, net of current portion, net of discount of $568,209 and $447,666, respectively | 5,700,791 | 4,568,213 |
Notes payable, long term, net of current portion | 812,500 | 614,486 |
Deferred revenue, long term, net of current portion | 2,393,068 | 1,385,017 |
Convertible notes payable, related parties, long term, net of current portion | 8,815,000 | 9,125,000 |
Convertible notes payable, long term, net of current portion | 775,000 | 465,000 |
Patent settlement liability, long term, net of current portion | 669,825 | 963,124 |
TOTAL LIABILITIES | 41,578,206 | 36,173,335 |
COMMITMENTS AND CONTINGENCIES (See Note 12) | ||
SHAREHOLDERS' (DEFICIT) | ||
Preferred stock | 0 | 0 |
Common stock, 250,000,000 shares authorized, 91,561,802 and 90,104,659 issued and outstanding, respectively, at $0.001 par value | 91,562 | 90,105 |
Additional paid in capital - preferred | 4,717,804 | 4,717,804 |
Additional paid in capital - common | 37,634,555 | 37,334,358 |
Accumulated other comprehensive (loss) | -243,827 | -87,604 |
Accumulated deficit | -77,979,301 | -73,519,917 |
TOTAL SHAREHOLDERS' (DEFICIT) | -35,774,832 | -31,460,879 |
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT) | 5,803,374 | 4,712,456 |
Conversion Feature Liability, Related Parties [Member] | ||
CURRENT LIABILITIES | ||
Derivative liabilities, current | 2,729,902 | 2,979,392 |
Conversion Feature Liability [Member] | ||
CURRENT LIABILITIES | ||
Derivative liabilities, current | 214,500 | 146,814 |
Warrant Liability, Related Parties [Member] | ||
CURRENT LIABILITIES | ||
Derivative liabilities, current | 6,496,448 | 5,799,946 |
Warrant Liability [Member] | ||
CURRENT LIABILITIES | ||
Derivative liabilities, current | 198,612 | 144,031 |
Series B Preferred Stock [Member] | ||
SHAREHOLDERS' (DEFICIT) | ||
Preferred stock | 0 | 0 |
Series C Preferred Stock [Member] | ||
SHAREHOLDERS' (DEFICIT) | ||
Preferred stock | 0 | 0 |
Series A Preferred Stock [Member] | ||
SHAREHOLDERS' (DEFICIT) | ||
Preferred stock | 4,125 | 4,125 |
Series D Preferred Stock [Member] | ||
SHAREHOLDERS' (DEFICIT) | ||
Preferred stock | $250 | $250 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parentheticals) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Allowance for doubtful accounts (in Dollars) | $186,085 | $65,341 |
Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 |
Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
Preferred stock, shares undesignated (in Dollars) | 3,772,500 | 3,772,500 |
Common stock, shares authorized | 250,000,000 | 250,000,000 |
Common stock, shares issued | 91,561,802 | 90,104,659 |
Common stock, shares outstanding | 91,561,802 | 90,104,659 |
Common stock, par value (in Dollars per share) | $0.00 | $0.00 |
Series B Preferred Stock [Member] | ||
Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 |
Preferred stock, shares authorized | 230,000 | 230,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Preferred stock, liquidation preference (in Dollars) | 0 | 0 |
Series C Preferred Stock [Member] | ||
Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 |
Preferred stock, shares authorized | 747,500 | 747,500 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Preferred stock, liquidation preference (in Dollars) | 0 | 0 |
Series A Preferred Stock [Member] | ||
Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 4,125,224 | 4,125,224 |
Preferred stock, shares outstanding | 4,125,224 | 4,125,224 |
Preferred stock, liquidation preference (in Dollars) | 4,125,224 | 4,125,224 |
Series D Preferred Stock [Member] | ||
Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 |
Preferred stock, shares authorized | 250,000 | 250,000 |
Preferred stock, shares issued | 250,000 | 250,000 |
Preferred stock, shares outstanding | 250,000 | 250,000 |
Convertible Notes Payable [Member] | ||
Notes payable discount (in Dollars) | 0 | 0 |
Notes Payable, Other Payables [Member] | ||
Notes payable discount (in Dollars) | $568,209 | $447,666 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Revenues | $16,017,897 | $13,887,520 |
Reimbursable revenues | 443,353 | 444,320 |
Total revenues | 16,461,250 | 14,331,840 |
Cost of goods sold | 3,245,300 | 2,560,191 |
Reimbursable expenses-cost of goods sold | 725,221 | 351,022 |
Gross margin | 12,490,729 | 11,420,627 |
Operating expenses | ||
Salaries, benefits and related taxes | 10,419,214 | 8,758,276 |
Rent and occupancy expenses | 889,880 | 894,121 |
Consulting services | 89,574 | 157,905 |
Legal and professional fees | 377,329 | 265,251 |
Travel | 794,193 | 534,135 |
Telephone and internet | 188,130 | 187,078 |
Selling, general and administrative | 1,159,174 | 851,642 |
Bad debt expense | 147,543 | 11,131 |
Depreciation expense | 235,591 | 230,323 |
Amortization expense | 45,433 | 7,720 |
Total operating expenses | 14,346,061 | 11,897,582 |
Operating income/(loss) | -1,855,332 | -476,955 |
Other income/(expense) | ||
Interest expense, related parties | -2,389,786 | -2,339,702 |
Interest expense | -224,459 | -150,410 |
Interest income | 81 | 9 |
Change in derivative liabilities | 58,807 | -95,121 |
Transaction gain/(loss) | -68,232 | -5,041 |
Income/(loss) before income taxes | -4,478,921 | -3,067,220 |
Income tax (expense)/benefit | 19,537 | -94,122 |
Net income/(loss) | -4,459,384 | -3,161,342 |
Preferred stock dividends in arrears | ||
Series A preferred | -206,261 | -206,261 |
Total preferred stock dividends | -206,261 | -206,261 |
Net income/(loss) attributable to common stockholders | -4,665,645 | -3,367,603 |
Net income/(loss) per share | ||
Basic and diluted (in Dollars per share) | ($0.05) | ($0.04) |
Weighted average number of shares outstanding | ||
Basic and diluted (in Shares) | 90,701,058 | 87,969,202 |
Cost of Goods Sold, Including Reimbursable Expenses [Member] | ||
Cost of goods sold | 3,970,521 | 2,911,213 |
Preferred Class A [Member] | ||
Preferred stock dividends in arrears | ||
Series A preferred | -206,261 | -206,261 |
Total preferred stock dividends | ($206,261) | ($206,261) |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive Income (Loss) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Net (loss) attributable to common stockholders | ($4,665,645) | ($3,367,603) |
Other comprehensive (loss) | ||
Change in foreign currency translation adjustment | -156,223 | -18,512 |
Other comprehensive (loss) | -156,223 | -18,512 |
Comprehensive (loss) | ($4,821,868) | ($3,386,115) |
Consolidated_Statement_of_Shar
Consolidated Statement of Shareholders' (Deficit) (USD $) | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] | Additional Paid In Capital, Preferred [Member] | Common Stock [Member] | Additional Paid In Capital, Common [Member] | Retained Earnings [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Total |
Preferred Stock [Member] | Preferred Stock [Member] | Preferred Stock [Member] | Preferred Stock [Member] | |||||||
Balance at Dec. 31, 2012 | $4,125 | $0 | $0 | $250 | $4,717,804 | $86,599 | $36,645,589 | ($70,358,575) | ($69,092) | ($28,973,300) |
Balance (in Shares) at Dec. 31, 2012 | 4,125,224 | 0 | 0 | 250,000 | 86,598,659 | |||||
Employee stock option expense | 83,875 | 83,875 | ||||||||
Foreign currency translation adjustment | -18,512 | -18,512 | ||||||||
Restricted stock issuance | 1,225 | 221,275 | 222,500 | |||||||
Restricted stock issuance (in Shares) | 1,225,000 | |||||||||
Stock option exercise | 11 | -11 | 0 | |||||||
Stock option exercise (in Shares) | 11,000 | 100,000 | ||||||||
Shares issued for purchase of Promasys | 2,270 | 383,630 | 385,900 | |||||||
Shares issued for purchase of Promasys (in Shares) | 2,270,000 | |||||||||
Net loss for the period | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3,161,342 | 0 | -3,161,342 |
Balance at Dec. 31, 2013 | 4,125 | 0 | 0 | 250 | 4,717,804 | 90,105 | 37,334,358 | -73,519,917 | -87,604 | -31,460,879 |
Balance (in Shares) at Dec. 31, 2013 | 4,125,224 | 0 | 0 | 250,000 | 90,104,659 | |||||
Employee stock option expense | 63,654 | 63,654 | ||||||||
Foreign currency translation adjustment | -156,223 | -156,223 | ||||||||
Restricted stock issuance | 1,400 | 236,600 | 238,000 | |||||||
Restricted stock issuance (in Shares) | 1,400,000 | |||||||||
Stock option exercise | 57 | -57 | 0 | |||||||
Stock option exercise (in Shares) | 57,143 | 150,000 | ||||||||
Net loss for the period | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4,459,384 | 0 | -4,459,384 |
Balance at Dec. 31, 2014 | $4,125 | $0 | $0 | $250 | $4,717,804 | $91,562 | $37,634,555 | ($77,979,301) | ($243,827) | ($35,774,832) |
Balance (in Shares) at Dec. 31, 2014 | 4,125,224 | 0 | 0 | 250,000 | 91,561,802 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net (loss) | ($4,459,384) | ($3,161,342) |
Adjustment to reconcile net (loss) to net cash (used in) operating activities | ||
Change in derivative liabilities | -58,807 | 95,121 |
Interest expense from derivative instruments | 507,542 | 609,000 |
Employee stock compensation | 170,876 | 137,000 |
Provision for doubtful accounts | 147,543 | 11,131 |
Depreciation and amortization | 281,024 | 238,043 |
Changes in operating assets and liabilities | ||
Accounts receivable | -1,964,126 | -153,514 |
Prepaid expenses | -81,175 | -14,966 |
Other current assets | -18,305 | 0 |
Other assets | 33,409 | -31,348 |
Accounts payable and accrued expenses | 523,229 | 775,251 |
Patent settlement liability | -293,299 | -260,591 |
Deferred revenue | 3,982,570 | -697,548 |
Net cash (used in) operating activities | -1,228,903 | -2,453,763 |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Payments to acquire business, net of cash acquired | 0 | -386,545 |
Purchase of property and equipment | -101,519 | -353,775 |
Net cash (used in) investing activities | -101,519 | -740,320 |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Repayments of notes payable | -36,365 | 0 |
Proceeds from notes payable, related parties | 280,000 | 0 |
Proceeds from revolving line of credit | 500,000 | 3,500,000 |
Net cash provided by financing activities | 743,635 | 3,500,000 |
Effect of exchange rate changes on fixed and intangible assets | 105,204 | 0 |
Effect of exchange rate changes on cash and cash equivalents | -156,223 | -18,512 |
Net increase/(decrease) in cash and cash equivalents | -637,806 | 287,405 |
Cash and cash equivalents at beginning of year | 1,160,720 | 873,315 |
Cash and cash equivalents at end of year | 522,914 | 1,160,720 |
Cash paid during the year for: | ||
Income taxes | 35,264 | 94,122 |
Interest | 1,114,666 | 835,154 |
Non-cash transactions: | ||
Common stock issued for the acquisition of Promasys B.V. | 385,900 | |
Restricted Stock [Member] | ||
Non-cash transactions: | ||
Restricted stock issuance | 238,000 | 222,500 |
Promasys B.V. [Member] | ||
Non-cash transactions: | ||
Common stock issued for the acquisition of Promasys B.V. | 0 | 385,900 |
Notes Payable Issued for Existing Notes Payable [Member] | ||
Non-cash transactions: | ||
Debt conversion, Notes Issued | 2,222,500 | 3,501,366 |
Promissory Notes Issued for Accrued Interest [Member] | ||
Non-cash transactions: | ||
Debt conversion, Notes Issued | $1,170,000 | $529,000 |
Note_1_Organization_and_Nature
Note 1 - Organization and Nature of Operations | 12 Months Ended | |
Dec. 31, 2014 | ||
Disclosure Text Block [Abstract] | ||
Nature of Operations [Text Block] | NOTE 1: | ORGANIZATION AND NATURE OF OPERATIONS |
OmniComm Systems, Inc. (“OmniComm” or the “Company”) is a healthcare technology company that provides Web-based electronic data capture (“EDC”) solutions and related value-added services to pharmaceutical and biotech companies, clinical research organizations, and other clinical trial sponsors principally located in the United States, Europe and Asia. Our proprietary EDC software applications; TrialMaster®; TrialOne®; Promasys®; and eClinical Suite, allow clinical trial sponsors and investigative sites to securely collect, validate, transmit, and analyze clinical trial data. | ||
Our ability to compete within the EDC industry is predicated on our ability to continue enhancing and broadening the scope of solutions offered through our EDC software and services. Our research and development (“R&D”) efforts are focused on developing new and complementary software solutions, as well as enhancing our existing software solutions through the addition of increased functionality. During the years ended December 31, 2014 and December 31, 2013 we spent approximately $2,754,367 and $2,403,504, respectively, on R&D activities, which is primarily comprised of salaries to our developers and other R&D personnel and related costs associated with the development of our software products. |
Note_2_Summary_of_Significant_
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended | ||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||
Significant Accounting Policies [Text Block] | NOTE 2: | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |||||||||||||||
BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION | |||||||||||||||||
The Company’s accounts include those of all its wholly-owned subsidiaries and have been prepared in conformity with (i) accounting principles generally accepted in the United States of America; and (ii) the rules and regulations of the United States Securities and Exchange Commission. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated in consolidation. | |||||||||||||||||
ESTIMATES IN FINANCIAL STATEMENTS | |||||||||||||||||
The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Significant estimates incorporated in our financial statements include the recorded allowance for doubtful accounts, the estimate of the appropriate amortization period of our intangible assets, the evaluation of whether our intangible assets have suffered any impairment, the allocation of revenues under multiple-element customer contracts, royalty-based patent liabilities, the value of derivatives associated with debt issued by the Company and the valuation of any corresponding discount to the issuance of our debt. Actual results may differ from those estimates. | |||||||||||||||||
RECLASSIFICATIONS | |||||||||||||||||
Certain reclassifications have been made in the 2013 financial statements to conform to the 2014 presentation. These reclassifications did not have any effect on our net loss or shareholders’ deficit. | |||||||||||||||||
FOREIGN CURRENCY TRANSLATION | |||||||||||||||||
The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830-30, Foreign Currency Matters—Translation of Financial Statements. The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s subsidiaries, OmniComm Europe GmbH in Germany, OmniComm Spain S.L. in Spain and OmniComm Promasys B.V. in the Netherlands is the Euro. The functional currency of the Company's subsidiary, OmniComm Ltd. in the United Kingdom is the British Pound Sterling. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income/(loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations. We record translation gains and losses in accumulated other comprehensive income as a component of stockholders’ equity. We recorded a translation loss of $156,223 for the year ended December 31, 2014 and a translation loss of $18,512 for the year ended December 31, 2013. | |||||||||||||||||
REVENUE RECOGNITION POLICY | |||||||||||||||||
The Company derives revenues from software licenses and services of its EDC products and services which can be purchased on a stand-alone basis. License revenues are derived principally from the sale of term licenses for the following software products offered by the Company: TrialMaster, TrialOne, Promasys and eClinical Suite (the “EDC Software”). Service revenues are derived principally from the Company's delivery of the hosted solutions of its TrialMaster and eClinical Suite software products, and consulting services and customer support, including training, for all of the Company's products. | |||||||||||||||||
The Company recognizes revenues when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the product or service has been provided to the customer; (3) the collection of fees is probable; and (4) the amount of fees to be paid by the customer is fixed or determinable. | |||||||||||||||||
The Company operates in one reportable segment which is the delivery of EDC Software and services to clinical trial sponsors. The Company segregates its revenues based on the activity cycle used to generate its revenues. Accordingly, revenues are currently generated through four main activities. These activities include hosted applications, licensing, professional services and maintenance-related services. | |||||||||||||||||
Hosted Application Revenues | |||||||||||||||||
The Company offers its TrialMaster and eClinical Suite software products as hosted application solutions delivered through a standard Web-browser, with customer support and training services. To date, hosted applications revenues have been primarily related to TrialMaster. | |||||||||||||||||
Revenues resulting from TrialMaster and eClinical Suite application hosting services consist of three components of services for each clinical trial: the first component is comprised of application set up, including design of electronic case report forms and edit checks, installation and server configuration of the system. The second component involves application hosting and related support services as well as billable change orders which consist of amounts billed to customers for functionality changes made. The third stage involves services required to close out, or lock, the database for the clinical trial. | |||||||||||||||||
Fees charged and costs incurred for the trial system design, set up and implementation are amortized and recognized ratably over the estimated hosting period. Work performed outside the original scope of work is contracted for separately as an additional fee and is generally recognized ratably over the remaining term of the hosting period. Fees for the first and third stages of the service are billed based upon milestones. Revenues earned upon completion of a contractual milestone are deferred and recognized over the estimated remaining hosting period. Fees for application hosting and related services in the second stage are generally billed quarterly in advance. Revenues resulting from hosting services for the eClinical Suite products consist of installation and server configuration, application hosting and related support services. Services for this offering are generally charged as a fixed fee payable on a quarterly or annual basis. Revenues are recognized ratably over the period of the service. | |||||||||||||||||
Licensing Revenues | |||||||||||||||||
The Company's software license revenues are earned from the sale of off-the-shelf software. From time-to-time a client might require significant modification or customization subsequent to delivery to the customer. The Company generally enters into software term licenses for its EDC Software products with its customers for 3 to 5 year periods, although customers have entered into both longer and shorter term license agreements. These arrangements typically include multiple elements: software license, consulting services and customer support. The Company bills its customers in accordance with the terms of the underlying contract. Generally, the Company bills license fees in advance for each billing cycle of the license term which typically is either on a quarterly or annual basis. Payment terms are generally net 30 days. | |||||||||||||||||
In the past the Company has sold perpetual licenses for EDC Software products in certain situations to existing customers with the option to purchase customer support, and may in the future do so for new customers based on customer requirements or market conditions. The Company has established vendor specific objective evidence of fair value for the customer support. Accordingly, license revenues are recognized upon delivery of the software and when all other revenue recognition criteria are met. Customer support revenues are recognized ratably over the term of the underlying support arrangement. The Company generates customer support and maintenance revenues from its perpetual license customer base. | |||||||||||||||||
Professional Services | |||||||||||||||||
The Company may also enter into arrangements to provide consulting services separate from a license arrangement. In these situations, revenue is recognized on a time-and-materials basis. Professional services can be deemed to be as essential to the functionality of the software at inception and typically are for initial trial configuration, implementation planning, loading of software, building simple interfaces and running test data and documentation of procedures. Subsequent additions or extensions to license terms do not generally include additional professional services. | |||||||||||||||||
Maintenance Revenues | |||||||||||||||||
Maintenance includes telephone-based help desk support and software maintenance. The Company generally bundles customer support with the software license for the entire term of the arrangement. As a result, the Company generally recognizes revenues for both maintenance and software licenses ratably over the term of the software license and support arrangement. The Company allocates the revenues recognized for these arrangements to the different elements based on management's estimate of the relative fair value of each element. The Company generally invoices each of the elements based on separately quoted amounts and thus has a fairly accurate estimate of the relative fair values of each of the invoiced revenue elements. | |||||||||||||||||
The fees associated with each business activity for the years ended December 31, 2014 and December 31, 2013, respectively are: | |||||||||||||||||
For the year ended | |||||||||||||||||
Revenue activity | 31-Dec-14 | 31-Dec-13 | |||||||||||||||
Set-up fees | $ | 4,814,378 | $ | 3,369,670 | |||||||||||||
Change orders | 467,815 | 475,680 | |||||||||||||||
Maintenance | 4,374,245 | 4,584,594 | |||||||||||||||
Software licenses | 3,404,655 | 2,911,509 | |||||||||||||||
Professional services | 2,605,010 | 2,207,181 | |||||||||||||||
Hosting | 795,147 | 783,206 | |||||||||||||||
Total | $ | 16,461,250 | $ | 14,331,840 | |||||||||||||
COST OF REVENUES | |||||||||||||||||
Cost of revenues primarily consists of costs related to hosting, maintaining and supporting the Company’s application suite and delivering professional services and support. These costs include salaries, benefits, bonuses and stock-based compensation for the Company’s professional services staff. Cost of revenues also includes outside service provider cost. Cost of revenues is expensed as incurred. | |||||||||||||||||
CASH AND CASH EQUIVALENTS | |||||||||||||||||
Cash equivalents consist of highly liquid, short-term investments with maturities of 90 days or less. The carrying amount reported in the accompanying consolidated balance sheets approximates fair value. | |||||||||||||||||
ACCOUNTS RECEIVABLE | |||||||||||||||||
Accounts receivable are judged as to collectability by management and an allowance for bad debts is established as necessary. The allowance is based on an evaluation of the collectability of accounts receivable and prior bad debt experience. The Company had recorded an allowance for uncollectible accounts receivable of $186,085 and $65,341 as of December 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||
The following table summarizes activity in the Company's allowance for doubtful accounts for the years presented. | |||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||
Beginning of period | $ | 65,341 | $ | 84,210 | |||||||||||||
Bad debt expense | 147,543 | 11,131 | |||||||||||||||
Write-offs | (26,875 | ) | (30,000 | ) | |||||||||||||
Exchange rate impact | 76 | -0- | |||||||||||||||
End of period | $ | 186,085 | $ | 65,341 | |||||||||||||
CONCENTRATION OF CREDIT RISK | |||||||||||||||||
Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of December 31, 2014, $264,234 was deposited in excess of FDIC-insured limits. Management believes the risk in these situations to be minimal. | |||||||||||||||||
Except as follows, the Company has no significant off balance sheet risk or credit risk concentrations. Financial instruments that subject the Company to potential credit risks are principally cash equivalents and accounts receivable. Concentrated credit risk with respect to accounts receivable is limited to creditworthy customers. The Company's customers are principally located in the United States and Europe. The Company is directly affected by the overall financial condition of the pharmaceutical, biotechnology and medical device industries and management believes that credit risk exists and that any credit risk the Company faces has been adequately reserved for as of December 31, 2014. The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses when incurred are charged to the allowance. The Company's losses related to collection of accounts receivable have consistently been within management's expectations. As of December 31, 2014, the Company believes no additional credit risk exists beyond the amounts provided for in our allowance for uncollectible accounts. The Company evaluates its allowance for uncollectable accounts on a monthly basis based on a specific review of receivable aging and the period that any receivables are beyond the standard payment terms. The Company does not require collateral from its customers in order to mitigate credit risk. | |||||||||||||||||
One customer accounted for 15% of our revenue during the year ended December 31, 2014 or approximately $2,395,000, respectively. One customer accounted for 11% of our revenues during the year ended December 31, 2013 or approximately $1,551,000. The following table summarizes the number of customers who individually comprise greater than 10% of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the years presented. | |||||||||||||||||
Revenues | Accounts receivable | ||||||||||||||||
For the year ended | Number of customers | Percentage of total revenues | Number of customers | Percentage of accounts receivable | |||||||||||||
31-Dec-14 | 1 | 15% | 1 | 18% | |||||||||||||
31-Dec-13 | 1 | 11% | 2 | 23% | |||||||||||||
The table below provides revenues from European customers for the years ended December 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||
European revenues | |||||||||||||||||
For the year ended | |||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||
European revenues | % of Total revenues | European revenues | % of Total revenues | ||||||||||||||
$ | 2,383,252 | 14.50% | $ | 1,847,305 | 12.90% | ||||||||||||
The Company serves all of its hosting customers from third-party web hosting facilities located in the United States. The Company does not control the operation of these facilities, and they are vulnerable to damage or interruption. The Company maintains redundant systems that can be used to provide service in the event the third-party web hosting facilities become unavailable, although in such circumstances, the Company's service may be interrupted during the transition. | |||||||||||||||||
PROPERTY AND EQUIPMENT | |||||||||||||||||
Property and equipment are recorded at cost. Additions and betterments are capitalized; maintenance and repairs are expensed as incurred. Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is 5 years for leasehold improvements, computers, equipment and furniture and 3 years for software. Gains or losses on disposal are charged to operations. | |||||||||||||||||
ASSET IMPAIRMENT | |||||||||||||||||
Acquisitions and Intangible Assets | |||||||||||||||||
We account for acquisitions in accordance with ASC 805, Business Combinations (“ASC 805”) and ASC 350, Intangibles- Goodwill and Other (“ASC 350”). The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of a business acquisition. Our consolidated financial statements and results of operations reflect an acquired business from the completion date of an acquisition. | |||||||||||||||||
The judgments that we make in determining the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact net income in periods following an asset acquisition. We generally use either the income, cost or market approach to aid in our conclusions of such fair values and asset lives. The income approach presumes that the value of an asset can be estimated by the net economic benefit to be received over the life of the asset, discounted to present value. The cost approach presumes that an investor would pay no more for an asset than its replacement or reproduction cost. The market approach estimates value based on what other participants in the market have paid for reasonably similar assets. Although each valuation approach is considered in valuing the assets acquired, the approach ultimately selected is based on the characteristics of the asset and the availability of information. | |||||||||||||||||
Long-lived Assets | |||||||||||||||||
We review long-lived assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. In turn, measurement of an impairment loss requires a determination of fair value, which is based on the best information available. We use quoted market prices when available and independent appraisals and management estimates of future operating cash flows, as appropriate, to determine fair value. | |||||||||||||||||
DEFERRED REVENUE | |||||||||||||||||
Deferred revenue represents cash advances received in excess of revenue earned on on-going contracts. Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones. In the event of contract cancellation, the Company is generally entitled to payment for all work performed through the point of cancellation. As of December 31, 2014, the Company had $8,233,943 in deferred revenues relating to contracts for services to be performed over periods ranging from 1 month to 5 years. The Company had $5,840,875 in deferred revenues that are expected to be recognized in the next twelve fiscal months. | |||||||||||||||||
ADVERTISING | |||||||||||||||||
Advertising costs are expensed as incurred. Advertising costs were $419,253 and $226,380 for the years ended December 31, 2014 and December 31, 2013, respectively and are included under selling, general and administrative expenses on our consolidated financial statements. | |||||||||||||||||
RESEARCH AND DEVELOPMENT EXPENSES | |||||||||||||||||
Software development costs are included in R&D and are expensed as incurred. ASC 985.20, Software Industry Costs of Software to Be Sold, Leased or Marketed, requires the capitalization of certain development costs of software to be sold once technological feasibility is established, which the Company defines as completion to the point of marketability. The capitalized cost is then amortized on a straight-line basis over the estimated product life. To date, the period between achieving technological feasibility and the general availability of such software has been short and software development costs qualifying for capitalization have been immaterial. Accordingly, the Company has not capitalized any software development costs under ASC 985.20. During the years ended December 31, 2014 and December 31, 2013 we spent approximately $2,754,367 and $2,403,504 respectively, on R&D activities, which include costs associated with the development of our software products and services for our client’s projects and which are primarily comprised of salaries and related expenses for our software developers and consulting fees paid to third-party consultants. R&D costs are primarily included under Salaries, benefits and related taxes in our Statement of Operations. | |||||||||||||||||
EMPLOYEE EQUITY INCENTIVE PLANS | |||||||||||||||||
The OmniComm Systems, Inc. 2009 Equity Incentive Plan (the “2009 Plan”) was approved at our Annual Meeting of Shareholders on July 10, 2009. The 2009 Plan provides for the issuance of up to 7.5 million shares to employees, directors and key consultants in accordance with the terms of the 2009 Plan documents. The predecessor plan, the OmniComm Systems, Inc., 1998 Stock Incentive Plan (the “1998 Plan”) expired on December 31, 2008. The 1998 Plan provided for the issuance of up to 12.5 million shares in accordance with the terms of the 1998 Plan document. Each plan is more fully described in “Note 15, Employee Equity Incentive Plans.” The Company accounts for its employee equity incentive plans under ASC 718, Compensation – Stock Compensation which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. | |||||||||||||||||
ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company currently uses the Black Scholes option pricing model to determine grant date fair value. | |||||||||||||||||
EARNINGS/(LOSS) PER SHARE | |||||||||||||||||
The Company accounts for Earnings/(loss) Per Share using ASC 260 – Earnings per Share. Unlike diluted earnings per share, basic earnings per share excludes any dilutive effects of options, warrants, and convertible securities. | |||||||||||||||||
INCOME TAXES | |||||||||||||||||
The Company accounts for income taxes in accordance ASC 740, Income Taxes. ASC 740 has as its basic objective the recognition of current and deferred income tax assets and liabilities based upon all events that have been recognized in the financial statements as measured by the provisions of the enacted tax laws | |||||||||||||||||
Valuation allowances are established when necessary to reduce deferred tax assets to the estimated amount to be realized. Income tax expense represents the tax payable for the current period and the change during the period in the deferred tax assets and liabilities. | |||||||||||||||||
IMPACT OF NEW ACCOUNTING STANDARDS | |||||||||||||||||
During fiscal 2014, we adopted the following new accounting pronouncements: | |||||||||||||||||
In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”, (“ASU No. 2013-11”). This ASU amends ASC 740, Income Taxes, to require that an unrecognized tax benefit be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward; to the extent that a net operating loss carryforward, a similar tax loss, or a tax credit carryforward does not exist at the reporting date, the unrecognized tax benefit should be presented in the financial statements as a liability and not combined with deferred tax assets. ASU No. 2013-11 is effective for interim and annual periods beginning after December 15, 2013, with early adoption permitted. Our adoption of this standard on January 1, 2014 did not have a material impact on our consolidated financial statements. | |||||||||||||||||
In May 2014, FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, (“ASU 2014-09”). This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on January 1, 2017. Management is currently evaluating which transition approach to use and the impact of the adoption of this ASU on the Company's consolidated financial statements. | |||||||||||||||||
In August 2014, FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, (“ASU 2014-15”), which requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We believe the adoption of this guidance will not have a material effect on our consolidated financial statements. | |||||||||||||||||
Accounting standards-setting organizations frequently issue new or revised accounting rules. We regularly review all new pronouncements to determine their impact, if any, on our financial statements. |
Note_3_Going_Concern
Note 3 - Going Concern | 12 Months Ended | |
Dec. 31, 2014 | ||
Going Concern Note [Abstract] | ||
Going Concern Note | NOTE 3: | GOING CONCERN |
We have experienced net losses and negative cash flows from operations and have utilized debt and equity financings to help provide for our working capital, capital expenditure and R&D needs. We will continue to require substantial funds to continue our R&D activities and to market, sell and commercialize our technology. We may need to raise substantial additional capital to fund our future operations. Our capital requirements will depend on many factors, including the problems, delays, expenses and complications frequently encountered by companies developing and commercializing new technologies; the progress of our R&D activities; the rate of technological advances; determinations as to the commercial potential of our technology under development; the status of competitive technology; the establishment of collaborative relationships; the success of our sales and marketing programs; and other changes in economic, regulatory or competitive conditions in our planned business. | ||
Estimates about the adequacy of funding for our activities are based upon certain assumptions, including assumptions that the R&D programs relating to our technology can be conducted at projected costs and that progress towards the commercialization of our technology will be timely and successful. There can be no assurance that changes in our R&D plans, acquisitions or other events will not result in accelerated or unexpected expenditures. | ||
To satisfy our capital requirements, we may seek additional financing through debt and equity financings. There can be no assurance that any such funding will be available to us on favorable terms or at all. If adequate funds are not available when needed, we may be required to delay, scale back or eliminate some or all of our R&D and marketing programs. If we are successful in obtaining additional financings, the terms of such financings may have the effect of diluting or adversely affecting the holdings or the rights of the holders of our common and preferred stock or result in increased interest expense in future periods. | ||
The ability of the Company to continue in existence is dependent on its having sufficient financial resources to bring products and services to market for marketplace acceptance. As a result of our historical operating losses, negative cash flows and accumulated deficits for the period ending December 31, 2014 there is substantial doubt about the Company’s ability to continue as a going concern. | ||
The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. |
Note_4_Earnings_Loss_Per_Share
Note 4 - Earnings (Loss) Per Share | 12 Months Ended | ||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||
Earnings Per Share [Text Block] | NOTE 4 | EARNINGS/(LOSS) PER SHARE | |||||||||||||||||||||||
Basic (loss) per share was calculated using the weighted average number of shares outstanding of 90,701,058 and 87,969,202 for the years ended December 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||||||||||
Antidilutive shares aggregating 80,012,198 and 79,546,913 have been omitted from the calculation of dilutive (loss) per share for the years ended December 31, 2014 and December 31, 2013 respectively as the shares were antidilutive. Provided below is the reconciliation between numerators and denominators of the basic and diluted (loss) per shares: There were no differences between basic and diluted (loss) per share. The table below provides a reconciliation of anti-dilutive securities outstanding as of December 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||||||||||
Anti-Dilutive security | 31-Dec-14 | 31-Dec-13 | |||||||||||||||||||||||
Preferred stock | 2,750,149 | 2,750,149 | |||||||||||||||||||||||
Employee stock options | 3,130,000 | 5,745,000 | |||||||||||||||||||||||
Warrants | 48,463,517 | 44,728,873 | |||||||||||||||||||||||
Convertible notes | 24,620,000 | 24,620,000 | |||||||||||||||||||||||
Shares issuable for accrued interest | 1,048,532 | 1,702,891 | |||||||||||||||||||||||
Total | 80,012,198 | 79,546,913 | |||||||||||||||||||||||
The employee stock options are exercisable at prices ranging from $0.045 to $0.50 per share. The exercise price on the stock warrants range from $0.25 to $0.60 per share. Shares issuable upon conversion of Convertible Debentures have conversion prices ranging from $0.25 to $0.50 per share. | |||||||||||||||||||||||||
The Company’s convertible debt and convertible preferred stock have an anti-dilutive effect on net (loss) per share and were not included in the computation of diluted (loss) per share. | |||||||||||||||||||||||||
For the year ended | |||||||||||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||||
Income/(loss) | Shares | Per-share | Income/(loss) | Shares | Per-share | ||||||||||||||||||||
numerator | denominator | amount | numerator | denominator | amount | ||||||||||||||||||||
Basic EPS | $ | (4,665,645 | ) | 90,701,058 | $ | (0.05 | ) | $ | (3,367,603 | ) | 87,969,202 | $ | (0.04 | ) | |||||||||||
Effect of dilutive securities - none | -0- | -0- | -0- | -0- | -0- | -0- | |||||||||||||||||||
Diluted EPS | $ | (4,665,645 | ) | 90,701,058 | $ | (0.05 | ) | $ | (3,367,603 | ) | 87,969,202 | $ | (0.04 | ) | |||||||||||
Note_5_Property_and_Equipment_
Note 5 - Property and Equipment, Net | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||
Property, Plant and Equipment Disclosure [Text Block] | NOTE 5: | PROPERTY AND EQUIPMENT, NET | |||||||||||||||||||||||||||
Property and equipment consists of the following: | |||||||||||||||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||||||||
Cost | Accumulated depreciation | Net book value | Cost | Accumulated depreciation | Net book value | Estimated useful life (years) | |||||||||||||||||||||||
Computer & office equipment | $ | 1,880,183 | $ | 1,482,737 | $ | 397,446 | $ | 1,822,098 | $ | 1,326,256 | $ | 495,842 | 5 | ||||||||||||||||
Leasehold improvements | 92,504 | 82,353 | 10,151 | 93,812 | 75,735 | 18,077 | 5 | ||||||||||||||||||||||
Computer software | 1,580,640 | 1,528,418 | 52,222 | 1,556,497 | 1,477,801 | 78,696 | 3 | ||||||||||||||||||||||
Office furniture | 113,365 | 105,048 | 8,317 | 114,373 | 99,555 | 14,818 | 5 | ||||||||||||||||||||||
Total | $ | 3,666,692 | $ | 3,198,556 | $ | 468,136 | $ | 3,586,780 | $ | 2,979,347 | $ | 607,433 | |||||||||||||||||
Depreciation expense for the years ended December 31, 2014 and December 31, 2013 was $235,591 and $230,323, respectively. |
Note_6_Intangible_Assets_at_Co
Note 6 - Intangible Assets, at Cost | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||||
Disclosure Text Block [Abstract] | |||||||||||||||||||||||||||||
Intangible Assets Disclosure [Text Block] | NOTE 6: | INTANGIBLE ASSETS, AT COST | |||||||||||||||||||||||||||
Intangible assets consist of the following: | |||||||||||||||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||||||||
Asset | Cost | Accumulated amortization | Net book value | Cost | Accumulated amortization | Net book value | Estimated useful life (years) | ||||||||||||||||||||||
eClinical customer lists | $ | 1,392,701 | $ | 1,392,701 | $ | -0- | $ | 1,392,701 | $ | 1,392,701 | $ | -0- | 3 | ||||||||||||||||
Promasys B.V. customer lists | 120,305 | 9,357 | 110,948 | 136,253 | 1,514 | 134,739 | 15 | ||||||||||||||||||||||
Promasys B.V. software code | 72,837 | 16,995 | 55,842 | 72,943 | 2,431 | 70,512 | 5 | ||||||||||||||||||||||
Promasys B.V. URLs/Website | 60,760 | 23,629 | 37,131 | 68,814 | 3,823 | 64,991 | 3 | ||||||||||||||||||||||
Total | $ | 1,646,603 | $ | 1,442,682 | $ | 203,921 | $ | 1,670,711 | $ | 1,400,469 | $ | 270,242 | |||||||||||||||||
Amortization expense was $45,433 and $7,720 for the years ended December 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||||||||||||||
Annual amortization expense for the Company’s intangible assets is as follows: | |||||||||||||||||||||||||||||
2015 | $ | 42,841 | |||||||||||||||||||||||||||
2016 | 39,466 | ||||||||||||||||||||||||||||
2017 | 22,588 | ||||||||||||||||||||||||||||
2018 | 20,160 | ||||||||||||||||||||||||||||
2019 | 8,020 | ||||||||||||||||||||||||||||
Thereafter | 70,846 | ||||||||||||||||||||||||||||
Total | $ | 203,921 | |||||||||||||||||||||||||||
Note_7_Accounts_Payable_and_Ac
Note 7 - Accounts Payable and Accrued Expenses | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Payables and Accruals [Abstract] | |||||||||
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | NOTE 7: | ACCOUNTS PAYABLE AND ACCRUED EXPENSES | |||||||
Accounts payable and accrued expenses consist of the following: | |||||||||
Account | 31-Dec-14 | 31-Dec-13 | |||||||
Accounts payable | $ | 613,584 | $ | 724,421 | |||||
Accrued payroll and related costs | 319,629 | 260,072 | |||||||
Other accrued expenses | 85,248 | 88,292 | |||||||
Accrued interest | 875,724 | 1,468,171 | |||||||
Total accounts payable and accrued expenses | $ | 1,894,185 | $ | 2,540,956 | |||||
Note_8_Promasys_BV_Acquisition
Note 8 - Promasys B.V. Acquisition (Promasys B.V. [Member]) | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
Promasys B.V. [Member] | |||||
Note 8 - Promasys B.V. Acquisition [Line Items] | |||||
Business Combination Disclosure [Text Block] | NOTE 8: | PROMASYS B.V. ACQUISITION | |||
On November 11, 2013, with economic effect as of October 31, 2013, we acquired 100% of the capital stock of Promasys B.V., a privately held Netherlands company, from the 4 shareholders of Promasys B.V. pursuant to a share purchase agreement and as a result, Promasys B.V. became our wholly owned subsidiary. Promasys B.V. is involved in the development and marketing of software and services relating to clinical data management (“Business”). Since its establishment in 2004, Promasys B.V. has built an international customer base, with a focus on the academic market and a strong presence in Asia. As consideration for the acquisition, we paid an aggregate of 435,998 euros (approximately $593,000) to one of the shareholders of Promasys B.V and issued an aggregate of 2,270,000 shares of our common stock to the other 3 shareholders of Promasys B.V. On the same day, and in connection with the share purchase agreement, we also entered into an employment agreement with one of the shareholders and a management agreement with the principal of a second shareholder pursuant to which, among other things, the individuals shall continue providing services to us as it relates to the Business. The foregoing description of the share purchase agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement which we have filed as Exhibit 10.71 to our 2014 Annual Report on Form 10K. | |||||
In conjunction with the share purchase agreement of the capital stock of Promasys B.V., effective October 31, 2013, our Board of Directors appointed Dr. Adam F. Cohen to serve on our Board of Directors. Dr. Cohen, age 61, has no family relationships with any of the executive officers or directors of the Company. Dr. Cohen was a director of Promasys B. V. and held a 10% equity interest in Promasys B.V. prior to the acquisition. He received 790,000 shares of OmniComm’s common shares in exchange for his interest in Promasys B.V. Other than the acquisition of Promasys B.V. there have been no related party transactions in the past two years in which the Company or any of its subsidiaries was or is to be a party, in which Dr. Cohen had, or will have, a direct or indirect material interest. | |||||
Dr. Cohen currently serves as the Chief Executive Officer of CHDR, a clinical research unit based in Leiden in the Netherlands. Dr. Cohen graduated in Pharmacy and Medicine from Leiden University. He subsequently joined the department of Clinical Pharmacology of the Wellcome Research Laboratories in Beckenham, UK where he obtained experience in early drug development. This work led to a PhD thesis about the development of an antihistamine (acrivastine) and an antiepileptic (lamotrigine). Further training in internal medicine was obtained at King’s College Hospital in London. Phase II-III drug development experience was obtained as European Clinical project leader for t-PA at Wellcome. He is a professor of Clinical Pharmacology at Leiden University and has a clinical attachment at the department of nephrology at Leiden University Medical Centre. He is author of more than two hundred publications about a wide range of clinical pharmacological subjects. He is executive editor of the British Journal of Clinical Pharmacology. | |||||
We accounted for the acquisition of Promasys B.V as a business combination and accordingly accounted for the acquisition under Statement of Financial Accounting Standards No. 141, Business Combinations (“SFAS 141”) (Codified within ASC 805, Business Combinations). We allocate the purchase price to the assets acquired and the liabilities assumed based on their estimated fair values on the date of the acquisition. The difference between the fair value of the net assets acquired and the purchase price is recorded as goodwill. We record the operating results of the acquired business in our consolidated statements of operations from the date of acquisition. | |||||
The table below summarizes the amounts of the assets acquired and liabilities assumed that were recognized at the acquisition date. | |||||
Cash | $ | 215,571 | |||
Receivables | 216,287 | ||||
Property and equipment | 2,178 | ||||
Identifiable intangibles | 276,356 | ||||
Goodwill | 671,689 | ||||
Total assets acquired | $ | 1,382,081 | |||
Accounts payable | (170,339 | ) | |||
Deferred revenue | (229,353 | ) | |||
Net assets acquired | $ | 982,389 | |||
The below table provides unaudited pro-forma results as if the acquisition had occurred effective January 1, 2013. | |||||
For the year ended | |||||
December 31, | |||||
2013 | |||||
Gross revenues | $ | 15,119,861 | |||
Total expenses | 18,145,210 | ||||
Net income/(loss) before taxes | (3,025,349 | ) | |||
Net income/(loss) per share | |||||
Weighted average number of shares outstanding | $ | (0.04 | ) | ||
Basic and diluted | 89,866,051 | ||||
Note_9_Line_of_Credit_and_Note
Note 9 - Line of Credit and Notes Payable | 12 Months Ended | ||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||
Debt Disclosure [Text Block] | NOTE 9: | LINES OF CREDIT AND NOTESPAYABLE | |||||||||||||||||||||||||
On March 18, 2013, the Company entered into a $2,000,000 revolving line of credit with The Northern Trust Company guaranteed by Cornelis F. Wit, Chief Executive Officer and Director. Mr. Wit receives 2.0% interest on the assets pledged for the line of credit. On December 18, 2013 the Company renewed the Line of Credit and increased the available balance to $4,000,000. On February 3, 2015 the Company renewed the Line of Credit and increased the available balance to $5,000,000. The line of credit matures on February 2, 2018 and carries a variable interest rate based on the prime rate. At December 31, 2014, $4,000,000 was outstanding on the line of credit at an interest rate of 2.25%. | |||||||||||||||||||||||||||
At December 31, 2014, the Company owed $7,081,500 in notes payable all of which are unsecured. The table below provides details as to the terms and conditions of the notes payable. | |||||||||||||||||||||||||||
Ending | |||||||||||||||||||||||||||
principal | Non related party | Related party | |||||||||||||||||||||||||
Origination | Maturity | Interest | December 31, | Long | Long | ||||||||||||||||||||||
date | date | rate | 2014 | Current | term | Current | term | ||||||||||||||||||||
1/1/13 | 1/1/16 | 12% | $ | 529,000 | $ | -0- | $ | -0- | $ | -0- | $ | 529,000 | |||||||||||||||
2/1/13 | 1/1/16 | 12% | 20,000 | -0- | -0- | -0- | 20,000 | ||||||||||||||||||||
4/1/13 | 3/31/16 | 12% | 2,860,000 | -0- | -0- | -0- | 2,860,000 | ||||||||||||||||||||
1/1/14 | 4/1/17 | 12% | 980,000 | -0- | -0- | -0- | 980,000 | ||||||||||||||||||||
4/4/14 | 4/1/17 | 12% | 1,600,000 | -0- | -0- | -0- | 1,600,000 | ||||||||||||||||||||
4/4/14 | 4/1/17 | 12% | 45,000 | -0- | 45,000 | -0- | -0- | ||||||||||||||||||||
4/4/14 | 4/1/17 | 12% | 137,500 | -0- | 137,500 | -0- | -0- | ||||||||||||||||||||
4/4/14 | 4/1/17 | 10% | 120,000 | -0- | 120,000 | -0- | -0- | ||||||||||||||||||||
12/1/14 | 4/1/17 | 10% | 300,000 | -0- | 300,000 | -0- | -0- | ||||||||||||||||||||
12/1/14 | 4/1/17 | 12% | 90,000 | -0- | 90,000 | -0- | -0- | ||||||||||||||||||||
12/1/14 | 4/1/17 | 12% | 100,000 | -0- | 100,000 | -0- | -0- | ||||||||||||||||||||
12/17/14 | 1/1/16 | 12% | 20,000 | -0- | 20,000 | -0- | -0- | ||||||||||||||||||||
12/23/14 | 4/1/17 | 12% | 280,000 | -0- | -0- | -0- | 280,000 | ||||||||||||||||||||
Discount on note payable | -0- | -0- | -0- | (568,209 | ) | ||||||||||||||||||||||
Total | $ | 7,081,500 | $ | -0- | $ | 812,500 | $ | -0- | $ | 5,700,791 | |||||||||||||||||
At December 31, 2013, the Company owed $5,667,865 in notes payable all of which are unsecured. The table below provides details as to the terms and conditions of the notes payable. | |||||||||||||||||||||||||||
Ending | |||||||||||||||||||||||||||
principal | Non related party | Related party | |||||||||||||||||||||||||
Origination | Maturity | Interest | December 31, | Long | Long | ||||||||||||||||||||||
date | date | rate | 2013 | Current | term | Current | term | ||||||||||||||||||||
12/31/11 | 1/1/15 | 12% | $ | 1,600,000 | $ | -0- | $ | -0- | $ | -0- | $ | 1,600,000 | |||||||||||||||
4/1/12 | 1/1/14 | 12% | 17,500 | 17,500 | -0- | -0- | -0- | ||||||||||||||||||||
12/17/12 | 12/16/14 | 12% | 20,000 | 20,000 | -0- | -0- | -0- | ||||||||||||||||||||
1/1/13 | 1/1/16 | 12% | 529,000 | -0- | -0- | -0- | 529,000 | ||||||||||||||||||||
1/1/13 | 1/1/15 | 10% | 308,561 | -0- | 308,561 | -0- | -0- | ||||||||||||||||||||
1/1/13 | 1/1/15 | 10% | 123,425 | -0- | 123,425 | -0- | -0- | ||||||||||||||||||||
1/1/13 | 1/1/15 | 12% | 45,000 | -0- | 45,000 | -0- | -0- | ||||||||||||||||||||
2/1/13 | 1/1/16 | 12% | 20,000 | -0- | -0- | -0- | 20,000 | ||||||||||||||||||||
3/5/13 | 1/1/15 | 12% | 137,500 | -0- | 137,500 | -0- | -0- | ||||||||||||||||||||
4/1/13 | 3/31/16 | 12% | 2,866,879 | -0- | -0- | -0- | 2,866,879 | ||||||||||||||||||||
Discount on note payable | -0- | -0- | -0- | (447,666 | ) | ||||||||||||||||||||||
Total | $ | 5,667,865 | $ | 37,500 | $ | 614,486 | $ | -0- | $ | 4,568,213 | |||||||||||||||||
On January 1, 2013, the Company issued a promissory note in the principal amount of $529,000 and warrants to purchase 2,116,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of January 31, 2016 to our Chief Executive Officer and Director, Cornelis F. Wit, in exchange for accrued interest in the amount of $529,000. The note carries an interest rate of 12% per annum and is due on January 1, 2016. | |||||||||||||||||||||||||||
This issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of $400,141 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore $128,859. The warrant liability (discount) will be amortized over the 36 month duration of the note payable. The Company will continue to perform a fair value calculation periodically on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities. | |||||||||||||||||||||||||||
On January 1, 2013, the Company issued a promissory note in the amount of $308,561 in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 10% per annum and matures on January 1, 2015. On December 1, 2014 the Company issued a promissory note in the amount of $300,000 and paid $8,561 in principal in exchange for the existing promissory note in the amount of $308,561. The promissory note carries an interest rate of 10% and has a maturity date of April 1, 2017. | |||||||||||||||||||||||||||
On January 1, 2013, the Company issued a promissory note in the amount of $123,425 in exchange for an existing promissory note in the same amount. The note carries an interest rate of 10% per annum and matures on January 1, 2015. On April 4, 2014 the Company issued a promissory note in the amount of $120,000 and paid $3,425 in principal in exchange for the existing promissory note in the amount of $123,425. The promissory note carries an interest rate of 10% and has a maturity date of April 1, 2017. | |||||||||||||||||||||||||||
On January 1, 2013 the Company issued a promissory note in the amount of $45,000 in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of January 1, 2015. On April 4, 2014 the Company issued a promissory note in the amount of $45,000 in exchange for the existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2017. | |||||||||||||||||||||||||||
On February 1, 2013 the Company issued a promissory note in the amount of $20,000 to our Chairman and Chief Technology Officer, Randall G. Smith, in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of January 1, 2016. | |||||||||||||||||||||||||||
On March 5, 2013 the Company issued a promissory note in the amount of $137,500 in exchange for a promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of January 1, 2015. On April 4, 2014 the Company issued a promissory note in the amount of $137,500 in exchange for the existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2017. | |||||||||||||||||||||||||||
On April 1, 2013 the Company issued a promissory note in the amount of $2,866,879 to our Chief Executive Officer and Director, Cornelis F. Wit, in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of March 31, 2016. The expiration date of the warrants associated with the promissory note was also extended to March 31, 2016. In December 2014, the principal amount was reduced by $6,879. On January 31, 2015 the Company issued a promissory note in the amount of $2,860,000 to our Chief Executive Officer and Director, Cornelis F. Wit, in exchange for the existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2017. The expiration date of the warrants associated with the promissory note was also extended to April 1, 2017. | |||||||||||||||||||||||||||
On January 1, 2014, the Company issued a promissory note in the principal amount of $980,000 and warrants to purchase 3,920,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2017 to our Chief Executive Officer and Director, Cornelis F. Wit, in exchange for accrued interest in the amount of $980,000. The note carries an interest rate of 12% per annum and is due on April 1, 2017. | |||||||||||||||||||||||||||
This issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of $628,086 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore $351,914. The warrant liability (discount) will be amortized over the 39 month duration of the note payable. The Company will continue to perform a fair value calculation periodically on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities. | |||||||||||||||||||||||||||
On April 4, 2014 the Company issued a promissory note payable to our Chief Executive Officer and Director, Cornelis F. Wit, in the amount of $1,600,000 in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2017. | |||||||||||||||||||||||||||
On December 1, 2014 the Company issued a promissory note in the amount of $100,000 in exchange for accrued interest in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2017. | |||||||||||||||||||||||||||
On December 1, 2014 the Company issued a promissory note in the amount of $90,000 in exchange for accrued interest in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2017. | |||||||||||||||||||||||||||
On December 17, 2014 the Company issued a promissory note in the amount of $20,000 in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of January 1, 2016. | |||||||||||||||||||||||||||
On December 23, 2014, the Company issued a promissory note in the amount of $280,000 to our Chief Executive Officer and Director, Cornelis F. Wit. The note carries an interest rate of 12% per annum and is due on April 1, 2017. | |||||||||||||||||||||||||||
On January 31, 2015 the Company issued a promissory note in the amount of $529,000 to our Chief Executive Officer and Director, Cornelis F. Wit, in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2017. The expiration date of the warrants associated with the promissory note was also extended to April 1, 2017. |
Note_10_Convertible_Notes_Paya
Note 10 - Convertible Notes Payable | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt Disclosure [Text Block] | NOTE 10 | CONVERTIBLE NOTES PAYABLE | |||||||||||||||||||||||||||||||||||||||||||||
The following table summarizes the convertible debt outstanding as of December 31, 2014. | |||||||||||||||||||||||||||||||||||||||||||||||
Principal | Carrying | Carrying amount | |||||||||||||||||||||||||||||||||||||||||||||
at | Total | Discount at | amount at | Short term | Long term | ||||||||||||||||||||||||||||||||||||||||||
Date of | Maturity | Interest | Original | December | Allocated discount | discount | December | December | Related | Non related | Related | Non related | |||||||||||||||||||||||||||||||||||
issuance | date | rate | principal | 31, 2014 | amortized | 31, 2014 | 31, 2014 | ||||||||||||||||||||||||||||||||||||||||
8/1/99 | 6/30/04 | 10% | 862,500 | $ | 75,000 | $ | -0- | $ | -0- | $ | -0- | $ | 75,000 | $ | -0- | $ | 75,000 | -0- | -0- | ||||||||||||||||||||||||||||
8/29/08 | 1/1/16 | 10% | 2,120,000 | 1,770,000 | 1,916,480 | 1,916,480 | -0- | 1,770,000 | -0- | -0- | 1,770,000 | -0- | |||||||||||||||||||||||||||||||||||
8/29/08 | 4/1/16 | 10% | 150,000 | 150,000 | 135,600 | 135,600 | -0- | 150,000 | -0- | -0- | -0- | 150,000 | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 375,000 | 375,000 | 101,250 | 101,250 | -0- | 375,000 | -0- | -0- | -0- | 375,000 | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 4,600,000 | 4,505,000 | 1,242,000 | 1,242,000 | -0- | 4,505,000 | -0- | -0- | 4,505,000 | -0- | |||||||||||||||||||||||||||||||||||
12/16/08 | 4/1/16 | 12% | 100,000 | 100,000 | 27,515 | 27,515 | -0- | 100,000 | -0- | -0- | -0- | 100,000 | |||||||||||||||||||||||||||||||||||
9/30/09 | 1/1/16 | 12% | 100,000 | 100,000 | 37,600 | 37,600 | -0- | 100,000 | -0- | -0- | -0- | 100,000 | |||||||||||||||||||||||||||||||||||
9/30/09 | 1/1/16 | 12% | 1,300,000 | 1,100,000 | 488,800 | 488,800 | -0- | 1,100,000 | -0- | -0- | 1,100,000 | -0- | |||||||||||||||||||||||||||||||||||
12/31/09 | 1/1/16 | 12% | 50,000 | 50,000 | 31,400 | 31,400 | -0- | 50,000 | -0- | -0- | -0- | 50,000 | |||||||||||||||||||||||||||||||||||
12/31/09 | 1/1/16 | 12% | 1,440,000 | 1,440,000 | 904,320 | 904,320 | -0- | 1,440,000 | -0- | -0- | 1,440,000 | -0- | |||||||||||||||||||||||||||||||||||
Total | $ | 11,097,500 | $ | 9,665,000 | $ | 4,884,450 | $ | 4,884,450 | $ | -0- | $ | 9,665,000 | $ | -0- | $ | 75,000 | $ | 8,815,000 | $ | 775,000 | |||||||||||||||||||||||||||
The following table summarizes the convertible debt outstanding as of December 31, 2013. | |||||||||||||||||||||||||||||||||||||||||||||||
Carrying amount | |||||||||||||||||||||||||||||||||||||||||||||||
Principal | Discount | Carrying | Short term | Long term | |||||||||||||||||||||||||||||||||||||||||||
Date of | Maturity date | Interest rate | Original principal | at December31, 2013 | Allocated discount | Total discount amortized | at December31, 2013 | amount at December 31, 2013 | Related | Non related | Related | Non related | |||||||||||||||||||||||||||||||||||
issuance | |||||||||||||||||||||||||||||||||||||||||||||||
8/1/99 | 6/30/04 | 10% | $ | 862,500 | $ | 75,000 | $ | -0- | $ | -0- | $ | -0- | $ | 75,000 | $ | -0- | $ | 75,000 | $ | -0- | $ | -0- | |||||||||||||||||||||||||
8/29/08 | 1/1/15 | 10% | 150,000 | 150,000 | 135,600 | 135,600 | -0- | 150,000 | -0- | -0- | 150,000 | -0- | |||||||||||||||||||||||||||||||||||
8/29/08 | 1/1/16 | 10% | 2,120,000 | 1,770,000 | 1,916,480 | 1,916,480 | -0- | 1,770,000 | -0- | -0- | 1,770,000 | -0- | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/15 | 12% | 100,000 | 100,000 | 27,515 | 27,515 | -0- | 100,000 | -0- | -0- | -0- | 100,000 | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 160,000 | 160,000 | 44,024 | 44,024 | -0- | 160,000 | -0- | -0- | 160,000 | -0- | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 200,000 | 200,000 | 55,030 | 55,030 | -0- | 200,000 | -0- | -0- | -0- | 200,000 | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 4,615,000 | 4,520,000 | 1,243,681 | 1,243,681 | -0- | 4,520,000 | -0- | -0- | 4,505,000 | 15,000 | |||||||||||||||||||||||||||||||||||
9/30/09 | 1/1/16 | 12% | 1,400,000 | 1,200,000 | 526,400 | 526,400 | -0- | 1,200,000 | -0- | -0- | 1,100,000 | 100,000 | |||||||||||||||||||||||||||||||||||
12/31/09 | 1/1/16 | 12% | 1,490,000 | 1,490,000 | 935,720 | 935,720 | -0- | 1,490,000 | -0- | -0- | 1,440,000 | 50,000 | |||||||||||||||||||||||||||||||||||
Total | $ | 11,097,500 | $ | 9,665,000 | $ | 4,884,450 | $ | 4,884,450 | $ | -0- | $ | 9,665,000 | $ | -0- | $ | 75,000 | $ | 9,125,000 | $ | 465,000 | |||||||||||||||||||||||||||
10% Convertible Notes | |||||||||||||||||||||||||||||||||||||||||||||||
During 1999, the Company issued 10% Convertible Notes payable in the amount of $862,500 pursuant to a Confidential Private Placement Memorandum. There were costs of $119,625 associated with this offering. The net proceeds to the Company were $742,875. The notes bear interest at ten percent annually, payable semi-annually. The notes were convertible after maturity, which was June 30, 2004, into shares of common stock of the Company at $1.25 per share. We are in default in the payment of principal and interest. As of December 31, 2014, approximately $787,500 of the Convertible Notes had been repaid in cash or converted into 1,495,179 shares of common stock of the Company leaving an outstanding principal balance of $75,000. There was $117,248 of accrued interest at December 31, 2014. | |||||||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Debentures | |||||||||||||||||||||||||||||||||||||||||||||||
On September 30, 2009, the Company sold an aggregate of $1,400,000 principal amount 12% Secured Convertible Debentures (the “Debentures”) and common stock purchase warrants (the “Warrants”) to purchase an aggregate of 5,600,000 shares of our common stock exercisable at a price of $0.25 per share for four years subsequent to the closing of the transaction to four accredited investors including our Chief Executive Officer and Director, Cornelis F. Wit. The Company received net proceeds of $1,400,000. The Debentures, which bear interest at 12% per annum, matured on March 30, 2011. The Debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.25 per share. On March 30, 2011, the Company repaid $200,000 of the outstanding principal amounts owed and extended $1,200,000 of the convertible notes until April 1, 2013, including $1,100,000 in convertible notes held by our Chief Executive Officer and Director, Cornelis F. Wit. The Company also extended the expiration date of the warrants associated with the September 2009 offering. On February 22, 2013, the Company and two lenders extended $1,200,000 of the convertible notes until January 1, 2016, including $1,100,000 in convertible notes held by our Chief Executive Officer and Director, Cornelis F. Wit. The expiration date of the warrants associated with the September 2009 offering was also extended to January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,100,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | |||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debentures | |||||||||||||||||||||||||||||||||||||||||||||||
On August 29, 2008, the Company sold $2,270,000 of convertible debentures and warrants to purchase an aggregate of 4,540,000 shares of our common stock to four accredited investors including our Chief Executive Officer and Director, Cornelis F. Wit and one of our Directors. The convertible debentures, which bear interest at 10% per annum, were due on August 29, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, two Affiliates of the Company extended $1,920,000 of the convertible debentures until August 29, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. On February 22, 2013 the Company and Mr. van Kesteren extended the maturity date of $150,000 of the convertible debentures due to our Director, Guus van Kesteren to January 1, 2015. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015. On April 21, 2014, the Company and our Director, Guus van Kesteren, extended the maturity date of his $150,000 of convertible debentures to April 1, 2016. The expiration date of the warrants associated with the debentures was also extended to April 1, 2016. On July 31, 2014 Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of $150,000 was reclassified from Related Party to Non-Related Party. On February 22, 2013 the Company and Mr. Wit extended the maturity date of $1,770,000 of the convertible debentures due to our Chief Executive Officer and Director, Cornelis F. Wit, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | |||||||||||||||||||||||||||||||||||||||||||||||
On December 16, 2008, we sold $5,075,000 of convertible debentures and warrants to purchase an aggregate of 10,150,000 shares of our common stock to eleven accredited investors including our Chief Executive Officer and Director, Cornelis F. Wit, our Chief Operating Officer and President, Stephen E. Johnson, our Chairman and Chief Technology Officer, Randall G. Smith, Chief Financial Officer, Ronald T. Linares, and four of our Directors. The convertible debentures, which bear interest at 12% per annum, were due on December 16, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009 Affiliates of the Company extended $4,980,000 of Convertible Notes until December 16, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. On February 22, 2013 the Company and the lenders agreed to extend the maturity date of $4,505,000 of the convertible debentures including $4,475,000 due to our Chief Executive Officer and Director, Cornelis F. Wit, $25,000 due to our Chief Operating Officer and President, Stephen E. Johnson, and $5,000 due to our Chairman and Chief Technology Officer, Randall G. Smith, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On February 27, 2013 the Company and Mr. Veatch extended the maturity date of $15,000 of convertible debentures issued to our former Director, Matthew Veatch, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On March 6, 2013, the Company and one of the lenders agreed to extend the maturity date of $200,000 of convertible debentures to January 1, 2014. The expiration date of the warrants associated with the debentures was also extended to January 1, 2014. On March 12, 2013, the Company and one of the lenders agreed to extend the maturity date of $100,000 of convertible debentures to January 1, 2015. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015. In December 2013, the Company and two lenders agreed to extend the maturity date of $360,000, including $160,000 due to our Director, Guus van Kesteren, of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On July 31, 2014 Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of $160,000 was reclassified from Related Party to Non-Related Party. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $4,475,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | |||||||||||||||||||||||||||||||||||||||||||||||
On December 31, 2009, the Company sold an aggregate of $1,490,000 principal amount 12% Convertible Debentures (the “Debentures”) and common stock purchase warrants (the “Warrants”) to purchase an aggregate of 5,960,000 shares of our common stock exercisable at a price of $0.25 per share for four years subsequent to the closing of the transaction to three accredited investors including our Chief Executive Officer and Director, Cornelis F. Wit. The Company received net proceeds of $1,490,000. The Debentures, which bear interest at 12% per annum, matured on June 30, 2011. The Debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.25 per share. On September 30, 2011, the Company extended all $1,490,000 of the convertible notes until October 1, 2013, including $1,440,000 in convertible notes held by our Chief Executive Officer and Director, Cornelis F. Wit. The Company also extended the expiration date of the warrants associated with the December 2009 offering until December 31, 2015. On February 22, 2013, the Company extended all $1,490,000 of the convertible notes until January 1, 2016, including $1,440,000 in convertible notes held by our Chief Executive Officer and Director, Cornelis F. Wit. The Company also extended the expiration date of the warrants associated with the December 2009 offering until January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,440,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | |||||||||||||||||||||||||||||||||||||||||||||||
The payments required at maturity under the Company’s outstanding convertible debt at December 31, 2014 are as follows: | |||||||||||||||||||||||||||||||||||||||||||||||
2015 | $ | 75,000 | |||||||||||||||||||||||||||||||||||||||||||||
2016 | 9,590,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 9,665,000 | |||||||||||||||||||||||||||||||||||||||||||||
Note_11_Fair_Value_Measurement
Note 11 - Fair Value Measurement | 12 Months Ended | ||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||
Fair Value Disclosures [Text Block] | NOTE 11: | FAIR VALUE MEASUREMENT | |||||||||||||||||||||||
The Company measures the fair value of its assets and liabilities under the guidance of ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. ASC 820 does not require any new fair value measurements, but its provisions apply to all other accounting pronouncements that require or permit fair value measurement. | |||||||||||||||||||||||||
ASC 820 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820 requires the Company to use valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows: | |||||||||||||||||||||||||
• | Level 1: Observable inputs such as quoted prices for identical assets or liabilities in active markets; | ||||||||||||||||||||||||
• | Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly such as quoted prices for similar assets or liabilities or market-corroborated inputs; and | ||||||||||||||||||||||||
• | Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions about how market participants would price the assets or liabilities. | ||||||||||||||||||||||||
The valuation techniques that may be used to measure fair value are as follows: | |||||||||||||||||||||||||
A. | Market approach - Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities | ||||||||||||||||||||||||
B. | Income approach - Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about those future amounts, including present value techniques, option-pricing models and excess earnings method | ||||||||||||||||||||||||
C. | Cost approach - Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost) | ||||||||||||||||||||||||
The Company also adopted the provisions of ASC 825, Financial Instruments. ASC 825 allows companies to choose to measure eligible assets and liabilities at fair value with changes in value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to re-measure any of its existing financial assets or liabilities under the provisions of this Statement and did not elect the fair value option for any financial assets and liabilities transacted in the years ended December 31, 2014 and December 31, 2013. | |||||||||||||||||||||||||
The Company’s financial assets or liabilities subject to ASC 820 as of December 31, 2014 include the conversion feature and warrant liability associated with convertible debentures issued during fiscal 2008 and 2009, the warrants issued during 2011, 2013 and 2014 that are associated with notes payable that were issued to our Chief Executive Officer and Director, Cornelis F. Wit, and the value of Intellectual Property and a customer list associated with the acquisition of Promasys B. V. during 2013. The conversion feature and warrants were deemed to be derivatives (the “Derivative Instruments”) since a fixed conversion price cannot be determined for either of the Derivative Instruments due to anti-dilution provisions embedded in the offering documents for the convertible debentures. The derivative instruments were not issued for risk management purposes and as such are not designated as hedging instruments under the provisions of ASC 815 Disclosures about Derivative Instruments and Hedging Activities. See Note 10 – Convertible Notes Payable. | |||||||||||||||||||||||||
Following is a description of the valuation methodologies used to determine the fair value of the Company’s financial assets including the general classification of such instruments pursuant to the valuation hierarchy. | |||||||||||||||||||||||||
A summary as of December 31, 2014 of the fair value of assets measured at fair value on a recurring basis follows: | |||||||||||||||||||||||||
Fair value at | Quoted prices in active markets for identical assets/ liabilities | Significant other observable inputs | Significant unobservable inputs | ||||||||||||||||||||||
December 31, | |||||||||||||||||||||||||
2014 | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||||||||||
Derivatives: (1) (2) | |||||||||||||||||||||||||
Conversion feature liability | $ | 2,944,402 | $ | -0- | $ | -0- | $ | 2,944,402 | |||||||||||||||||
Warrant liability | 6,695,060 | -0- | -0- | 6,695,060 | |||||||||||||||||||||
Total of derivative liabilities | $ | 9,639,462 | $ | -0- | $ | -0- | $ | 9,639,462 | |||||||||||||||||
(1) The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2014 | |||||||||||||||||||||||||
(2) The fair value at the measurement date is equal to their carrying value on the balance sheet | |||||||||||||||||||||||||
Significant valuation assumptions of derivative instruments at December 31, 2014 | |||||||||||||||||||||||||
Risk free interest rate | 0.13% | ||||||||||||||||||||||||
Dividend yield | 0.00% | ||||||||||||||||||||||||
Expected volatility | 119.80% | to | 155.70% | ||||||||||||||||||||||
Expected life (range in years) | |||||||||||||||||||||||||
Conversion feature liability | 1 | to | 1.25 | ||||||||||||||||||||||
Warrant liability | 1 | to | 2.25 | ||||||||||||||||||||||
A summary as of December 31, 2014 of the fair value of assets measured at fair value on a nonrecurring basis follows: | |||||||||||||||||||||||||
Carrying amount December 31, | Carrying amount December 31, | Quoted prices in active markets for identical assets/ liabilities | Significant other observable inputs | Significant unobservable inputs | |||||||||||||||||||||
2013 | 2014 | (Level 1) | (Level 2) | (Level 3) | |||||||||||||||||||||
Acquired assets (3) | |||||||||||||||||||||||||
Promasys B.V. customer lists (4) | $ | 134,739 | $ | 110,948 | $ | -0- | $ | -0- | $ | 136,253 | |||||||||||||||
Promasys B.V. software code (4) | 70,512 | 55,842 | -0- | -0- | 72,943 | ||||||||||||||||||||
Promasys B.V. URLs/website (4) | 64,991 | 37,131 | -0- | -0- | 68,814 | ||||||||||||||||||||
Total | $ | 270,242 | $ | 203,921 | $ | -0- | $ | -0- | $ | 278,010 | |||||||||||||||
(3) The fair value of the acquired assets was estimated using the Income Approach with a discounted cash flow valuation methodology applied. | |||||||||||||||||||||||||
(4) The acquired Promasys B.V. software code, customer list and URLs/website are not measured on a recurring basis since their initial fair value has been deemed to have a finite life and is being amortized periodically. Instead the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction. | |||||||||||||||||||||||||
A summary as of December 31, 2013 of the fair value of liabilities measured at fair value on a recurring basis follows: | |||||||||||||||||||||||||
Fair value at | Quoted prices in active markets for identical assets/ liabilities | Significant other observable inputs | Significant unobservable inputs | ||||||||||||||||||||||
December 31, | |||||||||||||||||||||||||
2013 | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||||||||||
Derivatives: (1) (2) | |||||||||||||||||||||||||
Conversion feature liability | $ | 3,126,206 | $ | -0- | $ | -0- | $ | 3,126,206 | |||||||||||||||||
Warrant liability | 5,943,977 | -0- | -0- | 5,943,977 | |||||||||||||||||||||
Total of derivative liabilities | $ | 9,070,183 | $ | -0- | $ | -0- | $ | 9,070,183 | |||||||||||||||||
(1) The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2013 | |||||||||||||||||||||||||
(2) The fair value at the measurement date is equal to their carrying value on the balance sheet | |||||||||||||||||||||||||
Significant valuation assumptions of derivative instruments at December 31, 2013 | |||||||||||||||||||||||||
Risk free interest rate | 0.12% | to | 0.13% | ||||||||||||||||||||||
Dividend yield | 0.00% | ||||||||||||||||||||||||
Expected volatility | 166.70% | to | 217.10% | ||||||||||||||||||||||
Expected life (range in years) | |||||||||||||||||||||||||
Conversion feature liability | 1 | to | 2 | ||||||||||||||||||||||
Warrant liability | 1 | to | 2.25 | ||||||||||||||||||||||
A summary as of December 31, 2013 of the fair value of assets measured at fair value on a nonrecurring basis follows: | |||||||||||||||||||||||||
Carrying amount December 31, | Carrying amount December 31, | Quoted prices in active markets for identical assets/ liabilities | Significant other observable inputs | Significant unobservable inputs | |||||||||||||||||||||
2012 | 2013 | (Level 1) | (Level 2) | (Level 3) | |||||||||||||||||||||
Acquired assets (3) | |||||||||||||||||||||||||
Promasys B.V. customer lists (4) | $ | -0- | $ | 134,739 | $ | -0- | $ | -0- | $ | 136,253 | |||||||||||||||
Promasys B.V. software code (4) | -0- | 70,512 | -0- | -0- | 72,943 | ||||||||||||||||||||
Promasys B.V. URLs/website (4) | -0- | 64,991 | -0- | -0- | 68,814 | ||||||||||||||||||||
Total | $ | -0- | $ | 270,242 | $ | -0- | $ | -0- | $ | 278,010 | |||||||||||||||
(3) The fair value of the acquired assets was estimated using the Income Approach with a discounted cash flow valuation methodology applied. | |||||||||||||||||||||||||
(4) The acquired Promasys B.V. software code, customer list and URLs/website are not measured on a recurring basis since their initial fair value has been deemed to have a finite life and is being amortized periodically. Instead the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction. | |||||||||||||||||||||||||
The Company’s goodwill and other identifiable intangible assets with indefinite lives are measured at fair value on a nonrecurring basis using significant unobservable inputs (Level 3). | |||||||||||||||||||||||||
Goodwill and other identifiable intangible assets with indefinite lives are reviewed for impairment annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Long-lived assets and identifiable intangible assets are also reviewed for impairment whenever events or changes in circumstances indicate that amounts may not be recoverable. If the testing performed indicates that impairment has occurred, the Company will record a noncash impairment charge for the difference between the carrying amount of the goodwill or other intangible assets and the implied fair value of the goodwill or other intangible assets in the period the determination is made. | |||||||||||||||||||||||||
The table below presents the fair value of the Goodwill as of December 31, 2014 and December 31, 2013. | |||||||||||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||||
(Level 3) | |||||||||||||||||||||||||
Goodwill | $ | 596,620 | $ | 675,710 | |||||||||||||||||||||
Other identifiable intangible assets, which are subject to amortization, are being amortized using the straight-line method over their estimated useful lives ranging from 3 to 15 years. The Impairment or Disposal of Long-Lived Asset subsection of the Property, Plant and Equipment Topic of the FASB ASC, requires us to test the recoverability of long-lived assets, including identifiable intangible assets with definite lives, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In testing for potential impairment, if the carrying value of the asset group exceeds the expected undiscounted cash flows, we must then determine the amount by which the fair value of those assets exceeds the carrying value and determine the amount of impairment, if any. | |||||||||||||||||||||||||
Other income/(expense) | |||||||||||||||||||||||||
for the year ended | |||||||||||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||||
The net amount of gains/(losses) for the period included in earnings attributable to the unrealized gain/(loss) from changes in derivative liabilities at the reporting date | $ | 58,807 | $ | (95,121 | ) | ||||||||||||||||||||
Total unrealized gains/(losses) included in earnings | $ | 58,807 | $ | (95,121 | ) | ||||||||||||||||||||
The tables below set forth a summary of changes in fair value of the Company’s Level 3 financial liabilities at fair value for the years ended December 31, 2014 and December 31, 2013. The tables reflect gains and losses for all financial liabilities at fair value categorized as Level 3 as of December 31, 2014 and December 31, 2013. | |||||||||||||||||||||||||
Level 3 financial liabilities at fair value | |||||||||||||||||||||||||
Net unrealized | |||||||||||||||||||||||||
gains/(losses) | Net | ||||||||||||||||||||||||
relating to | purchases, | ||||||||||||||||||||||||
Balance, | instruments still | issuances | Net transfers | Balance, | |||||||||||||||||||||
beginning | Net realized | held at the | and | in and/or out | end of | ||||||||||||||||||||
of year | gains/(losses) | reporting date | settlements | of Level 3 | year | ||||||||||||||||||||
Year ended December 31, 2014 | |||||||||||||||||||||||||
Derivatives: | |||||||||||||||||||||||||
Conversion feature liability | $ | (3,126,206 | ) | $ | -0- | $ | 181,804 | $ | -0- | $ | -0- | $ | (2,944,402 | ) | |||||||||||
Warrant liability | (5,943,977 | ) | -0- | (122,997 | ) | (628,086 | ) | -0- | (6,695,060 | ) | |||||||||||||||
Total of derivative liabilities | $ | (9,070,183 | ) | $ | -0- | $ | 58,807 | $ | (628,086 | ) | $ | -0- | $ | (9,639,462 | ) | ||||||||||
Level 3 financial liabilities at fair value | |||||||||||||||||||||||||
Net unrealized | |||||||||||||||||||||||||
gains/(losses) | Net | ||||||||||||||||||||||||
relating to | purchases, | ||||||||||||||||||||||||
Balance, | instruments still | issuances | Net transfers | Balance, | |||||||||||||||||||||
beginning | Net realized | held at the | and | in and/or out | end of | ||||||||||||||||||||
of year | gains/(losses) | reporting date | settlements | of Level 3 | year | ||||||||||||||||||||
Year ended December 31, 2013 | |||||||||||||||||||||||||
Derivatives: | |||||||||||||||||||||||||
Conversion feature liability | $ | (2,287,323 | ) | $ | -0- | $ | (838,883 | ) | $ | -0- | $ | -0- | $ | (3,126,206 | ) | ||||||||||
Warrant liability | (6,287,598 | ) | -0- | 743,762 | (400,141 | ) | -0- | (5,943,977 | ) | ||||||||||||||||
Total of derivative liabilities | $ | (8,574,921 | ) | $ | -0- | $ | (95,121 | ) | $ | (400,141 | ) | $ | -0- | $ | (9,070,183 | ) | |||||||||
Note_12_Commitments_and_Contin
Note 12 - Commitments and Contingencies | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
Commitments and Contingencies Disclosure [Abstract] | |||||
Commitments and Contingencies Disclosure [Text Block] | NOTE 12: | COMMITMENTS AND CONTINGENCIES | |||
The Company currently leases office space under operating leases for its office locations and has several operating leases related to server and network co-location and disaster recovery for its operations. The minimum future lease payments required under the Company’s operating leases at December 31, 2014 are as follows: | |||||
2015 | $ | 654,134 | |||
2016 | 367,327 | ||||
2017 | 50,266 | ||||
2018 | 5,165 | ||||
Total | $ | 1,076,892 | |||
In addition to annual base rental payments, the Company pays for the operating expenses associated with its leased office space and is responsible for any escalation in operating expenses as determined in the leases. Rent expense was $889,880 and $894,121 for the years ended December 31, 2014 and December 31, 2013, respectively. | |||||
The Company’s corporate office lease expires in September 2016. The Company’s lease on its New Jersey field office expires in February 2016. The Company currently operates its wholly-owned subsidiary, OmniComm Ltd., in the United Kingdom under the terms of a lease that expires in September 2016. The Company currently operates its wholly-owned subsidiary, OmniComm Europe, GmbH, in Germany under the terms of a lease that expires in July 2015. The Company currently operates its wholly-owned subsidiary, Promasys B.V., in the Netherlands under the terms of a lease that expires in October 2018. | |||||
LEGAL PROCEEDINGS | |||||
From time to time the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of December 31, 2014, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of our operations. | |||||
PATENT LITIGATION SETTLEMENT | |||||
On April 9, 2009, we entered into a Settlement and License Agreement with DataSci, LLC (“DataSci”) which relates to a lawsuit filed on September 18, 2008 in the United States District Court for the District of Maryland by DataSci against OmniComm alleging infringement of a U.S. Patent No. 6,496,827 B2 entitled “Methods and Apparatus for the Centralized Collection and Validation of Geographically Distributed Clinical Study Data with Verification of Input Data to the Distributed System” (“Licensed Patent”) claimed to be owned by DataSci. Pursuant to the agreement, the parties entered into a Stipulated Order of Dismissal of the lawsuit filed by DataSci and DataSci granted us a worldwide, non-exclusive non-transferable right and license under the Licensed Patent, the subject of the claim, and the right to sublicense TrialMaster on a Technology Transfer and Technology Transition basis. The license expressly excludes the right to make, use, sell, import, market, distribute, oversee the operation of, or service systems covered by, a claim (if any) of the Licensed Patent to the extent such systems are used for creating and managing source documentation and conducting remote data validation in clinical trial studies using a tablet PC with stylus, touch screen device, digitizing tablet, digitizer pen, or similar mobile processing device (“Digitizing Device”), wherein the source documentation is electronic and is completed using a Digitizing Device. Under the terms of the license, we are obligated to pay royalties quarterly for sales of Licensed Products, as defined therein, from January 1, 2009 until the expiration of the Licensed Patent equal to two percent (2%) of OmniComm’s annual Gross Revenues or, alternatively, the annual minimum royalty payment(s), whichever is greater. The remaining minimum royalty payments per year are as follows: | |||||
2015 | $ | 450,000 | |||
2016 | 450,000 | ||||
2017 | 450,000 | ||||
Total | $ | 1,350,000 | |||
In conjunction with the acquisition of the eResearch Technology, Inc. EDC assets, the Company entered into the First Amendment to Settlement and Licensing Agreement with DataSci, LLC in June 2009 to provide for license payments totaling $300,000 to DataSci over the next three years for the EDC assets acquired in that transaction. The Company has, to-date, made payments totaling $200,000. | |||||
During the years ended December 31, 2014 and December 31, 2013, respectively, the Company recorded a charge to earnings of $156,701 and $189,408 respectively, which amounts represent (1) the amount of additional license expense incurred above the stipulated minimum in the DataSci License Agreement during the years ended December 31, 2014 and December 31, 2013 and (2) the accretion of the difference between the total stipulated annual minimum royalty payments and the recorded present value accrual of the annual minimum royalty payments. | |||||
EMPLOYMENT AGREEMENTS | |||||
In December 2014, we renewed an employment agreement with Mr. Cornelis F. Wit to serve as our Chief Executive Officer through December 31, 2015. As part of the renewal the employment agreement will renew for successive one-year terms unless the employment agreement is expressly cancelled by either Mr. Wit or the Company ninety days prior to the end of the term. Mr. Wit receives an annual salary of $196,000 payable in cash and/or stock. In the event that we consummate a transaction with a third party resulting in the sale, merger, consolidation, reorganization or other business combination involving all or a majority of our business, assets or stock, whether effected in one transaction or a series of transactions due to the initiative of Mr. Wit (whether or not during the term of the agreement), Mr. Wit will receive a fee equal to 2% of the aggregate consideration. The agreement also provides, among other things, for participation in employee benefits available to employees and executives. Under the terms of the agreement, we may terminate Mr. Wit’s employment upon 30 days notice of a material breach and Mr. Wit may terminate the agreement under the same terms and conditions. The employment agreement contains non-disclosure provisions, as well as a one year non-compete clause if Mr. Wit leaves the company voluntarily or a six month non-compete clause following his termination by the Company. | |||||
In December 2014, we renewed our employment agreement with Mr. Randall Smith to serve as our Chief Technology Officer. As part of the renewal the employment agreement will renew for successive one-year terms unless the employment agreement is expressly cancelled by either Mr. Smith or the Company ninety days prior to the end of the term. Under the terms of the agreement, as compensation for his services, Mr. Smith receives an annual salary of $310,500 to be paid in the form of cash and/or stock, as agreed upon by the parties. The agreement also provides, among other things, for participation in employee benefit plans or programs applicable to employees and executives. Under the terms of the agreement, we may terminate the employment of Mr. Smith upon 30 days notice of a material breach and Mr. Smith may terminate the agreement under the same terms and conditions. If Mr. Smith is terminated by us for any reason other than for cause, we must pay him severance benefits equal to six month’s salary. The employment agreement contains non-disclosure provisions, as well as a one year non-competition restriction following the termination of the agreement. | |||||
In September 2014, we renewed our employment agreement with Mr. Stephen Johnson to serve as our President and Chief Operating Officer. As part of the renewal the employment agreement will renew for successive one-year terms unless the employment agreement is expressly cancelled by either Mr. Johnson or the Company ninety days prior to the end of the term. Under the terms of this agreement, Mr. Johnson receives an annual salary of $310,500. The agreement also provides, among other things, for participation in employee benefit plans or programs applicable to employees and executives. Under the terms of the agreement, we may terminate the employment of Mr. Johnson upon 30 days notice of a material breach and Mr. Johnson may terminate the agreement under the same terms and conditions. If Mr. Johnson is terminated by us for any reason other than for cause, we must pay him severance benefits equal to three month’s salary for every year of service up to a maximum of twelve months salary. The employment agreement contains non-disclosure provisions as well as a one year non-compete clause if Mr. Johnson leaves the company voluntarily or a six month non-compete clause following his termination by the Company. |
Note_13_Related_Party_Transact
Note 13 - Related Party Transactions | 12 Months Ended | |||
Dec. 31, 2014 | ||||
Related Party Transactions [Abstract] | ||||
Related Party Transactions Disclosure [Text Block] | NOTE 13: | RELATED PARTY TRANSACTIONS | ||
On February 1, 2013, the Company and our Chairman and Chief Technology Officer, Randall Smith, extended the maturity date of $20,000 promissory note until January 1, 2016. The promissory note bears interest at 12% per annum. | ||||
On February 22, 2013, the Company and our Director, Guus van Kesteren, extended the maturity date of $150,000 of convertible debentures to January 1, 2015. The debentures bear interest at 10% per annum and were originally issued in August 2008. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015. On April 21, 2014, the Company and Mr. van Kesteren extended the maturity date of his $150,000 of convertible debentures to April 1, 2016. The expiration date of the warrants associated with the debentures was also extended to April 1, 2016. On July 31, 2014 Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of $150,000 was reclassified from Related Party to Non-Related Party. | ||||
On February 22, 2013, the Company and our Chief Operating Officer and President, Stephen Johnson, extended the maturity date of $25,000 of convertible debentures to January 1, 2016. The debentures bear interest at 12% per annum. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. The convertible debentures were originally issued in December 2008. | ||||
On February 22, 2013, the Company and our Chairman and Chief Technology Officer, Randall Smith, extended the maturity date of $5,000 of convertible debentures to January 1, 2016. The debentures bear interest at 12% per annum. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. The convertible debentures were originally issued in December 2008. | ||||
On December 5, 2013, the Company and our Director Guus van Kesteren, extended the maturity date of $160,000 of convertible debentures to January 1, 2016. The debentures bear interest at 12% per annum. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. The convertible debentures were originally issued in December 2008. On July 31, 2014 Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of $160,000 was reclassified from Related Party to Non-Related Party. | ||||
As of December 31, 2014, we have an aggregate of $15,034,000 principal amount of convertible debentures and promissory notes outstanding to Cornelis F. Wit, our Chief Executive Officer and Director, and have issued certain warrants to Mr. Wit, as follows: | ||||
● | In June 2008, Mr. Wit invested $510,000 in convertible notes. On August 29, 2008, Mr. Wit converted the $510,000 and invested an additional $1,260,000 in a private placement of convertible debentures and warrants to purchase 3,540,000 shares of our common stock. The convertible debentures, which bear interest at 10% per annum, were due on August 29, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, the Company and Mr. Wit extended the $1,770,000 of convertible debentures until August 29, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. On February 22, 2013, the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | |||
● | In February 2008, Mr. Wit invested $150,000 in promissory notes and from September 2008 to December 2008, Mr. Wit invested $4,200,000 in convertible notes. On December 16, 2008, Mr. Wit converted the $4,350,000 into a private placement of convertible debentures and warrants to purchase 8,700,000 shares of our common stock. The convertible debentures, which bear interest at 12% per annum, were due on December 16, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, the Company and Mr. Wit extended the $4,350,000 of convertible debentures until December 16, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. In a private transaction on October 16, 2012, Mr. Wit purchased $125,000 of the December 2008 convertible debentures and the related 250,000 warrants from Mr. Ronald Linares, the Company’s former Chief Financial Officer. On February 22, 2013, the Company and Mr. Wit extended the maturity date of the $4,475,000 of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $4,475,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | |||
● | From July 2009 to September 2009, Mr. Wit invested $1,100,000 which amount was aggregated under the terms of one convertible note dated September 30, 2009. On September 30, 2009, Mr. Wit agreed to convert this convertible note into a private placement of secured convertible debentures bearing interest at a rate of 12% per annum with a maturity date of March 30, 2011. The convertible debentures were convertible into 4,400,000 shares of common stock and Mr. Wit received 4,400,000 warrants to purchase common stock of the Company at a price of $0.25. On March 30, 2011, the Company and Mr. Wit extended the maturity date of his convertible note until April 1, 2013 in accordance with the terms of Amendment Number One To Securities Purchase Agreement. The Company also extended the expiration date of the 4,400,000 warrants issued with convertible note by two years to September 30, 2015. On February 22, 2013, the Company and Mr. Wit extended the maturity date of his convertible debentures to January 1, 2016 in accordance with the terms of Amendment Number Two To Securities Purchase Agreement. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,100,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | |||
● | From October 2009 to December 2009, Mr. Wit invested $1,440,000, which amount was aggregated under the terms of one convertible note dated December 31, 2009. On December 31, 2009, Mr. Wit agreed to convert this Convertible Note into a private placement of unsecured convertible debentures bearing interest at a rate of 12% per annum, which Convertible Debentures were due on June 30, 2011. The Company and Mr. Wit extended the maturity date of his convertible note until October 1, 2013 in accordance with the terms of Amendment Number One To Securities Purchase Agreement. The Company also extended the expiration date of the 5,760,000 warrants issued with convertible note by two years to December 31, 2015. On February 22, 2013, the Company and Mr. Wit extended the maturity date of his convertible debentures to January 1, 2016 in accordance with the terms of Amendment Number Two To Securities Purchase Agreement. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,440,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | |||
● | On March 31, 2011, the Company issued a note payable in the principal amount of $2,866,879 and warrants to purchase 11,467,517 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of March 31, 2016 to Mr. Wit. The note accrues interest at a rate of 12% per annum and had a maturity date of April 1, 2014. The Promissory Note replaced the following Promissory Notes that had been previously issued: | |||
i. | Promissory Note issued on April 13, 2010 for $450,000 with a maturity date of December 31, 2011; | |||
ii. | Promissory Note issued on June 29, 2010 for $115,000 with a maturity date of December 31, 2011; | |||
iii. | Promissory Note issued on September 30, 2010 for $695,000 with a maturity date of December 31, 2011; | |||
iv. | Promissory Note issued on December 31, 2010 for $1,197,500 with a maturity date of December 31, 2011; and | |||
v. | Promissory Note issued on December 31, 2010 for $409,379 with a maturity date of April 01, 2012. | |||
On April 1, 2013, the Company and Mr. Wit extended the maturity date of the promissory note to March 31, 2016. In December 2014, the outstanding principal was reduced by $6,879. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $2,860,000 promissory note to April 1, 2017. The expiration date of the warrants associated with the $2,860,000 promissory note was also extended to April 1, 2017 | ||||
● | On December 31, 2011, the Company issued a promissory note in the principal amount of $1,600,000 and warrants to purchase 6,400,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of December 31, 2015 to Mr. Wit. The note carries an interest rate of 12% per annum and is due on January 1, 2015. On April 4, 2014, the Company and Mr. Wit extended the maturity date of the promissory note until April 1, 2017. The expiration date of the warrants associated with the promissory note was also extended to April 1, 2017. The promissory note consolidates the amounts owed as detailed below: | |||
i. | Promissory Note issued on May 13, 2011 for $96,000 with a maturity date of January 01, 2013; | |||
ii. | Promissory Note issued on September 30, 2011 for $342,000 with a maturity date of April 01, 2014; | |||
iii. | Promissory Note issued on October 05, 2011 for $130,000 with a maturity date of April 01, 2014; | |||
iv. | Promissory Note issued on October 28, 2011 for $123,000 with a maturity date of April 01, 2014; | |||
v. | Promissory Note issued on October 31, 2011 for $82,000 with a maturity date of April 01, 2014; | |||
vi. | Promissory Note issued on November 23, 2011 for $60,000 with a maturity date of January 1, 2013; and | |||
vii. | Accrued and unpaid interest in the amount of $767,000. | |||
● | On January 1, 2013, the Company issued a promissory note in the principal amount of $529,000 and warrants to purchase 2,116,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of January 31, 2016 to Mr. Wit. The note carries an interest rate of 12% per annum and is due on January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the promissory note until April 1, 2017. The expiration date of the warrants associated with the promissory note was also extended to April 1, 2017. | |||
● | On January 1, 2014, the Company issued a promissory note in the principal amount of $980,000 and warrants to purchase 3,920,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2017 to Mr. Wit in exchange for accrued interest in the amount of $980,000. The note carries an interest rate of 12% per annum and is due on April 1, 2017. | |||
● | On December 23, 2014, the Company issued a promissory note in the principal amount of $280,000 to Mr. Wit. The note carries an interest rate of 12% per annum and is due on April 1, 2017. | |||
On March 18, 2013, the Company entered into a $2,000,000 revolving line of credit with The Northern Trust Company guaranteed by Cornelis F. Wit, our Chief Executive Officer and Director. On December 18, 2013 the Company renewed the Line of Credit and increased the available balance to $4,000,000. On February 3, 2015 the Company renewed the Line of Credit and increased the available balance to $5,000,000. Mr. Wit receives 2.0% interest on the assets pledged for the line for credit. The line of credit matures on February 2, 2018 and carries a variable interest rate based on the prime rate. At December 31, 2014, $4,000,000 was outstanding on the line of credit at an interest rate of 2.25%. | ||||
For the years December 31, 2014 and December 31, 2013 we incurred $2,389,786 and $2,339,702, respectively, in interest expense payable to related parties. |
Note_14_Stockholders_Deficit
Note 14 - Stockholders' (Deficit) | 12 Months Ended | ||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | |||||||||||||||||||||||
Stockholders' Equity Note Disclosure [Text Block] | NOTE 14: | STOCKHOLDERS’ (DEFICIT) | |||||||||||||||||||||
Our authorized capital stock consists of 250,000,000 shares of common stock, $.001 par value per share, and 10,000,000 shares of preferred stock, par value $.001 per share, of which 5,000,000 shares have been designated as 5% Series A Preferred, 230,000 shares have been designated as Series B Preferred Stock, 747,500 shares have been designated as Series C Preferred Stock and 250,000 shares have been designated as Series D Preferred Stock. | |||||||||||||||||||||||
As of December 31, 2014 we had the following outstanding securities: | |||||||||||||||||||||||
o | 91,561,802 shares of common stock issued and outstanding; | ||||||||||||||||||||||
o | 48,463,517 warrants issued and outstanding to purchase shares of our common stock; | ||||||||||||||||||||||
o | 4,125,224 shares of our Series A Preferred Stock issued and outstanding, | ||||||||||||||||||||||
o | -0- shares of our Series B Preferred Stock issued and outstanding; | ||||||||||||||||||||||
o | -0- shares of our Series C Preferred Stock issued and outstanding; | ||||||||||||||||||||||
o | 250,000 Series D Preferred Stock issued and outstanding; and | ||||||||||||||||||||||
o | $9,665,000 principal amount Convertible Debentures convertible into 24,620,000 shares of common stock. | ||||||||||||||||||||||
Common Stock | |||||||||||||||||||||||
Holders of common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of our voting securities do not have cumulative voting rights. Holders of common stock are entitled to share in all dividends that the Board of Directors, in its discretion, declares from legally available funds. In the event of our liquidation, dissolution or winding up, subject to the preferences of the Series A Preferred Stockholders, each outstanding share of common stock entitles its holder to participate in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. | |||||||||||||||||||||||
Holders of common stock have no conversion, preemptive or other subscription rights, and there are no redemption provisions for the common stock. The rights of the holders of common stock are subject to any rights that may be fixed for holders of preferred stock, when and if any preferred stock is outstanding. All outstanding shares of common stock are duly authorized, validly issued, fully paid and non-assessable. | |||||||||||||||||||||||
During 2014, we issued 1,400,000 restricted shares of our common stock to our senior management team and our Board of Directors. The restrictions on the shares lapse ratably over a 3 year period. In 2014 we recognized $33,055 in compensation expense related to the share issuance. | |||||||||||||||||||||||
In October 2014 a former director exercised options granted to the director during his term of service. As a result of the exercise, 57,143 common shares were issued to the individual. | |||||||||||||||||||||||
During 2013, we issued 1,225,000 restricted shares of our common stock to our senior management team and our Board of Directors. The restrictions on the shares lapse ratably over a 3 year period. In 2014 we recognized $74,167 and in 2013 we recognized $53,125 in compensation expense related to the share issuance. | |||||||||||||||||||||||
In June 2013 a former employee exercised options granted to the employee during their employment. As a result of the exercise, 11,000 common shares were issued to the individual. | |||||||||||||||||||||||
In November 2013, we issued 2,270,000 shares of our common in relation to our acquisition of Promasys B. V. We issued the shares to the Promasys B.V. shareholders who were all non US-persons/ non US-entities and the issuance of the shares to them occurred in an offshore transaction. The issuance of the 2,270,000 shares of common stock to the 3 shareholders of Promasys B.V pursuant to the share exchange agreement was exempt from registration under the Securities Act of 1933, as amended, pursuant to Regulation S thereof. (See Note 8) | |||||||||||||||||||||||
Preferred stock | |||||||||||||||||||||||
Our Board of Directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. In addition, the Board of Directors may fix and determine all privileges and rights of the authorized preferred stock series including: | |||||||||||||||||||||||
o | dividend and liquidation preferences, | ||||||||||||||||||||||
o | voting rights, | ||||||||||||||||||||||
o | conversion privileges, and | ||||||||||||||||||||||
o | redemption terms. | ||||||||||||||||||||||
Our Board of Directors may authorize the issuance of preferred stock which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our Board of Directors can fix limitations and restrictions, if any, upon the payment of dividends on our common stock to be effective while any shares of preferred stock are outstanding. | |||||||||||||||||||||||
The following table presents the cumulative arrearage of undeclared dividends by class of preferred stock as of December 31, 2014 and December 31, 2013, respectively, and the per share amount by class of preferred stock. | |||||||||||||||||||||||
Cumulative arrearage as of | Cumulative arrearage per share | ||||||||||||||||||||||
December 31, | as of December 31, | ||||||||||||||||||||||
Series of preferred stock | 2014 | 2013 | 2014 | 2013 | |||||||||||||||||||
Series A | $ | 2,586,700 | $ | 2,380,439 | $ | 0.63 | $ | 0.58 | |||||||||||||||
Series B | 609,887 | 609,887 | $ | 3.05 | $ | 3.05 | |||||||||||||||||
Series C | 1,472,093 | 1,472,093 | $ | 4.37 | $ | 4.37 | |||||||||||||||||
Total preferred stock arrearage | $ | 4,668,680 | $ | 4,462,419 | |||||||||||||||||||
Series A Preferred Stock | |||||||||||||||||||||||
In 1999, our Board of Directors designated 5,000,000 shares of our preferred stock as 5% Series A Convertible Preferred Stock (“Series A Preferred Stock”), of which 4,125,224 shares are issued and outstanding. | |||||||||||||||||||||||
The designations, rights and preferences of the Series A Preferred include: | |||||||||||||||||||||||
o | the shares are not redeemable, | ||||||||||||||||||||||
o | each share of Series A Preferred Stock is convertible into shares of our common stock at any time at the option of the holder at a conversion price of $1.50 per share, or if not so converted after one year from issuance, at any time at our option if the closing bid price of our common stock has exceeded $3.00 for 20 consecutive trading days, our common stock is listed on The NASDAQ Stock Market or other national stock exchange, and the shares of common stock issuable upon conversion of the Series A Preferred Stock are registered under a registration statement, | ||||||||||||||||||||||
o | the conversion price has certain anti-dilution protections for any stock splits, stock dividends, and corporate reorganizations, and certain other corporate transactions and issuances of securities at below the applicable conversion price per share. The Series A Preferred Stockholders have waived their rights to an anti-dilution adjustment reducing their conversion price as a result of the issuance of the Series B Preferred Stock and Series C Preferred Stock, | ||||||||||||||||||||||
o | the shares of Series A Preferred Stock pay a cumulative dividend at a rate of 5% per annum based on the stated value of $1.00 per share, payable when and as declared by the Board of Directors, or upon conversion or liquidation. Dividends on the Series A Preferred Stock have priority to our common stock and are junior to Series B Preferred Stock and Series C Preferred Stock. At our option, dividends can be paid in cash or shares of common stock valued at the conversion price of the Series A Preferred Stock, | ||||||||||||||||||||||
o | in the event of our liquidation or winding up, each share of Series A Preferred Stock has a liquidation preference equal to $1.00 per share, and | ||||||||||||||||||||||
o | the holders of the Series A Preferred Stock are entitled to vote together with the holders of our common stock, on the basis of one vote for each share of common stock issuable upon the conversion of the Series A Preferred Stock. | ||||||||||||||||||||||
There were cumulative arrearages of $2,586,700 and $2,380,439, or $0.63 and $0.58 per share, on the Series A Preferred Stock for undeclared dividends as of December 31, 2014 and December 31, 2013 respectively. | |||||||||||||||||||||||
The Company has 235,000 shares of its 5% Series A Preferred stock that have been converted by the shareholders into shares of our common stock. Pursuant to Delaware General Corporate Law, once the Company has a positive net worth, the cumulative dividends would be payable in either cash or in shares of our common stock upon the declaration of dividends by our board of directors. | |||||||||||||||||||||||
In addition, the holders of the Series A Preferred Stock were granted certain demand and piggy-back registration rights for the shares of our common stock issuable upon the conversion of the Series A Preferred Stock. | |||||||||||||||||||||||
Series B Preferred Stock | |||||||||||||||||||||||
In August 2001, our Board of Directors designated 200,000 shares of our preferred stock as Series B Convertible Preferred Stock (“Series B Preferred Stock”). A Corrected Certificate of Designations was filed on February 7, 2002 with the Delaware Secretary of State increasing the number of shares authorized as Series B Preferred Stock to 230,000 shares, of which -0- shares are issued and outstanding. | |||||||||||||||||||||||
The designations, rights and preferences of the Series B Preferred Stock include: | |||||||||||||||||||||||
o | the stated value of each share is $10.00 per share, | ||||||||||||||||||||||
o | the shares are not redeemable, | ||||||||||||||||||||||
o | each share of Series B Preferred Stock is convertible into shares of our common stock at the option of the holder at any time commencing January 31, 2002 at the option of the holder at $0.25 per share, as adjusted, and the shares automatically convert, subject to limitations based on trading volume, into shares of our common stock at $0.25 per share at such time as we complete a public offering raising proceeds in excess of $25 million at an offering price of at least $0.75 per share. We may require all outstanding shares of the Series B Preferred Stock to convert in the event the closing bid price of our common stock exceeds $0.50 for 20 consecutive trading days, and our common stock has been listed on The NASDAQ Stock Market or other comparable national stock exchange or the OTC Bulletin board and a registration statement registering the shares of common stock issuable upon conversion of the Series B Preferred Stock has been declared effective, | ||||||||||||||||||||||
o | the conversion price has certain anti-dilution protections for any stock splits, stock dividends, and corporate reorganizations, and certain other corporate transactions and issuances of securities at below the applicable conversion price per share or market value of the common stock, | ||||||||||||||||||||||
o | the shares of Series B Preferred Stock pay a cumulative dividend at a rate of 8% per annum based on the stated value of $10.00 per share, payable when and as declared by the Board of Directors, or upon conversion or liquidation. At our option, dividends can be paid in cash or shares of common stock valued at the conversion price of the Series B Preferred Stock, | ||||||||||||||||||||||
o | each share of Series B Preferred Stock will rank senior to our Series A Preferred and pari passu with our Series C Preferred Stock, | ||||||||||||||||||||||
o | in the event of our liquidation or winding up, each share of Series B Preferred Stock has a liquidation preference equal to $10.00 per share plus accrued and unpaid dividends, and | ||||||||||||||||||||||
o | the holders of the Series B Preferred Stock are entitled to vote, together with the holders of our common stock, on the basis of one vote for each share of common stock issuable upon the conversion of the Series B Preferred Stock, | ||||||||||||||||||||||
There were cumulative arrearages of $609,887 and $609,887, or $3.05 and $3.05 per share, on the Series B Preferred Stock dividends as of December 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||||||||
The Company has 200,000 shares of its Series B Preferred stock that have been converted by the shareholders into shares of our common stock. Pursuant to Delaware General Corporate Law, once the Company has a positive net worth, the cumulative dividends would be payable in either cash or in shares of our common stock upon the declaration of dividends by our board of directors. | |||||||||||||||||||||||
In addition, the holders of the Series B Preferred Stock were granted certain mandatory and piggy-back registration rights for the shares of our common stock issuable upon the conversion of the Series B Preferred Stock and are entitled to vote one member to our Board of Directors. | |||||||||||||||||||||||
Series C Preferred Stock | |||||||||||||||||||||||
In March 2002, our Board of Directors designated 747,500 shares of our preferred stock as Series C Convertible Preferred Stock of which -0- shares are issued and outstanding. | |||||||||||||||||||||||
The designations, rights and preferences of the Series C Preferred Stock include: | |||||||||||||||||||||||
o | the stated value of each share is $10.00 per share, | ||||||||||||||||||||||
o | the shares are not redeemable, | ||||||||||||||||||||||
o | each share of Series C Preferred Stock is convertible at any time, at the option of the holder, into a number of shares of common stock determined by dividing the stated value per share of the Series C Preferred Stock by $0.25, which is the Series C Conversion Price. The Series C Preferred Stock will automatically convert, subject to limitations based on trading volume, into shares of our common stock upon a public offering of our securities raising gross proceeds in excess of $25,000,000 at a per share price greater than 2.5 times the Series C Conversion Price per share, as adjusted for any stock split, stock dividend, recapitalization, or other similar transaction. In addition, the Series C Preferred Stock will automatically convert into shares of our common stock at the Series C Conversion Price at such time as the closing bid price for our common stock has traded at two times the then prevailing Series C Conversion Price for a period of 20 consecutive trading days, provided that (i) a public trading market exists for our common stock on a national securities exchange, the NASDAQ Stock Market, or the over the counter market; and (ii) the Conversion Shares have been registered for resale and are not subject to any lock-up and the number of shares of the Series C Preferred Stock which can be converted in any 30-day period will be limited to the number of shares of common stock underlying the Series C Preferred Stock equal to 10 times the average daily trading volume during the 20-day look-back period set forth above, | ||||||||||||||||||||||
o | the conversion price has certain anti-dilution protections for any stock splits, stock dividends, and corporate reorganizations, and certain other corporate transactions and issuances of securities at below the applicable conversion price per share or market value of the common stock, | ||||||||||||||||||||||
o | the shares of Series C Preferred Stock pay a cumulative dividend at a rate of 8% per annum based on the stated value of $10.00 per share, payable when and as declared by the Board of Directors, or upon conversion or liquidation. At our option, dividends can be paid in cash or shares of common stock valued at the conversion price of the Series C Preferred Stock, | ||||||||||||||||||||||
o | each share of Series C Preferred Stock will rank pari passu with our Series B Preferred Stock and senior to our Series A Preferred Stock, | ||||||||||||||||||||||
o | in the event of our liquidation or winding up, each share of Series C Preferred Stock has a liquidation preference equal to $10.00 per share plus accrued and unpaid dividends, and | ||||||||||||||||||||||
o | the holders of the Series C Preferred Stock are entitled to vote, together with the holders of our common stock, on the basis of one vote for each share of common stock issuable upon the conversion of the Series C Preferred Stock. | ||||||||||||||||||||||
There were cumulative arrearages of $1,472,093 and $1,472,093, or $4.37 and $4.37 per share, on the Series C Preferred Stock for undeclared dividends as of December 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||||||||
The Company has 337,150 shares of its Series C Preferred stock that have been converted by the shareholders into shares of our common stock. Pursuant to Delaware General Corporate Law, once the Company has a positive net worth, the cumulative dividends would be payable in either cash or in shares of our common stock upon the declaration of dividends by our board of directors. | |||||||||||||||||||||||
In addition, the holders of the Series C Preferred Stock were granted certain mandatory and piggy-back registration rights covering the shares of our common stock issuable upon the conversion of the Series C Preferred Stock and are entitled to vote two members to our Board of Directors. | |||||||||||||||||||||||
Series D Preferred Stock | |||||||||||||||||||||||
In November 2010, our Board of Directors designated 250,000 shares of our preferred stock as Series D Convertible Preferred Stock of which 250,000 shares are issued and outstanding. | |||||||||||||||||||||||
The designations, rights and preferences of the Series D Preferred Stock include: | |||||||||||||||||||||||
o | the stated value of the Series D Preferred is $0.001 per share, | ||||||||||||||||||||||
o | the Series D Preferred has no rights to receive dividend distributions or to participate in any dividends declared by the Corporation to or for the benefit of the holders of its common stock, | ||||||||||||||||||||||
o | the shares of Series D Preferred are not convertible into or exchangeable for any other security of the Corporation, | ||||||||||||||||||||||
o | except as provided in Series D Preferred Designation, in the case of the death or disability of Series D Preferred holder, the Series D Preferred is not redeemable without the prior express written consent of the holders of the majority of the voting power of all then outstanding shares of such Series D Preferred. In the event any shares of Series D Preferred are redeemed pursuant, the shares redeemed will automatically be canceled and returned to the status of authorized but unissued shares of preferred stock, | ||||||||||||||||||||||
o | each share of Series D Preferred entitles the holder to Four Hundred (400) votes. With respect to such vote, the holder is entitled to notice of any stockholders' meeting in accordance with the bylaws of the Company, and is entitled to vote, together as a single class with holders of common stock and any other series of preferred stock then outstanding, with respect to any question or matter upon which holders of common stock have the right to vote. The Series D Preferred will also entitle the holders to vote the shares as a separate class as set forth herein and as required by law. In the event of any stock split, stock dividend or reclassification of the Corporation's common stock, the number of votes which attach to each share of Series D Preferred shall be adjusted in the same proportion as any adjustment to the number of outstanding shares of common stock. The shares of Series D Preferred present at a meeting of the Company’s shareholders shall vote in the same percentage as all voting shares voted for each director at the Company’s shareholder meeting in connection with the election or removal of directors to or from the Corporation’s Board of Directors, | ||||||||||||||||||||||
o | in the event of the liquidation, dissolution or winding up of the affairs of the Corporation, whether voluntary or involuntary, the holders of shares of the Series D Preferred then outstanding are entitled to receive before holders of shares of common stock receive any amounts, out of the remaining assets of the Corporation available for distribution to its stockholders, an amount equal to $0.001 per share, | ||||||||||||||||||||||
o | so long as any shares of Series D Preferred are outstanding, the Company cannot without first obtaining the written approval of the holders of at least a majority of the voting power of the then outstanding shares of such Series D Preferred Stock (i) alter or change the rights, preferences or privileges of the Series D Preferred, or (ii) increase or decrease the total number of authorized shares of Series D Preferred Stock, | ||||||||||||||||||||||
o | the holders of the Series D Preferred are not entitled to rights to subscribe for, purchase or receive any part of any new or additional shares of any class, whether now or hereinafter authorized, or of bonds or debentures, or other evidences of indebtedness convertible into or exchangeable for shares of any class, | ||||||||||||||||||||||
o | the Company has a thirty (30) day “right of first refusal” in which to match the terms and conditions set forth in any bona fide offer received by holders of the Series D Preferred Stock. The Company must purchase all of those shares of Series D Preferred offered by the holder of the Series D Preferred Stock, and | ||||||||||||||||||||||
o | the holders of Series D Preferred cannot, directly or indirectly, transfer any shares of Series D Preferred. Any such purported transfer shall be of no force or effect and shall not be recognized by the Company. | ||||||||||||||||||||||
The following table presents preferred dividends accreted for the years ended December 31, 2014 and December 31, 2013, respectively, and the per share effect of the preferred dividends if their effect was not anti-dilutive. | |||||||||||||||||||||||
Dividends accreted | Dividends per share | ||||||||||||||||||||||
year ended December 31, | year ended December 31, | ||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||
Preferred stock dividends in arrears Series A | $ | 206,261 | $ | 206,261 | $ | 0.05 | $ | 0.05 | |||||||||||||||
Preferred stock dividends in arrears Series B | $ | -0- | $ | -0- | $ | -0- | $ | -0- | |||||||||||||||
Preferred stock dividends in arrears Series C | $ | -0- | $ | -0- | $ | -0- | $ | -0- | |||||||||||||||
Warrants Issued for Services and in Capital Transactions | |||||||||||||||||||||||
The following tables summarize all warrants issued to consultants and warrants issued as part of convertible debt transactions for the year ended December 31, 2014 and December 31, 2013, and the related changes during these years. | |||||||||||||||||||||||
December 31, 2014 warrants outstanding | December 31, 2014 warrants exercisable | ||||||||||||||||||||||
Range of exercise price | Number outstanding at | Weighted average | Weighted average | Number exercisable at | Weighted average | ||||||||||||||||||
31-Dec-14 | remaining contractual life | exercise price | 31-Dec-14 | exercise price | |||||||||||||||||||
$0.25 | – | $0.60 | 48,463,517 | 1.17 | $ | 0.35 | 48,463,517 | $ | 0.35 | ||||||||||||||
December 31, 2013 warrants outstanding | December 31, 2013 warrants exercisable | ||||||||||||||||||||||
Range of exercise price | Number outstanding at | Weighted average | Weighted average | Number exercisable at | Weighted average | ||||||||||||||||||
31-Dec-13 | remaining contractual life | exercise price | 31-Dec-13 | exercise price | |||||||||||||||||||
$0.25 | – | $0.60 | 44,728,873 | 2.05 | $ | 0.36 | 44,728,873 | $ | 0.36 | ||||||||||||||
Warrants | |||||||||||||||||||||||
Balance at December 31, 2012 | 43,412,873 | ||||||||||||||||||||||
Issued | 2,116,000 | ||||||||||||||||||||||
Exercised | -0- | ||||||||||||||||||||||
Expired/forfeited | (800,000 | ) | |||||||||||||||||||||
Balance at December 31, 2013 | 44,728,873 | ||||||||||||||||||||||
Issued | 3,920,000 | ||||||||||||||||||||||
Exercised | -0- | ||||||||||||||||||||||
Expired/forfeited | (185,356 | ) | |||||||||||||||||||||
Balance at December 31, 2014 | 48,463,517 | ||||||||||||||||||||||
Warrants exercisable at December 31, 2014 | 48,463,517 | ||||||||||||||||||||||
Weighted average fair value of warrants granted during 2013 | $ | 0.19 | |||||||||||||||||||||
Weighted average fair value of warrants granted during 2014 | $ | 0.15 | |||||||||||||||||||||
Other Comprehensive (Loss) | |||||||||||||||||||||||
Due to the availability of net operating losses and related deferred tax valuations, there is no tax effect associated with any component of other comprehensive (loss). The following table lists the beginning balance, yearly activity and ending balance of the components of accumulated other comprehensive (loss). | |||||||||||||||||||||||
Foreign currency translation | Accumulated other comprehensive (loss) | ||||||||||||||||||||||
Balance at December 31, 2012 | $ | (69,092 | ) | $ | (69,092 | ) | |||||||||||||||||
2013 Activity | (18,512 | ) | (18,512 | ) | |||||||||||||||||||
Balance at December 31, 2013 | (87,604 | ) | (87,604 | ) | |||||||||||||||||||
2014 Activity | (156,223 | ) | (156,223 | ) | |||||||||||||||||||
Balance at December 31, 2014 | $ | (243,827 | ) | $ | (243,827 | ) | |||||||||||||||||
Note_15_Employee_Equity_Incent
Note 15 - Employee Equity Incentive Plans | 12 Months Ended | |||||||||||||||||||||||||||
Dec. 31, 2014 | ||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | NOTE 15: | EMPLOYEE EQUITY INCENTIVE PLANS | ||||||||||||||||||||||||||
Stock Option Plan | ||||||||||||||||||||||||||||
Description of 2009 Equity Incentive Plan | ||||||||||||||||||||||||||||
In 2009, the Company’s Board of Directors and shareholders approved the 2009 Equity Incentive Plan of OmniComm Systems, Inc. (the “2009 Plan”). The 2009 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. Pursuant to the 2009 Plan, 7,500,000 shares of the Company’s common stock are authorized for issuance. | ||||||||||||||||||||||||||||
The maximum term for any option grant under the 2009 Plan is ten years from the date of the grant; however, options granted under the 2009 Plan will generally expire five years from the date of grant for most employees, officers and directors of the Company. Options granted to employees generally vest either upon grant or in two installments. The first vesting, which is equal to 50% of the granted stock options, occurs upon completion of one full year of employment from the date of grant and the second vesting occurs on the second anniversary of the employee’s employment. The vesting period typically begins on the date of hire for new employees and on the date of grant for existing employees. | ||||||||||||||||||||||||||||
As of December 31, 2014, there were 2,680,000 outstanding options and 2,625,000 restricted stock shares that have been granted under the 2009 Plan. At December 31, 2014, there were 2,195,000 shares available for grant as options or other forms of share-based compensation under the 2009 Plan. | ||||||||||||||||||||||||||||
Description of 1998 Stock Incentive Plan | ||||||||||||||||||||||||||||
In 1998, the Company’s Board of Directors and shareholders approved the 1998 Stock Incentive Plan of OmniComm Systems, Inc. (the “1998 Plan”). The 1998 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. Pursuant to the 1998 Plan, 12,500,000 shares of the Company’s common stock were authorized for issuance. The 1998 Plan expired as of December 31, 2008. As of December 31, 2014, there were 450,000 outstanding options that have been granted under the 1998 Plan. | ||||||||||||||||||||||||||||
The following table summarizes the stock option activity for the Company’s equity incentive plans: | ||||||||||||||||||||||||||||
Number of shares | Weighted average exercise price | Weighted average remaining contractual term | Aggregate intrinsic value | |||||||||||||||||||||||||
(per share) | (in years) | |||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 10,452,500 | $ | 0.36 | 1.68 | $ | 149,598 | ||||||||||||||||||||||
Granted | 350,000 | 0.17 | ||||||||||||||||||||||||||
Exercised | (100,000 | ) | 0.18 | |||||||||||||||||||||||||
Forfeited/cancelled/expired | (4,957,500 | ) | 0.42 | |||||||||||||||||||||||||
Outstanding at December 31, 2013 | 5,745,000 | 0.29 | 1.7 | $ | 93,945 | |||||||||||||||||||||||
Granted | 150,000 | 0.16 | ||||||||||||||||||||||||||
Exercised | (150,000 | ) | 0.13 | |||||||||||||||||||||||||
Forfeited/cancelled/expired | (2,615,000 | ) | 0.4 | |||||||||||||||||||||||||
Outstanding at December 31, 2014 | 3,130,000 | $ | 0.2 | 1.59 | $ | 364,900 | ||||||||||||||||||||||
Vested and exercisable at December 31, 2014 | 2,855,000 | $ | 0.21 | 1.35 | $ | 332,850 | ||||||||||||||||||||||
The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price at fiscal year-end and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2014. | ||||||||||||||||||||||||||||
The total number of shares vested and the fair value of shares vested for the years ended December 31, 2014 and December 31, 2013, respectively, was: | ||||||||||||||||||||||||||||
Number of | Fair value of | |||||||||||||||||||||||||||
options vested | options vested | |||||||||||||||||||||||||||
Fair value of options vesting during the year ended December 31, 2014 | 695,834 | $ | 84,450 | |||||||||||||||||||||||||
Fair value of options vesting during the year ended December 31, 2013 | 768,833 | $ | 81,391 | |||||||||||||||||||||||||
Cash received from stock option exercises for the years ended December 31, 2014 and December 31, 2013 was $-0- and $-0-, respectively. Due to the Company’s net loss position, no income tax benefit has been realized during the years ended December 31, 2014 and December 31, 2013. | ||||||||||||||||||||||||||||
The following table summarizes information concerning options outstanding at December 31, 2014: | ||||||||||||||||||||||||||||
Awards breakdown by price range at December 31, 2014 | ||||||||||||||||||||||||||||
Outstanding | Vested | |||||||||||||||||||||||||||
Strike price range ($) | Outstanding stock options | Weighted average remaining contractual life | Weighted average outstanding strike price | Vested stock options | Weighted average remaining vested contractual life | Weighted average vested strike price | ||||||||||||||||||||||
0 | to | 0.2 | 2,080,000 | 1.98 | $ | 0.13 | 1,855,000 | 1.72 | $ | 0.12 | ||||||||||||||||||
0.21 | to | 0.29 | 600,000 | 0.92 | 0.24 | 550,000 | 0.69 | 0.25 | ||||||||||||||||||||
0.3 | to | 0.49 | -0- | 0 | 0 | -0- | 0 | 0 | ||||||||||||||||||||
0.5 | to | 0.7 | 450,000 | 0.68 | 0.5 | 450,000 | 0.68 | 0.5 | ||||||||||||||||||||
0 | to | 0.7 | 3,130,000 | 1.59 | $ | 0.2 | 2,855,000 | 1.35 | $ | 0.21 | ||||||||||||||||||
The following table summarizes information concerning options outstanding at December 31, 2013: | ||||||||||||||||||||||||||||
Awards breakdown by price range at December 31, 2013 | ||||||||||||||||||||||||||||
Outstanding | Vested | |||||||||||||||||||||||||||
Strike price range ($) | Outstanding stock options | Weighted average remaining contractual life | Weighted average outstanding strike price | Vested stock options | Weighted average remaining vested contractual life | Weighted average vested strike price | ||||||||||||||||||||||
0 | to | 0.2 | 3,251,000 | 2.16 | $ | 0.15 | 2,530,166 | 1.86 | $ | 0.16 | ||||||||||||||||||
0.21 | to | 0.29 | 750,000 | 1.64 | 0.25 | 650,000 | 1.2 | 0.25 | ||||||||||||||||||||
0.3 | to | 0.49 | 110,000 | 0.98 | 0.38 | 110,000 | 0.98 | 0.38 | ||||||||||||||||||||
0.5 | to | 0.7 | 1,634,000 | 0.87 | 0.59 | 1,634,000 | 0.87 | 0.59 | ||||||||||||||||||||
0 | to | 0.7 | 5,745,000 | 1.7 | $ | 0.29 | 4,924,166 | 1.42 | $ | 0.32 | ||||||||||||||||||
The weighted average fair value (per share) of options granted during the years ended December 31, 2014 and December 31, 2013 using the Black Scholes option-pricing model was $0.16 and $0.17, respectively. | ||||||||||||||||||||||||||||
Basis for Fair Value Estimate of Share-Based Payments | ||||||||||||||||||||||||||||
Based on analysis of its historical volatility, the Company expects that the future volatility of its share price is likely to be similar to the historical volatility the Company experienced since the Company’s commercialization activities were initiated during the second half of 2000. The Company used a volatility calculation utilizing the Company’s own historical volatility to estimate its future volatility for purposes of valuing the share-based payments granted during fiscal 2014 and 2013. Actual volatility, and future changes in estimated volatility, may differ substantially from the Company’s current estimates. | ||||||||||||||||||||||||||||
The Company utilizes the historical data available regarding employee and director exercise activity to calculate an expected life of the options. The table below presents the weighted average expected life in years of options granted under the Plan as described above. The risk-free rate of the stock options is based on the U.S. Treasury yield curve in effect at the time of grant, which corresponds with the expected term of the option granted. | ||||||||||||||||||||||||||||
The fair value of share-based payments was estimated using the Black Scholes option pricing model with the following assumptions for grants made during the periods indicated. | ||||||||||||||||||||||||||||
Stock option assumptions for the year ended | ||||||||||||||||||||||||||||
Stock option assumptions | 31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||||||
Risk-free interest rate | 0.93% | 0.58% | ||||||||||||||||||||||||||
Expected dividend yield | 0.00% | 0.00% | ||||||||||||||||||||||||||
Expected volatility | 199.00% | 202.70% | ||||||||||||||||||||||||||
Expected life of options (in years) | 5 | 5 | ||||||||||||||||||||||||||
The following table summarizes weighted average grant date fair value activity for the Company incentive stock plans: | ||||||||||||||||||||||||||||
Weighted average grant date fair value | ||||||||||||||||||||||||||||
2014 | 2013 | |||||||||||||||||||||||||||
Stock options granted during the year ended December 31, | $ | 0.16 | $ | 0.17 | ||||||||||||||||||||||||
Stock options vested during the year ended December 31, | $ | 0.12 | $ | 0.11 | ||||||||||||||||||||||||
Stock options forfeited during the year ended December 31, | $ | 0.31 | $ | 0.29 | ||||||||||||||||||||||||
A summary of the status of the Company’s non-vested shares underlying stock options as of December 31, 2014, and changes during the year ended December 31, 2014 is as follows: | ||||||||||||||||||||||||||||
Shares underlying stock options | Weighted average grant date fair value | |||||||||||||||||||||||||||
Nonvested shares at January 1, 2014 | 820,834 | $ | 0.13 | |||||||||||||||||||||||||
Nonvested shares at December 31, 2014 | 275,000 | $ | 0.17 | |||||||||||||||||||||||||
As of December 31, 2014, approximately $29,825 of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a weighted-average period of 1.07 years. |
Note_16_Income_Taxes
Note 16 - Income Taxes | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Income Tax Disclosure [Abstract] | |||||||||
Income Tax Disclosure [Text Block] | NOTE 16: | INCOME TAXES | |||||||
A reconciliation of income tax expense and the amount computed by applying the statutory federal income tax rate to the income before provision for income taxes is as follows: | |||||||||
31-Dec-14 | 31-Dec-13 | ||||||||
Federal statutory rate applied to (loss) before income taxes | $ | (1,685,418 | ) | $ | (1,154,195 | ) | |||
Increase/(decrease) in income taxes results from: | |||||||||
Current tax expense/(benefit) | (19,537 | ) | 94,122 | ||||||
Non deductible expenses | 198,295 | 296,783 | |||||||
Change in deferred assets | 64,449 | 71,274 | |||||||
Change in valuation allowance | 1,422,674 | 786,138 | |||||||
Income tax expense/(benefit) | $ | (19,537 | ) | $ | 94,122 | ||||
The components of income tax expense (benefit) for the years ended: | |||||||||
31-Dec-14 | 31-Dec-13 | ||||||||
Current tax expense/(benefit): | $ | (19,537 | ) | $ | 94,122 | ||||
Deferred tax expense/(benefit): | |||||||||
Bad debt allowance | (45,407 | ) | 7,100 | ||||||
Operating loss carryforward | (1,441,716 | ) | (864,512 | ) | |||||
Amortization of intangibles | 5,482 | -0- | |||||||
Patent litigation settlement | 58,967 | 71,274 | |||||||
(1,442,211 | ) | (692,016 | ) | ||||||
Valuation allowance | 1,422,674 | 786,138 | |||||||
Total tax expense/(benefit) | $ | (19,537 | ) | $ | 94,122 | ||||
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows: | |||||||||
31-Dec-14 | 31-Dec-13 | ||||||||
Amortization of intangibles | $ | 278,216 | $ | 283,698 | |||||
Bad debt allowance | 69,022 | 23,615 | |||||||
Patent litigation liability accrual | 256,441 | 315,408 | |||||||
Operating loss carryforwards | 19,662,198 | 18,220,482 | |||||||
Gross deferred tax assets | 20,265,877 | 18,843,203 | |||||||
Valuation allowance | (20,265,877 | ) | (18,843,203 | ) | |||||
Net deferred tax liability/(asset) | $ | -0- | $ | -0- | |||||
The Company has net operating loss carry forwards (NOL) for income tax purposes of approximately $54,497,491. This loss is allowed to be offset against future income until the year 2034 when the NOL’s will expire. Other timing differences relate to depreciation and amortization for the stock acquisition of Education Navigator in 1998. The tax benefits relating to all timing differences have been fully reserved for in the valuation allowance account due to the substantial losses incurred through December 31, 2014. The change in the valuation allowance for the year ended December 31, 2014 was an increase of $1,422,676. The Company's tax returns for the prior three years remain subject to examination by major tax jurisdictions. |
Note_17_Subsequent_Events
Note 17 - Subsequent Events | 12 Months Ended | |
Dec. 31, 2014 | ||
Subsequent Events [Abstract] | ||
Subsequent Events [Text Block] | NOTE 17: | SUBSEQUENT EVENTS |
On January 31, 2015 the Company issued a promissory note payable in the amount of $950,000 and 3,800,000 common stock purchase warrants (“Warrants”) to our Chief Executive Officer and Director, Cornelis F. Wit, in exchange for an existing promissory note in the amount of $280,000 and accrued interest in the amount of $670,000. The note carries an interest rate of 12% per annum and matures on April 1, 2017. The Warrants are exercisable until April 1, 2017 at an exercise price of $0.25. | ||
On January 31, 2015 the Company issued a promissory note in the amount of $2,860,000 to our Chief Executive Officer and Director, Cornelis F. Wit, in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2017. The expiration date of the warrants associated with the promissory note was also extended to April 1, 2017. | ||
On January 31, 2015 the Company issued a promissory note in the amount of $529,000 to our Chief Executive Officer and Director, Cornelis F. Wit, in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2017. The expiration date of the warrants associated with the promissory note was also extended to April 1, 2017. | ||
On January 31, 2015 the Company and Mr. Wit extended the maturity date of $1,100,000 of convertible debentures to April 1, 2017. The debentures bear interest at 12% per annum. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | ||
On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2017. The debentures bear interest at 10% per annum. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | ||
On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $4,475,000 of convertible debentures to April 1, 2017. The debentures bear interest at 12% per annum. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | ||
On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,440,000 of convertible debentures to April 1, 2017. The debentures bear interest at 12% per annum. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. | ||
On January 31, 2015 the Company extended the expiration date of the warrants associated with the promissory note due to Mr. Wit in the amount of $1,600,000 with a maturity date of April 1, 2017. The Warrants are exercisable at $0.25 per share and the new expiration date of the Warrants is April 1, 2017. | ||
On February 3, 2015 the Company renewed the Line of Credit with The Northern Trust Company and increased the available balance to $5,000,000. The line of credit matures on February 2, 2018 and carries a variable interest rate based on the prime rate. | ||
On March 20, 2015 the Company awarded 275,000 restricted shares to our Chairman and Chief Technology Officer, Randall G. Smith, 175,000 restricted shares to our Chief Executive Officer and Director, Cornelis F. Wit, 115,000 restricted shares to our Chief Operating Officer and President, Stephen E. Johnson, and 100,000 restricted shares to our Chief Financial Officer, Thomas E. Vickers. The restrictions on the shares lapse ratably over a three year period contingent on continued employment. | ||
On March 23, 2015 a former employee exercised 7,500 stock options. | ||
Subsequent to December 31, 2014 the Company drew an additional $750,000 on its line of credit. |
Accounting_Policies_by_Policy_
Accounting Policies, by Policy (Policies) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||
Basis of Accounting, Policy [Policy Text Block] | BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION | ||||||||||||||||
The Company’s accounts include those of all its wholly-owned subsidiaries and have been prepared in conformity with (i) accounting principles generally accepted in the United States of America; and (ii) the rules and regulations of the United States Securities and Exchange Commission. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated in consolidation. | |||||||||||||||||
Use of Estimates, Policy [Policy Text Block] | ESTIMATES IN FINANCIAL STATEMENTS | ||||||||||||||||
The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Significant estimates incorporated in our financial statements include the recorded allowance for doubtful accounts, the estimate of the appropriate amortization period of our intangible assets, the evaluation of whether our intangible assets have suffered any impairment, the allocation of revenues under multiple-element customer contracts, royalty-based patent liabilities, the value of derivatives associated with debt issued by the Company and the valuation of any corresponding discount to the issuance of our debt. Actual results may differ from those estimates. | |||||||||||||||||
Reclassification, Policy [Policy Text Block] | RECLASSIFICATIONS | ||||||||||||||||
Certain reclassifications have been made in the 2013 financial statements to conform to the 2014 presentation. These reclassifications did not have any effect on our net loss or shareholders’ deficit. | |||||||||||||||||
Foreign Currency Transactions and Translations Policy [Policy Text Block] | FOREIGN CURRENCY TRANSLATION | ||||||||||||||||
The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830-30, Foreign Currency Matters—Translation of Financial Statements. The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s subsidiaries, OmniComm Europe GmbH in Germany, OmniComm Spain S.L. in Spain and OmniComm Promasys B.V. in the Netherlands is the Euro. The functional currency of the Company's subsidiary, OmniComm Ltd. in the United Kingdom is the British Pound Sterling. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income/(loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations. We record translation gains and losses in accumulated other comprehensive income as a component of stockholders’ equity. We recorded a translation loss of $156,223 for the year ended December 31, 2014 and a translation loss of $18,512 for the year ended December 31, 2013. | |||||||||||||||||
Revenue Recognition, Policy [Policy Text Block] | REVENUE RECOGNITION POLICY | ||||||||||||||||
The Company derives revenues from software licenses and services of its EDC products and services which can be purchased on a stand-alone basis. License revenues are derived principally from the sale of term licenses for the following software products offered by the Company: TrialMaster, TrialOne, Promasys and eClinical Suite (the “EDC Software”). Service revenues are derived principally from the Company's delivery of the hosted solutions of its TrialMaster and eClinical Suite software products, and consulting services and customer support, including training, for all of the Company's products. | |||||||||||||||||
The Company recognizes revenues when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the product or service has been provided to the customer; (3) the collection of fees is probable; and (4) the amount of fees to be paid by the customer is fixed or determinable. | |||||||||||||||||
The Company operates in one reportable segment which is the delivery of EDC Software and services to clinical trial sponsors. The Company segregates its revenues based on the activity cycle used to generate its revenues. Accordingly, revenues are currently generated through four main activities. These activities include hosted applications, licensing, professional services and maintenance-related services. | |||||||||||||||||
Hosted Application Revenues | |||||||||||||||||
The Company offers its TrialMaster and eClinical Suite software products as hosted application solutions delivered through a standard Web-browser, with customer support and training services. To date, hosted applications revenues have been primarily related to TrialMaster. | |||||||||||||||||
Revenues resulting from TrialMaster and eClinical Suite application hosting services consist of three components of services for each clinical trial: the first component is comprised of application set up, including design of electronic case report forms and edit checks, installation and server configuration of the system. The second component involves application hosting and related support services as well as billable change orders which consist of amounts billed to customers for functionality changes made. The third stage involves services required to close out, or lock, the database for the clinical trial. | |||||||||||||||||
Fees charged and costs incurred for the trial system design, set up and implementation are amortized and recognized ratably over the estimated hosting period. Work performed outside the original scope of work is contracted for separately as an additional fee and is generally recognized ratably over the remaining term of the hosting period. Fees for the first and third stages of the service are billed based upon milestones. Revenues earned upon completion of a contractual milestone are deferred and recognized over the estimated remaining hosting period. Fees for application hosting and related services in the second stage are generally billed quarterly in advance. Revenues resulting from hosting services for the eClinical Suite products consist of installation and server configuration, application hosting and related support services. Services for this offering are generally charged as a fixed fee payable on a quarterly or annual basis. Revenues are recognized ratably over the period of the service. | |||||||||||||||||
Licensing Revenues | |||||||||||||||||
The Company's software license revenues are earned from the sale of off-the-shelf software. From time-to-time a client might require significant modification or customization subsequent to delivery to the customer. The Company generally enters into software term licenses for its EDC Software products with its customers for 3 to 5 year periods, although customers have entered into both longer and shorter term license agreements. These arrangements typically include multiple elements: software license, consulting services and customer support. The Company bills its customers in accordance with the terms of the underlying contract. Generally, the Company bills license fees in advance for each billing cycle of the license term which typically is either on a quarterly or annual basis. Payment terms are generally net 30 days. | |||||||||||||||||
In the past the Company has sold perpetual licenses for EDC Software products in certain situations to existing customers with the option to purchase customer support, and may in the future do so for new customers based on customer requirements or market conditions. The Company has established vendor specific objective evidence of fair value for the customer support. Accordingly, license revenues are recognized upon delivery of the software and when all other revenue recognition criteria are met. Customer support revenues are recognized ratably over the term of the underlying support arrangement. The Company generates customer support and maintenance revenues from its perpetual license customer base. | |||||||||||||||||
Professional Services | |||||||||||||||||
The Company may also enter into arrangements to provide consulting services separate from a license arrangement. In these situations, revenue is recognized on a time-and-materials basis. Professional services can be deemed to be as essential to the functionality of the software at inception and typically are for initial trial configuration, implementation planning, loading of software, building simple interfaces and running test data and documentation of procedures. Subsequent additions or extensions to license terms do not generally include additional professional services. | |||||||||||||||||
Maintenance Revenues | |||||||||||||||||
Maintenance includes telephone-based help desk support and software maintenance. The Company generally bundles customer support with the software license for the entire term of the arrangement. As a result, the Company generally recognizes revenues for both maintenance and software licenses ratably over the term of the software license and support arrangement. The Company allocates the revenues recognized for these arrangements to the different elements based on management's estimate of the relative fair value of each element. The Company generally invoices each of the elements based on separately quoted amounts and thus has a fairly accurate estimate of the relative fair values of each of the invoiced revenue elements. | |||||||||||||||||
The fees associated with each business activity for the years ended December 31, 2014 and December 31, 2013, respectively are: | |||||||||||||||||
For the year ended | |||||||||||||||||
Revenue activity | 31-Dec-14 | 31-Dec-13 | |||||||||||||||
Set-up fees | $ | 4,814,378 | $ | 3,369,670 | |||||||||||||
Change orders | 467,815 | 475,680 | |||||||||||||||
Maintenance | 4,374,245 | 4,584,594 | |||||||||||||||
Software licenses | 3,404,655 | 2,911,509 | |||||||||||||||
Professional services | 2,605,010 | 2,207,181 | |||||||||||||||
Hosting | 795,147 | 783,206 | |||||||||||||||
Total | $ | 16,461,250 | $ | 14,331,840 | |||||||||||||
Cost of Sales, Policy [Policy Text Block] | COST OF REVENUES | ||||||||||||||||
Cost of revenues primarily consists of costs related to hosting, maintaining and supporting the Company’s application suite and delivering professional services and support. These costs include salaries, benefits, bonuses and stock-based compensation for the Company’s professional services staff. Cost of revenues also includes outside service provider cost. Cost of revenues is expensed as incurred. | |||||||||||||||||
Cash and Cash Equivalents, Policy [Policy Text Block] | CASH AND CASH EQUIVALENTS | ||||||||||||||||
Cash equivalents consist of highly liquid, short-term investments with maturities of 90 days or less. The carrying amount reported in the accompanying consolidated balance sheets approximates fair value. | |||||||||||||||||
Receivables, Policy [Policy Text Block] | ACCOUNTS RECEIVABLE | ||||||||||||||||
Accounts receivable are judged as to collectability by management and an allowance for bad debts is established as necessary. The allowance is based on an evaluation of the collectability of accounts receivable and prior bad debt experience. The Company had recorded an allowance for uncollectible accounts receivable of $186,085 and $65,341 as of December 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||
The following table summarizes activity in the Company's allowance for doubtful accounts for the years presented. | |||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||
Beginning of period | $ | 65,341 | $ | 84,210 | |||||||||||||
Bad debt expense | 147,543 | 11,131 | |||||||||||||||
Write-offs | (26,875 | ) | (30,000 | ) | |||||||||||||
Exchange rate impact | 76 | -0- | |||||||||||||||
End of period | $ | 186,085 | $ | 65,341 | |||||||||||||
Concentration Risk, Credit Risk, Policy [Policy Text Block] | CONCENTRATION OF CREDIT RISK | ||||||||||||||||
Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of December 31, 2014, $264,234 was deposited in excess of FDIC-insured limits. Management believes the risk in these situations to be minimal. | |||||||||||||||||
Except as follows, the Company has no significant off balance sheet risk or credit risk concentrations. Financial instruments that subject the Company to potential credit risks are principally cash equivalents and accounts receivable. Concentrated credit risk with respect to accounts receivable is limited to creditworthy customers. The Company's customers are principally located in the United States and Europe. The Company is directly affected by the overall financial condition of the pharmaceutical, biotechnology and medical device industries and management believes that credit risk exists and that any credit risk the Company faces has been adequately reserved for as of December 31, 2014. The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses when incurred are charged to the allowance. The Company's losses related to collection of accounts receivable have consistently been within management's expectations. As of December 31, 2014, the Company believes no additional credit risk exists beyond the amounts provided for in our allowance for uncollectible accounts. The Company evaluates its allowance for uncollectable accounts on a monthly basis based on a specific review of receivable aging and the period that any receivables are beyond the standard payment terms. The Company does not require collateral from its customers in order to mitigate credit risk. | |||||||||||||||||
One customer accounted for 15% of our revenue during the year ended December 31, 2014 or approximately $2,395,000, respectively. One customer accounted for 11% of our revenues during the year ended December 31, 2013 or approximately $1,551,000. The following table summarizes the number of customers who individually comprise greater than 10% of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the years presented. | |||||||||||||||||
Revenues | Accounts receivable | ||||||||||||||||
For the year ended | Number of customers | Percentage of total revenues | Number of customers | Percentage of accounts receivable | |||||||||||||
31-Dec-14 | 1 | 15% | 1 | 18% | |||||||||||||
31-Dec-13 | 1 | 11% | 2 | 23% | |||||||||||||
The table below provides revenues from European customers for the years ended December 31, 2014 and December 31, 2013, respectively. | |||||||||||||||||
European revenues | |||||||||||||||||
For the year ended | |||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||
European revenues | % of Total revenues | European revenues | % of Total revenues | ||||||||||||||
$ | 2,383,252 | 14.50% | $ | 1,847,305 | 12.90% | ||||||||||||
The Company serves all of its hosting customers from third-party web hosting facilities located in the United States. The Company does not control the operation of these facilities, and they are vulnerable to damage or interruption. The Company maintains redundant systems that can be used to provide service in the event the third-party web hosting facilities become unavailable, although in such circumstances, the Company's service may be interrupted during the transition. | |||||||||||||||||
Property, Plant and Equipment, Policy [Policy Text Block] | PROPERTY AND EQUIPMENT | ||||||||||||||||
Property and equipment are recorded at cost. Additions and betterments are capitalized; maintenance and repairs are expensed as incurred. Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is 5 years for leasehold improvements, computers, equipment and furniture and 3 years for software. Gains or losses on disposal are charged to operations. | |||||||||||||||||
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] | ASSET IMPAIRMENT | ||||||||||||||||
Acquisitions and Intangible Assets | |||||||||||||||||
We account for acquisitions in accordance with ASC 805, Business Combinations (“ASC 805”) and ASC 350, Intangibles- Goodwill and Other (“ASC 350”). The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of a business acquisition. Our consolidated financial statements and results of operations reflect an acquired business from the completion date of an acquisition. | |||||||||||||||||
The judgments that we make in determining the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact net income in periods following an asset acquisition. We generally use either the income, cost or market approach to aid in our conclusions of such fair values and asset lives. The income approach presumes that the value of an asset can be estimated by the net economic benefit to be received over the life of the asset, discounted to present value. The cost approach presumes that an investor would pay no more for an asset than its replacement or reproduction cost. The market approach estimates value based on what other participants in the market have paid for reasonably similar assets. Although each valuation approach is considered in valuing the assets acquired, the approach ultimately selected is based on the characteristics of the asset and the availability of information. | |||||||||||||||||
Long-lived Assets | |||||||||||||||||
We review long-lived assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. In turn, measurement of an impairment loss requires a determination of fair value, which is based on the best information available. We use quoted market prices when available and independent appraisals and management estimates of future operating cash flows, as appropriate, to determine fair value. | |||||||||||||||||
Revenue Recognition, Deferred Revenue [Policy Text Block] | DEFERRED REVENUE | ||||||||||||||||
Deferred revenue represents cash advances received in excess of revenue earned on on-going contracts. Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones. In the event of contract cancellation, the Company is generally entitled to payment for all work performed through the point of cancellation. As of December 31, 2014, the Company had $8,233,943 in deferred revenues relating to contracts for services to be performed over periods ranging from 1 month to 5 years. The Company had $5,840,875 in deferred revenues that are expected to be recognized in the next twelve fiscal months. | |||||||||||||||||
Advertising Costs, Policy [Policy Text Block] | ADVERTISING | ||||||||||||||||
Advertising costs are expensed as incurred. Advertising costs were $419,253 and $226,380 for the years ended December 31, 2014 and December 31, 2013, respectively and are included under selling, general and administrative expenses on our consolidated financial statements. | |||||||||||||||||
Research, Development, and Computer Software, Policy [Policy Text Block] | RESEARCH AND DEVELOPMENT EXPENSES | ||||||||||||||||
Software development costs are included in R&D and are expensed as incurred. ASC 985.20, Software Industry Costs of Software to Be Sold, Leased or Marketed, requires the capitalization of certain development costs of software to be sold once technological feasibility is established, which the Company defines as completion to the point of marketability. The capitalized cost is then amortized on a straight-line basis over the estimated product life. To date, the period between achieving technological feasibility and the general availability of such software has been short and software development costs qualifying for capitalization have been immaterial. Accordingly, the Company has not capitalized any software development costs under ASC 985.20. During the years ended December 31, 2014 and December 31, 2013 we spent approximately $2,754,367 and $2,403,504 respectively, on R&D activities, which include costs associated with the development of our software products and services for our client’s projects and which are primarily comprised of salaries and related expenses for our software developers and consulting fees paid to third-party consultants. R&D costs are primarily included under Salaries, benefits and related taxes in our Statement of Operations. | |||||||||||||||||
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | EMPLOYEE EQUITY INCENTIVE PLANS | ||||||||||||||||
The OmniComm Systems, Inc. 2009 Equity Incentive Plan (the “2009 Plan”) was approved at our Annual Meeting of Shareholders on July 10, 2009. The 2009 Plan provides for the issuance of up to 7.5 million shares to employees, directors and key consultants in accordance with the terms of the 2009 Plan documents. The predecessor plan, the OmniComm Systems, Inc., 1998 Stock Incentive Plan (the “1998 Plan”) expired on December 31, 2008. The 1998 Plan provided for the issuance of up to 12.5 million shares in accordance with the terms of the 1998 Plan document. Each plan is more fully described in “Note 15, Employee Equity Incentive Plans.” The Company accounts for its employee equity incentive plans under ASC 718, Compensation – Stock Compensation which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. | |||||||||||||||||
ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company currently uses the Black Scholes option pricing model to determine grant date fair value. | |||||||||||||||||
Earnings Per Share, Policy [Policy Text Block] | EARNINGS/(LOSS) PER SHARE | ||||||||||||||||
The Company accounts for Earnings/(loss) Per Share using ASC 260 – Earnings per Share. Unlike diluted earnings per share, basic earnings per share excludes any dilutive effects of options, warrants, and convertible securities. | |||||||||||||||||
Income Tax, Policy [Policy Text Block] | INCOME TAXES | ||||||||||||||||
The Company accounts for income taxes in accordance ASC 740, Income Taxes. ASC 740 has as its basic objective the recognition of current and deferred income tax assets and liabilities based upon all events that have been recognized in the financial statements as measured by the provisions of the enacted tax laws | |||||||||||||||||
Valuation allowances are established when necessary to reduce deferred tax assets to the estimated amount to be realized. Income tax expense represents the tax payable for the current period and the change during the period in the deferred tax assets and liabilities. | |||||||||||||||||
New Accounting Pronouncements, Policy [Policy Text Block] | IMPACT OF NEW ACCOUNTING STANDARDS | ||||||||||||||||
During fiscal 2014, we adopted the following new accounting pronouncements: | |||||||||||||||||
In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”, (“ASU No. 2013-11”). This ASU amends ASC 740, Income Taxes, to require that an unrecognized tax benefit be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward; to the extent that a net operating loss carryforward, a similar tax loss, or a tax credit carryforward does not exist at the reporting date, the unrecognized tax benefit should be presented in the financial statements as a liability and not combined with deferred tax assets. ASU No. 2013-11 is effective for interim and annual periods beginning after December 15, 2013, with early adoption permitted. Our adoption of this standard on January 1, 2014 did not have a material impact on our consolidated financial statements. | |||||||||||||||||
In May 2014, FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers”, (“ASU 2014-09”). This ASU is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This ASU is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. Accordingly, the Company will adopt this ASU on January 1, 2017. Management is currently evaluating which transition approach to use and the impact of the adoption of this ASU on the Company's consolidated financial statements. | |||||||||||||||||
In August 2014, FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, (“ASU 2014-15”), which requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events, considered in the aggregate, that raise substantial doubt about an entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We believe the adoption of this guidance will not have a material effect on our consolidated financial statements. | |||||||||||||||||
Accounting standards-setting organizations frequently issue new or revised accounting rules. We regularly review all new pronouncements to determine their impact, if any, on our financial statements. |
Note_2_Summary_of_Significant_1
Note 2 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||
Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block] | For the year ended | ||||||||||||||||
Revenue activity | 31-Dec-14 | 31-Dec-13 | |||||||||||||||
Set-up fees | $ | 4,814,378 | $ | 3,369,670 | |||||||||||||
Change orders | 467,815 | 475,680 | |||||||||||||||
Maintenance | 4,374,245 | 4,584,594 | |||||||||||||||
Software licenses | 3,404,655 | 2,911,509 | |||||||||||||||
Professional services | 2,605,010 | 2,207,181 | |||||||||||||||
Hosting | 795,147 | 783,206 | |||||||||||||||
Total | $ | 16,461,250 | $ | 14,331,840 | |||||||||||||
Allowance for Credit Losses on Financing Receivables [Table Text Block] | 31-Dec-14 | 31-Dec-13 | |||||||||||||||
Beginning of period | $ | 65,341 | $ | 84,210 | |||||||||||||
Bad debt expense | 147,543 | 11,131 | |||||||||||||||
Write-offs | (26,875 | ) | (30,000 | ) | |||||||||||||
Exchange rate impact | 76 | -0- | |||||||||||||||
End of period | $ | 186,085 | $ | 65,341 | |||||||||||||
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | Revenues | Accounts receivable | |||||||||||||||
For the year ended | Number of customers | Percentage of total revenues | Number of customers | Percentage of accounts receivable | |||||||||||||
31-Dec-14 | 1 | 15% | 1 | 18% | |||||||||||||
31-Dec-13 | 1 | 11% | 2 | 23% | |||||||||||||
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] | European revenues | ||||||||||||||||
For the year ended | |||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||
European revenues | % of Total revenues | European revenues | % of Total revenues | ||||||||||||||
$ | 2,383,252 | 14.50% | $ | 1,847,305 | 12.90% |
Note_4_Earnings_Loss_Per_Share1
Note 4 - Earnings (Loss) Per Share (Tables) | 12 Months Ended | ||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Anti-Dilutive security | 31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||
Preferred stock | 2,750,149 | 2,750,149 | |||||||||||||||||||||||
Employee stock options | 3,130,000 | 5,745,000 | |||||||||||||||||||||||
Warrants | 48,463,517 | 44,728,873 | |||||||||||||||||||||||
Convertible notes | 24,620,000 | 24,620,000 | |||||||||||||||||||||||
Shares issuable for accrued interest | 1,048,532 | 1,702,891 | |||||||||||||||||||||||
Total | 80,012,198 | 79,546,913 | |||||||||||||||||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | For the year ended | ||||||||||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||||
Income/(loss) | Shares | Per-share | Income/(loss) | Shares | Per-share | ||||||||||||||||||||
numerator | denominator | amount | numerator | denominator | amount | ||||||||||||||||||||
Basic EPS | $ | (4,665,645 | ) | 90,701,058 | $ | (0.05 | ) | $ | (3,367,603 | ) | 87,969,202 | $ | (0.04 | ) | |||||||||||
Effect of dilutive securities - none | -0- | -0- | -0- | -0- | -0- | -0- | |||||||||||||||||||
Diluted EPS | $ | (4,665,645 | ) | 90,701,058 | $ | (0.05 | ) | $ | (3,367,603 | ) | 87,969,202 | $ | (0.04 | ) |
Note_5_Property_and_Equipment_1
Note 5 - Property and Equipment, Net (Tables) | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||
Property, Plant and Equipment [Table Text Block] | 31-Dec-14 | 31-Dec-13 | |||||||||||||||||||||||||||
Cost | Accumulated depreciation | Net book value | Cost | Accumulated depreciation | Net book value | Estimated useful life (years) | |||||||||||||||||||||||
Computer & office equipment | $ | 1,880,183 | $ | 1,482,737 | $ | 397,446 | $ | 1,822,098 | $ | 1,326,256 | $ | 495,842 | 5 | ||||||||||||||||
Leasehold improvements | 92,504 | 82,353 | 10,151 | 93,812 | 75,735 | 18,077 | 5 | ||||||||||||||||||||||
Computer software | 1,580,640 | 1,528,418 | 52,222 | 1,556,497 | 1,477,801 | 78,696 | 3 | ||||||||||||||||||||||
Office furniture | 113,365 | 105,048 | 8,317 | 114,373 | 99,555 | 14,818 | 5 | ||||||||||||||||||||||
Total | $ | 3,666,692 | $ | 3,198,556 | $ | 468,136 | $ | 3,586,780 | $ | 2,979,347 | $ | 607,433 |
Note_6_Intangible_Assets_at_Co1
Note 6 - Intangible Assets, at Cost (Tables) | 12 Months Ended | ||||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||||
Disclosure Text Block [Abstract] | |||||||||||||||||||||||||||||
Schedule of Finite-Lived Intangible Assets [Table Text Block] | 31-Dec-14 | 31-Dec-13 | |||||||||||||||||||||||||||
Asset | Cost | Accumulated amortization | Net book value | Cost | Accumulated amortization | Net book value | Estimated useful life (years) | ||||||||||||||||||||||
eClinical customer lists | $ | 1,392,701 | $ | 1,392,701 | $ | -0- | $ | 1,392,701 | $ | 1,392,701 | $ | -0- | 3 | ||||||||||||||||
Promasys B.V. customer lists | 120,305 | 9,357 | 110,948 | 136,253 | 1,514 | 134,739 | 15 | ||||||||||||||||||||||
Promasys B.V. software code | 72,837 | 16,995 | 55,842 | 72,943 | 2,431 | 70,512 | 5 | ||||||||||||||||||||||
Promasys B.V. URLs/Website | 60,760 | 23,629 | 37,131 | 68,814 | 3,823 | 64,991 | 3 | ||||||||||||||||||||||
Total | $ | 1,646,603 | $ | 1,442,682 | $ | 203,921 | $ | 1,670,711 | $ | 1,400,469 | $ | 270,242 | |||||||||||||||||
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | 2015 | $ | 42,841 | ||||||||||||||||||||||||||
2016 | 39,466 | ||||||||||||||||||||||||||||
2017 | 22,588 | ||||||||||||||||||||||||||||
2018 | 20,160 | ||||||||||||||||||||||||||||
2019 | 8,020 | ||||||||||||||||||||||||||||
Thereafter | 70,846 | ||||||||||||||||||||||||||||
Total | $ | 203,921 |
Note_7_Accounts_Payable_and_Ac1
Note 7 - Accounts Payable and Accrued Expenses (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Payables and Accruals [Abstract] | |||||||||
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | Account | 31-Dec-14 | 31-Dec-13 | ||||||
Accounts payable | $ | 613,584 | $ | 724,421 | |||||
Accrued payroll and related costs | 319,629 | 260,072 | |||||||
Other accrued expenses | 85,248 | 88,292 | |||||||
Accrued interest | 875,724 | 1,468,171 | |||||||
Total accounts payable and accrued expenses | $ | 1,894,185 | $ | 2,540,956 |
Note_8_Promasys_BV_Acquisition1
Note 8 - Promasys B.V. Acquisition (Tables) | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
Business Combinations [Abstract] | |||||
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | Cash | $ | 215,571 | ||
Receivables | 216,287 | ||||
Property and equipment | 2,178 | ||||
Identifiable intangibles | 276,356 | ||||
Goodwill | 671,689 | ||||
Total assets acquired | $ | 1,382,081 | |||
Accounts payable | (170,339 | ) | |||
Deferred revenue | (229,353 | ) | |||
Net assets acquired | $ | 982,389 | |||
Business Acquisition, Pro Forma Information [Table Text Block] | For the year ended | ||||
December 31, | |||||
2013 | |||||
Gross revenues | $ | 15,119,861 | |||
Total expenses | 18,145,210 | ||||
Net income/(loss) before taxes | (3,025,349 | ) | |||
Net income/(loss) per share | |||||
Weighted average number of shares outstanding | $ | (0.04 | ) | ||
Basic and diluted | 89,866,051 |
Note_9_Line_of_Credit_and_Note1
Note 9 - Line of Credit and Notes Payable (Tables) | 12 Months Ended | ||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||
Schedule of Debt [Table Text Block] | Ending | ||||||||||||||||||||||||||
principal | Non related party | Related party | |||||||||||||||||||||||||
Origination | Maturity | Interest | December 31, | Long | Long | ||||||||||||||||||||||
date | date | rate | 2014 | Current | term | Current | term | ||||||||||||||||||||
1/1/13 | 1/1/16 | 12% | $ | 529,000 | $ | -0- | $ | -0- | $ | -0- | $ | 529,000 | |||||||||||||||
2/1/13 | 1/1/16 | 12% | 20,000 | -0- | -0- | -0- | 20,000 | ||||||||||||||||||||
4/1/13 | 3/31/16 | 12% | 2,860,000 | -0- | -0- | -0- | 2,860,000 | ||||||||||||||||||||
1/1/14 | 4/1/17 | 12% | 980,000 | -0- | -0- | -0- | 980,000 | ||||||||||||||||||||
4/4/14 | 4/1/17 | 12% | 1,600,000 | -0- | -0- | -0- | 1,600,000 | ||||||||||||||||||||
4/4/14 | 4/1/17 | 12% | 45,000 | -0- | 45,000 | -0- | -0- | ||||||||||||||||||||
4/4/14 | 4/1/17 | 12% | 137,500 | -0- | 137,500 | -0- | -0- | ||||||||||||||||||||
4/4/14 | 4/1/17 | 10% | 120,000 | -0- | 120,000 | -0- | -0- | ||||||||||||||||||||
12/1/14 | 4/1/17 | 10% | 300,000 | -0- | 300,000 | -0- | -0- | ||||||||||||||||||||
12/1/14 | 4/1/17 | 12% | 90,000 | -0- | 90,000 | -0- | -0- | ||||||||||||||||||||
12/1/14 | 4/1/17 | 12% | 100,000 | -0- | 100,000 | -0- | -0- | ||||||||||||||||||||
12/17/14 | 1/1/16 | 12% | 20,000 | -0- | 20,000 | -0- | -0- | ||||||||||||||||||||
12/23/14 | 4/1/17 | 12% | 280,000 | -0- | -0- | -0- | 280,000 | ||||||||||||||||||||
Discount on note payable | -0- | -0- | -0- | (568,209 | ) | ||||||||||||||||||||||
Total | $ | 7,081,500 | $ | -0- | $ | 812,500 | $ | -0- | $ | 5,700,791 | |||||||||||||||||
Ending | |||||||||||||||||||||||||||
principal | Non related party | Related party | |||||||||||||||||||||||||
Origination | Maturity | Interest | December 31, | Long | Long | ||||||||||||||||||||||
date | date | rate | 2013 | Current | term | Current | term | ||||||||||||||||||||
12/31/11 | 1/1/15 | 12% | $ | 1,600,000 | $ | -0- | $ | -0- | $ | -0- | $ | 1,600,000 | |||||||||||||||
4/1/12 | 1/1/14 | 12% | 17,500 | 17,500 | -0- | -0- | -0- | ||||||||||||||||||||
12/17/12 | 12/16/14 | 12% | 20,000 | 20,000 | -0- | -0- | -0- | ||||||||||||||||||||
1/1/13 | 1/1/16 | 12% | 529,000 | -0- | -0- | -0- | 529,000 | ||||||||||||||||||||
1/1/13 | 1/1/15 | 10% | 308,561 | -0- | 308,561 | -0- | -0- | ||||||||||||||||||||
1/1/13 | 1/1/15 | 10% | 123,425 | -0- | 123,425 | -0- | -0- | ||||||||||||||||||||
1/1/13 | 1/1/15 | 12% | 45,000 | -0- | 45,000 | -0- | -0- | ||||||||||||||||||||
2/1/13 | 1/1/16 | 12% | 20,000 | -0- | -0- | -0- | 20,000 | ||||||||||||||||||||
3/5/13 | 1/1/15 | 12% | 137,500 | -0- | 137,500 | -0- | -0- | ||||||||||||||||||||
4/1/13 | 3/31/16 | 12% | 2,866,879 | -0- | -0- | -0- | 2,866,879 | ||||||||||||||||||||
Discount on note payable | -0- | -0- | -0- | (447,666 | ) | ||||||||||||||||||||||
Total | $ | 5,667,865 | $ | 37,500 | $ | 614,486 | $ | -0- | $ | 4,568,213 |
Note_10_Convertible_Notes_Paya1
Note 10 - Convertible Notes Payable (Tables) | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Tables) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Maturities of Long-term Debt [Table Text Block] | 2015 | $ | 75,000 | ||||||||||||||||||||||||||||||||||||||||||||
2016 | 9,590,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Total | $ | 9,665,000 | |||||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Tables) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Long-term Debt Instruments [Table Text Block] | |||||||||||||||||||||||||||||||||||||||||||||||
Principal | Carrying | Carrying amount | |||||||||||||||||||||||||||||||||||||||||||||
at | Total | Discount at | amount at | Short term | Long term | ||||||||||||||||||||||||||||||||||||||||||
Date of | Maturity | Interest | Original | December | Allocated discount | discount | December | December | Related | Non related | Related | Non related | |||||||||||||||||||||||||||||||||||
issuance | date | rate | principal | 31, 2014 | amortized | 31, 2014 | 31, 2014 | ||||||||||||||||||||||||||||||||||||||||
8/1/99 | 6/30/04 | 10% | 862,500 | $ | 75,000 | $ | -0- | $ | -0- | $ | -0- | $ | 75,000 | $ | -0- | $ | 75,000 | -0- | -0- | ||||||||||||||||||||||||||||
8/29/08 | 1/1/16 | 10% | 2,120,000 | 1,770,000 | 1,916,480 | 1,916,480 | -0- | 1,770,000 | -0- | -0- | 1,770,000 | -0- | |||||||||||||||||||||||||||||||||||
8/29/08 | 4/1/16 | 10% | 150,000 | 150,000 | 135,600 | 135,600 | -0- | 150,000 | -0- | -0- | -0- | 150,000 | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 375,000 | 375,000 | 101,250 | 101,250 | -0- | 375,000 | -0- | -0- | -0- | 375,000 | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 4,600,000 | 4,505,000 | 1,242,000 | 1,242,000 | -0- | 4,505,000 | -0- | -0- | 4,505,000 | -0- | |||||||||||||||||||||||||||||||||||
12/16/08 | 4/1/16 | 12% | 100,000 | 100,000 | 27,515 | 27,515 | -0- | 100,000 | -0- | -0- | -0- | 100,000 | |||||||||||||||||||||||||||||||||||
9/30/09 | 1/1/16 | 12% | 100,000 | 100,000 | 37,600 | 37,600 | -0- | 100,000 | -0- | -0- | -0- | 100,000 | |||||||||||||||||||||||||||||||||||
9/30/09 | 1/1/16 | 12% | 1,300,000 | 1,100,000 | 488,800 | 488,800 | -0- | 1,100,000 | -0- | -0- | 1,100,000 | -0- | |||||||||||||||||||||||||||||||||||
12/31/09 | 1/1/16 | 12% | 50,000 | 50,000 | 31,400 | 31,400 | -0- | 50,000 | -0- | -0- | -0- | 50,000 | |||||||||||||||||||||||||||||||||||
12/31/09 | 1/1/16 | 12% | 1,440,000 | 1,440,000 | 904,320 | 904,320 | -0- | 1,440,000 | -0- | -0- | 1,440,000 | -0- | |||||||||||||||||||||||||||||||||||
Total | $ | 11,097,500 | $ | 9,665,000 | $ | 4,884,450 | $ | 4,884,450 | $ | -0- | $ | 9,665,000 | $ | -0- | $ | 75,000 | $ | 8,815,000 | $ | 775,000 | |||||||||||||||||||||||||||
Carrying amount | |||||||||||||||||||||||||||||||||||||||||||||||
Principal | Discount | Carrying | Short term | Long term | |||||||||||||||||||||||||||||||||||||||||||
Date of | Maturity date | Interest rate | Original principal | at December31, 2013 | Allocated discount | Total discount amortized | at December31, 2013 | amount at December 31, 2013 | Related | Non related | Related | Non related | |||||||||||||||||||||||||||||||||||
issuance | |||||||||||||||||||||||||||||||||||||||||||||||
8/1/99 | 6/30/04 | 10% | $ | 862,500 | $ | 75,000 | $ | -0- | $ | -0- | $ | -0- | $ | 75,000 | $ | -0- | $ | 75,000 | $ | -0- | $ | -0- | |||||||||||||||||||||||||
8/29/08 | 1/1/15 | 10% | 150,000 | 150,000 | 135,600 | 135,600 | -0- | 150,000 | -0- | -0- | 150,000 | -0- | |||||||||||||||||||||||||||||||||||
8/29/08 | 1/1/16 | 10% | 2,120,000 | 1,770,000 | 1,916,480 | 1,916,480 | -0- | 1,770,000 | -0- | -0- | 1,770,000 | -0- | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/15 | 12% | 100,000 | 100,000 | 27,515 | 27,515 | -0- | 100,000 | -0- | -0- | -0- | 100,000 | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 160,000 | 160,000 | 44,024 | 44,024 | -0- | 160,000 | -0- | -0- | 160,000 | -0- | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 200,000 | 200,000 | 55,030 | 55,030 | -0- | 200,000 | -0- | -0- | -0- | 200,000 | |||||||||||||||||||||||||||||||||||
12/16/08 | 1/1/16 | 12% | 4,615,000 | 4,520,000 | 1,243,681 | 1,243,681 | -0- | 4,520,000 | -0- | -0- | 4,505,000 | 15,000 | |||||||||||||||||||||||||||||||||||
9/30/09 | 1/1/16 | 12% | 1,400,000 | 1,200,000 | 526,400 | 526,400 | -0- | 1,200,000 | -0- | -0- | 1,100,000 | 100,000 | |||||||||||||||||||||||||||||||||||
12/31/09 | 1/1/16 | 12% | 1,490,000 | 1,490,000 | 935,720 | 935,720 | -0- | 1,490,000 | -0- | -0- | 1,440,000 | 50,000 | |||||||||||||||||||||||||||||||||||
Total | $ | 11,097,500 | $ | 9,665,000 | $ | 4,884,450 | $ | 4,884,450 | $ | -0- | $ | 9,665,000 | $ | -0- | $ | 75,000 | $ | 9,125,000 | $ | 465,000 |
Note_11_Fair_Value_Measurement1
Note 11 - Fair Value Measurement (Tables) | 12 Months Ended | ||||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] | Fair value at | Quoted prices in active markets for identical assets/ liabilities | Significant other observable inputs | Significant unobservable inputs | |||||||||||||||||||||
December 31, | |||||||||||||||||||||||||
2014 | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||||||||||
Derivatives: (1) (2) | |||||||||||||||||||||||||
Conversion feature liability | $ | 2,944,402 | $ | -0- | $ | -0- | $ | 2,944,402 | |||||||||||||||||
Warrant liability | 6,695,060 | -0- | -0- | 6,695,060 | |||||||||||||||||||||
Total of derivative liabilities | $ | 9,639,462 | $ | -0- | $ | -0- | $ | 9,639,462 | |||||||||||||||||
Fair value at | Quoted prices in active markets for identical assets/ liabilities | Significant other observable inputs | Significant unobservable inputs | ||||||||||||||||||||||
December 31, | |||||||||||||||||||||||||
2013 | (Level 1) | (Level 2) | (Level 3) | ||||||||||||||||||||||
Derivatives: (1) (2) | |||||||||||||||||||||||||
Conversion feature liability | $ | 3,126,206 | $ | -0- | $ | -0- | $ | 3,126,206 | |||||||||||||||||
Warrant liability | 5,943,977 | -0- | -0- | 5,943,977 | |||||||||||||||||||||
Total of derivative liabilities | $ | 9,070,183 | $ | -0- | $ | -0- | $ | 9,070,183 | |||||||||||||||||
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] | Risk free interest rate | 0.13% | |||||||||||||||||||||||
Dividend yield | 0.00% | ||||||||||||||||||||||||
Expected volatility | 119.80% | to | 155.70% | ||||||||||||||||||||||
Expected life (range in years) | |||||||||||||||||||||||||
Conversion feature liability | 1 | to | 1.25 | ||||||||||||||||||||||
Warrant liability | 1 | to | 2.25 | ||||||||||||||||||||||
Risk free interest rate | 0.12% | to | 0.13% | ||||||||||||||||||||||
Dividend yield | 0.00% | ||||||||||||||||||||||||
Expected volatility | 166.70% | to | 217.10% | ||||||||||||||||||||||
Expected life (range in years) | |||||||||||||||||||||||||
Conversion feature liability | 1 | to | 2 | ||||||||||||||||||||||
Warrant liability | 1 | to | 2.25 | ||||||||||||||||||||||
Fair Value Measurements, Nonrecurring [Table Text Block] | Carrying amount December 31, | Carrying amount December 31, | Quoted prices in active markets for identical assets/ liabilities | Significant other observable inputs | Significant unobservable inputs | ||||||||||||||||||||
2013 | 2014 | (Level 1) | (Level 2) | (Level 3) | |||||||||||||||||||||
Acquired assets (3) | |||||||||||||||||||||||||
Promasys B.V. customer lists (4) | $ | 134,739 | $ | 110,948 | $ | -0- | $ | -0- | $ | 136,253 | |||||||||||||||
Promasys B.V. software code (4) | 70,512 | 55,842 | -0- | -0- | 72,943 | ||||||||||||||||||||
Promasys B.V. URLs/website (4) | 64,991 | 37,131 | -0- | -0- | 68,814 | ||||||||||||||||||||
Total | $ | 270,242 | $ | 203,921 | $ | -0- | $ | -0- | $ | 278,010 | |||||||||||||||
Carrying amount December 31, | Carrying amount December 31, | Quoted prices in active markets for identical assets/ liabilities | Significant other observable inputs | Significant unobservable inputs | |||||||||||||||||||||
2012 | 2013 | (Level 1) | (Level 2) | (Level 3) | |||||||||||||||||||||
Acquired assets (3) | |||||||||||||||||||||||||
Promasys B.V. customer lists (4) | $ | -0- | $ | 134,739 | $ | -0- | $ | -0- | $ | 136,253 | |||||||||||||||
Promasys B.V. software code (4) | -0- | 70,512 | -0- | -0- | 72,943 | ||||||||||||||||||||
Promasys B.V. URLs/website (4) | -0- | 64,991 | -0- | -0- | 68,814 | ||||||||||||||||||||
Total | $ | -0- | $ | 270,242 | $ | -0- | $ | -0- | $ | 278,010 | |||||||||||||||
Schedule of Goodwill [Table Text Block] | 31-Dec-14 | 31-Dec-13 | |||||||||||||||||||||||
(Level 3) | |||||||||||||||||||||||||
Goodwill | $ | 596,620 | $ | 675,710 | |||||||||||||||||||||
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block] | Other income/(expense) | ||||||||||||||||||||||||
for the year ended | |||||||||||||||||||||||||
31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||||
The net amount of gains/(losses) for the period included in earnings attributable to the unrealized gain/(loss) from changes in derivative liabilities at the reporting date | $ | 58,807 | $ | (95,121 | ) | ||||||||||||||||||||
Total unrealized gains/(losses) included in earnings | $ | 58,807 | $ | (95,121 | ) | ||||||||||||||||||||
Schedule of Derivative Liabilities at Fair Value [Table Text Block] | Level 3 financial liabilities at fair value | ||||||||||||||||||||||||
Net unrealized | |||||||||||||||||||||||||
gains/(losses) | Net | ||||||||||||||||||||||||
relating to | purchases, | ||||||||||||||||||||||||
Balance, | instruments still | issuances | Net transfers | Balance, | |||||||||||||||||||||
beginning | Net realized | held at the | and | in and/or out | end of | ||||||||||||||||||||
of year | gains/(losses) | reporting date | settlements | of Level 3 | year | ||||||||||||||||||||
Year ended December 31, 2014 | |||||||||||||||||||||||||
Derivatives: | |||||||||||||||||||||||||
Conversion feature liability | $ | (3,126,206 | ) | $ | -0- | $ | 181,804 | $ | -0- | $ | -0- | $ | (2,944,402 | ) | |||||||||||
Warrant liability | (5,943,977 | ) | -0- | (122,997 | ) | (628,086 | ) | -0- | (6,695,060 | ) | |||||||||||||||
Total of derivative liabilities | $ | (9,070,183 | ) | $ | -0- | $ | 58,807 | $ | (628,086 | ) | $ | -0- | $ | (9,639,462 | ) | ||||||||||
Level 3 financial liabilities at fair value | |||||||||||||||||||||||||
Net unrealized | |||||||||||||||||||||||||
gains/(losses) | Net | ||||||||||||||||||||||||
relating to | purchases, | ||||||||||||||||||||||||
Balance, | instruments still | issuances | Net transfers | Balance, | |||||||||||||||||||||
beginning | Net realized | held at the | and | in and/or out | end of | ||||||||||||||||||||
of year | gains/(losses) | reporting date | settlements | of Level 3 | year | ||||||||||||||||||||
Year ended December 31, 2013 | |||||||||||||||||||||||||
Derivatives: | |||||||||||||||||||||||||
Conversion feature liability | $ | (2,287,323 | ) | $ | -0- | $ | (838,883 | ) | $ | -0- | $ | -0- | $ | (3,126,206 | ) | ||||||||||
Warrant liability | (6,287,598 | ) | -0- | 743,762 | (400,141 | ) | -0- | (5,943,977 | ) | ||||||||||||||||
Total of derivative liabilities | $ | (8,574,921 | ) | $ | -0- | $ | (95,121 | ) | $ | (400,141 | ) | $ | -0- | $ | (9,070,183 | ) |
Note_12_Commitments_and_Contin1
Note 12 - Commitments and Contingencies (Tables) | 12 Months Ended | ||||
Dec. 31, 2014 | |||||
Commitments and Contingencies Disclosure [Abstract] | |||||
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | 2015 | $ | 654,134 | ||
2016 | 367,327 | ||||
2017 | 50,266 | ||||
2018 | 5,165 | ||||
Total | $ | 1,076,892 | |||
Schedule of Minimum Royalty Payments [Table Text Block] | 2015 | $ | 450,000 | ||
2016 | 450,000 | ||||
2017 | 450,000 | ||||
Total | $ | 1,350,000 |
Note_14_Stockholders_Deficit_T
Note 14 - Stockholders' (Deficit) (Tables) | 12 Months Ended | ||||||||||||||||||||||
Dec. 31, 2014 | |||||||||||||||||||||||
Note 14 - Stockholders' (Deficit) (Tables) [Line Items] | |||||||||||||||||||||||
Schedule of Dividends in Arrears [Table Text Block] | Cumulative arrearage as of | Cumulative arrearage per share | |||||||||||||||||||||
December 31, | as of December 31, | ||||||||||||||||||||||
Series of preferred stock | 2014 | 2013 | 2014 | 2013 | |||||||||||||||||||
Series A | $ | 2,586,700 | $ | 2,380,439 | $ | 0.63 | $ | 0.58 | |||||||||||||||
Series B | 609,887 | 609,887 | $ | 3.05 | $ | 3.05 | |||||||||||||||||
Series C | 1,472,093 | 1,472,093 | $ | 4.37 | $ | 4.37 | |||||||||||||||||
Total preferred stock arrearage | $ | 4,668,680 | $ | 4,462,419 | |||||||||||||||||||
Schedule of Dividends Payable [Table Text Block] | Dividends accreted | Dividends per share | |||||||||||||||||||||
year ended December 31, | year ended December 31, | ||||||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||||
Preferred stock dividends in arrears Series A | $ | 206,261 | $ | 206,261 | $ | 0.05 | $ | 0.05 | |||||||||||||||
Preferred stock dividends in arrears Series B | $ | -0- | $ | -0- | $ | -0- | $ | -0- | |||||||||||||||
Preferred stock dividends in arrears Series C | $ | -0- | $ | -0- | $ | -0- | $ | -0- | |||||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | December 31, 2014 warrants outstanding | December 31, 2014 warrants exercisable | |||||||||||||||||||||
Range of exercise price | Number outstanding at | Weighted average | Weighted average | Number exercisable at | Weighted average | ||||||||||||||||||
31-Dec-14 | remaining contractual life | exercise price | 31-Dec-14 | exercise price | |||||||||||||||||||
$0.25 | – | $0.60 | 48,463,517 | 1.17 | $ | 0.35 | 48,463,517 | $ | 0.35 | ||||||||||||||
December 31, 2013 warrants outstanding | December 31, 2013 warrants exercisable | ||||||||||||||||||||||
Range of exercise price | Number outstanding at | Weighted average | Weighted average | Number exercisable at | Weighted average | ||||||||||||||||||
31-Dec-13 | remaining contractual life | exercise price | 31-Dec-13 | exercise price | |||||||||||||||||||
$0.25 | – | $0.60 | 44,728,873 | 2.05 | $ | 0.36 | 44,728,873 | $ | 0.36 | ||||||||||||||
Schedule of Share-based Compensation, Activity [Table Text Block] | Weighted average grant date fair value | ||||||||||||||||||||||
2014 | 2013 | ||||||||||||||||||||||
Stock options granted during the year ended December 31, | $ | 0.16 | $ | 0.17 | |||||||||||||||||||
Stock options vested during the year ended December 31, | $ | 0.12 | $ | 0.11 | |||||||||||||||||||
Stock options forfeited during the year ended December 31, | $ | 0.31 | $ | 0.29 | |||||||||||||||||||
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | Foreign currency translation | Accumulated other comprehensive (loss) | |||||||||||||||||||||
Balance at December 31, 2012 | $ | (69,092 | ) | $ | (69,092 | ) | |||||||||||||||||
2013 Activity | (18,512 | ) | (18,512 | ) | |||||||||||||||||||
Balance at December 31, 2013 | (87,604 | ) | (87,604 | ) | |||||||||||||||||||
2014 Activity | (156,223 | ) | (156,223 | ) | |||||||||||||||||||
Balance at December 31, 2014 | $ | (243,827 | ) | $ | (243,827 | ) | |||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||
Note 14 - Stockholders' (Deficit) (Tables) [Line Items] | |||||||||||||||||||||||
Schedule of Share-based Compensation, Activity [Table Text Block] | Warrants | ||||||||||||||||||||||
Balance at December 31, 2012 | 43,412,873 | ||||||||||||||||||||||
Issued | 2,116,000 | ||||||||||||||||||||||
Exercised | -0- | ||||||||||||||||||||||
Expired/forfeited | (800,000 | ) | |||||||||||||||||||||
Balance at December 31, 2013 | 44,728,873 | ||||||||||||||||||||||
Issued | 3,920,000 | ||||||||||||||||||||||
Exercised | -0- | ||||||||||||||||||||||
Expired/forfeited | (185,356 | ) | |||||||||||||||||||||
Balance at December 31, 2014 | 48,463,517 | ||||||||||||||||||||||
Warrants exercisable at December 31, 2014 | 48,463,517 | ||||||||||||||||||||||
Weighted average fair value of warrants granted during 2013 | $ | 0.19 | |||||||||||||||||||||
Weighted average fair value of warrants granted during 2014 | $ | 0.15 |
Note_15_Employee_Equity_Incent1
Note 15 - Employee Equity Incentive Plans (Tables) | 12 Months Ended | |||||||||||||||||||||||||||
Dec. 31, 2014 | ||||||||||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Number of shares | Weighted average exercise price | Weighted average remaining contractual term | Aggregate intrinsic value | ||||||||||||||||||||||||
(per share) | (in years) | |||||||||||||||||||||||||||
Outstanding at December 31, 2012 | 10,452,500 | $ | 0.36 | 1.68 | $ | 149,598 | ||||||||||||||||||||||
Granted | 350,000 | 0.17 | ||||||||||||||||||||||||||
Exercised | (100,000 | ) | 0.18 | |||||||||||||||||||||||||
Forfeited/cancelled/expired | (4,957,500 | ) | 0.42 | |||||||||||||||||||||||||
Outstanding at December 31, 2013 | 5,745,000 | 0.29 | 1.7 | $ | 93,945 | |||||||||||||||||||||||
Granted | 150,000 | 0.16 | ||||||||||||||||||||||||||
Exercised | (150,000 | ) | 0.13 | |||||||||||||||||||||||||
Forfeited/cancelled/expired | (2,615,000 | ) | 0.4 | |||||||||||||||||||||||||
Outstanding at December 31, 2014 | 3,130,000 | $ | 0.2 | 1.59 | $ | 364,900 | ||||||||||||||||||||||
Vested and exercisable at December 31, 2014 | 2,855,000 | $ | 0.21 | 1.35 | $ | 332,850 | ||||||||||||||||||||||
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block] | Number of | Fair value of | ||||||||||||||||||||||||||
options vested | options vested | |||||||||||||||||||||||||||
Fair value of options vesting during the year ended December 31, 2014 | 695,834 | $ | 84,450 | |||||||||||||||||||||||||
Fair value of options vesting during the year ended December 31, 2013 | 768,833 | $ | 81,391 | |||||||||||||||||||||||||
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | Awards breakdown by price range at December 31, 2014 | |||||||||||||||||||||||||||
Outstanding | Vested | |||||||||||||||||||||||||||
Strike price range ($) | Outstanding stock options | Weighted average remaining contractual life | Weighted average outstanding strike price | Vested stock options | Weighted average remaining vested contractual life | Weighted average vested strike price | ||||||||||||||||||||||
0 | to | 0.2 | 2,080,000 | 1.98 | $ | 0.13 | 1,855,000 | 1.72 | $ | 0.12 | ||||||||||||||||||
0.21 | to | 0.29 | 600,000 | 0.92 | 0.24 | 550,000 | 0.69 | 0.25 | ||||||||||||||||||||
0.3 | to | 0.49 | -0- | 0 | 0 | -0- | 0 | 0 | ||||||||||||||||||||
0.5 | to | 0.7 | 450,000 | 0.68 | 0.5 | 450,000 | 0.68 | 0.5 | ||||||||||||||||||||
0 | to | 0.7 | 3,130,000 | 1.59 | $ | 0.2 | 2,855,000 | 1.35 | $ | 0.21 | ||||||||||||||||||
Awards breakdown by price range at December 31, 2013 | ||||||||||||||||||||||||||||
Outstanding | Vested | |||||||||||||||||||||||||||
Strike price range ($) | Outstanding stock options | Weighted average remaining contractual life | Weighted average outstanding strike price | Vested stock options | Weighted average remaining vested contractual life | Weighted average vested strike price | ||||||||||||||||||||||
0 | to | 0.2 | 3,251,000 | 2.16 | $ | 0.15 | 2,530,166 | 1.86 | $ | 0.16 | ||||||||||||||||||
0.21 | to | 0.29 | 750,000 | 1.64 | 0.25 | 650,000 | 1.2 | 0.25 | ||||||||||||||||||||
0.3 | to | 0.49 | 110,000 | 0.98 | 0.38 | 110,000 | 0.98 | 0.38 | ||||||||||||||||||||
0.5 | to | 0.7 | 1,634,000 | 0.87 | 0.59 | 1,634,000 | 0.87 | 0.59 | ||||||||||||||||||||
0 | to | 0.7 | 5,745,000 | 1.7 | $ | 0.29 | 4,924,166 | 1.42 | $ | 0.32 | ||||||||||||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Stock option assumptions for the year ended | |||||||||||||||||||||||||||
Stock option assumptions | 31-Dec-14 | 31-Dec-13 | ||||||||||||||||||||||||||
Risk-free interest rate | 0.93% | 0.58% | ||||||||||||||||||||||||||
Expected dividend yield | 0.00% | 0.00% | ||||||||||||||||||||||||||
Expected volatility | 199.00% | 202.70% | ||||||||||||||||||||||||||
Expected life of options (in years) | 5 | 5 | ||||||||||||||||||||||||||
Schedule of Share-based Compensation, Activity [Table Text Block] | Weighted average grant date fair value | |||||||||||||||||||||||||||
2014 | 2013 | |||||||||||||||||||||||||||
Stock options granted during the year ended December 31, | $ | 0.16 | $ | 0.17 | ||||||||||||||||||||||||
Stock options vested during the year ended December 31, | $ | 0.12 | $ | 0.11 | ||||||||||||||||||||||||
Stock options forfeited during the year ended December 31, | $ | 0.31 | $ | 0.29 | ||||||||||||||||||||||||
Schedule of Nonvested Share Activity [Table Text Block] | Shares underlying stock options | Weighted average grant date fair value | ||||||||||||||||||||||||||
Nonvested shares at January 1, 2014 | 820,834 | $ | 0.13 | |||||||||||||||||||||||||
Nonvested shares at December 31, 2014 | 275,000 | $ | 0.17 |
Note_16_Income_Taxes_Tables
Note 16 - Income Taxes (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Income Tax Disclosure [Abstract] | |||||||||
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 31-Dec-14 | 31-Dec-13 | |||||||
Federal statutory rate applied to (loss) before income taxes | $ | (1,685,418 | ) | $ | (1,154,195 | ) | |||
Increase/(decrease) in income taxes results from: | |||||||||
Current tax expense/(benefit) | (19,537 | ) | 94,122 | ||||||
Non deductible expenses | 198,295 | 296,783 | |||||||
Change in deferred assets | 64,449 | 71,274 | |||||||
Change in valuation allowance | 1,422,674 | 786,138 | |||||||
Income tax expense/(benefit) | $ | (19,537 | ) | $ | 94,122 | ||||
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | 31-Dec-14 | 31-Dec-13 | |||||||
Current tax expense/(benefit): | $ | (19,537 | ) | $ | 94,122 | ||||
Deferred tax expense/(benefit): | |||||||||
Bad debt allowance | (45,407 | ) | 7,100 | ||||||
Operating loss carryforward | (1,441,716 | ) | (864,512 | ) | |||||
Amortization of intangibles | 5,482 | -0- | |||||||
Patent litigation settlement | 58,967 | 71,274 | |||||||
(1,442,211 | ) | (692,016 | ) | ||||||
Valuation allowance | 1,422,674 | 786,138 | |||||||
Total tax expense/(benefit) | $ | (19,537 | ) | $ | 94,122 | ||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 31-Dec-14 | 31-Dec-13 | |||||||
Amortization of intangibles | $ | 278,216 | $ | 283,698 | |||||
Bad debt allowance | 69,022 | 23,615 | |||||||
Patent litigation liability accrual | 256,441 | 315,408 | |||||||
Operating loss carryforwards | 19,662,198 | 18,220,482 | |||||||
Gross deferred tax assets | 20,265,877 | 18,843,203 | |||||||
Valuation allowance | (20,265,877 | ) | (18,843,203 | ) | |||||
Net deferred tax liability/(asset) | $ | -0- | $ | -0- |
Note_1_Organization_and_Nature1
Note 1 - Organization and Nature of Operations (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Disclosure Text Block [Abstract] | ||
Research and Development Expense | $2,754,367 | $2,403,504 |
Note_2_Summary_of_Significant_2
Note 2 - Summary of Significant Accounting Policies (Details) (USD $) | 12 Months Ended | |||
Dec. 31, 2014 | Dec. 31, 2013 | Jul. 10, 2009 | Dec. 31, 2008 | |
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | ||||
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | ($156,223) | ($18,512) | ||
Number of Reportable Segments | 1 | |||
Allowance for Doubtful Accounts Receivable, Current | 186,085 | 65,341 | ||
Cash, Uninsured Amount | 264,234 | |||
Revenues | 16,461,250 | 14,331,840 | ||
Deferred Revenue | 8,233,943 | |||
Deferred Revenue, Current | 5,840,875 | 2,866,356 | ||
Advertising Expense | 419,253 | 226,380 | ||
Research and Development Expense | 2,754,367 | 2,403,504 | ||
Leasehold Improvements, Computers, Equipment and Furniture [Member] | ||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | ||||
Property, Plant and Equipment, Useful Life | 5 years | |||
Software Development [Member] | ||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | ||||
Property, Plant and Equipment, Useful Life | 3 years | |||
Customer 1 [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | ||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | ||||
Concentration Risk, Percentage | 15.00% | 11.00% | ||
Customer 1 [Member] | ||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | ||||
Revenues | $2,395,000 | $1,551,000 | ||
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | ||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | ||||
Concentration Risk, Percentage | 15.00% | 11.00% | ||
Minimum [Member] | ||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | ||||
Term of Software License | 3 years | |||
Derivative, Term of Contract | 1 month | |||
Maximum [Member] | ||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | ||||
Term of Software License | 5 years | |||
Derivative, Term of Contract | 5 years | |||
2009 Plan [Member] | ||||
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares) | 7,500,000 | 12,500,000 |
Note_2_Summary_of_Significant_3
Note 2 - Summary of Significant Accounting Policies (Details) - Revenue by Business Activity (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Revenue | $16,461,250 | $14,331,840 |
Set-up Fees [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Revenue | 4,814,378 | 3,369,670 |
Change Orders [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Revenue | 467,815 | 475,680 |
Maintenance [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Revenue | 4,374,245 | 4,584,594 |
Software Licenses [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Revenue | 3,404,655 | 2,911,509 |
Professional Services [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Revenue | 2,605,010 | 2,207,181 |
Hosting [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Revenue | $795,147 | $783,206 |
Note_2_Summary_of_Significant_4
Note 2 - Summary of Significant Accounting Policies (Details) - Allowance for Doubtful Account Summary (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Allowance for Doubtful Account Summary [Abstract] | ||
Beginning of period | $65,341 | $84,210 |
Bad debt expense | 147,543 | 11,131 |
Write-offs | -26,875 | -30,000 |
Exchange rate impact | 76 | 0 |
End of period | $186,085 | $65,341 |
Note_2_Summary_of_Significant_5
Note 2 - Summary of Significant Accounting Policies (Details) - Customer Concentration (Customer Concentration Risk [Member]) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Sales Revenue, Net [Member] | ||
Concentration Risk [Line Items] | ||
Number of Customers | 1 | 1 |
Percentage of Concentration Risk | 15.00% | 11.00% |
Accounts Receivable [Member] | ||
Concentration Risk [Line Items] | ||
Number of Customers | 1 | 2 |
Percentage of Concentration Risk | 18.00% | 23.00% |
Note_2_Summary_of_Significant_6
Note 2 - Summary of Significant Accounting Policies (Details) - Revenue from European Operations (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Note 2 - Summary of Significant Accounting Policies (Details) - Revenue from European Operations [Line Items] | ||
$16,461,250 | $14,331,840 | |
Reportable Geographical Components [Member] | Europe [Member] | ||
Note 2 - Summary of Significant Accounting Policies (Details) - Revenue from European Operations [Line Items] | ||
$2,383,252 | $1,847,305 | |
Sales Revenue, Net [Member] | Europe [Member] | ||
Note 2 - Summary of Significant Accounting Policies (Details) - Revenue from European Operations [Line Items] | ||
14.50% | 12.90% |
Note_4_Earnings_Loss_Per_Share2
Note 4 - Earnings (Loss) Per Share (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Note 4 - Earnings (Loss) Per Share (Details) [Line Items] | ||
Weighted Average Number of Shares Outstanding, Basic (in Shares) | 90,701,058 | 87,969,202 |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | 80,012,198 | 79,546,913 |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | $0.05 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $0.50 | |
Lower Range Limit [Member] | ||
Note 4 - Earnings (Loss) Per Share (Details) [Line Items] | ||
Investment Warrants, Exercise Price | $0.25 | |
Upper Range Limit [Member] | ||
Note 4 - Earnings (Loss) Per Share (Details) [Line Items] | ||
Investment Warrants, Exercise Price | $0.60 | |
Lower Range Limit [Member] | ||
Note 4 - Earnings (Loss) Per Share (Details) [Line Items] | ||
Debt Instrument, Convertible, Conversion Price | $0.25 | |
Upper Range Limit [Member] | ||
Note 4 - Earnings (Loss) Per Share (Details) [Line Items] | ||
Debt Instrument, Convertible, Conversion Price | $0.50 |
Note_4_Earnings_Loss_Per_Share3
Note 4 - Earnings (Loss) Per Share (Details) - Reconciliation of Anti-Dilutive Securities | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-Dilutive Security | 80,012,198 | 79,546,913 |
Shares Of Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-Dilutive Security | 2,750,149 | 2,750,149 |
Equity Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-Dilutive Security | 3,130,000 | 5,745,000 |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-Dilutive Security | 48,463,517 | 44,728,873 |
Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-Dilutive Security | 24,620,000 | 24,620,000 |
Shares Issuable For Accrued Interest [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-Dilutive Security | 1,048,532 | 1,702,891 |
Note_4_Earnings_Loss_Per_Share4
Note 4 - Earnings (Loss) Per Share (Details) - Computation of Diluted Earnings Per Share (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Computation of Diluted Earnings Per Share [Abstract] | ||
Basic EPS | ($4,665,645) | ($3,367,603) |
Basic EPS | 90,701,058 | 87,969,202 |
Basic EPS | ($0.05) | ($0.04) |
Effect of dilutive securities - none | 0 | 0 |
Effect of dilutive securities - none | 0 | 0 |
Effect of dilutive securities - none | $0 | $0 |
Diluted EPS | ($4,665,645) | ($3,367,603) |
Diluted EPS | 90,701,058 | 87,969,202 |
Diluted EPS | ($0.05) | ($0.04) |
Note_5_Property_and_Equipment_2
Note 5 - Property and Equipment, Net (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation | $235,591 | $230,323 |
Note_5_Property_and_Equipment_3
Note 5 - Property and Equipment, Net (Details) - Property and Equipment (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Property, Plant and Equipment [Line Items] | ||
Cost | $3,666,692 | $3,586,780 |
Accumulated Depreciation | 3,198,556 | 2,979,347 |
Net Book Value | 468,136 | 607,433 |
Computer And Office Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 1,880,183 | 1,822,098 |
Accumulated Depreciation | 1,482,737 | 1,326,256 |
Net Book Value | 397,446 | 495,842 |
Estimated Useful Lives | 5 years | |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 92,504 | 93,812 |
Accumulated Depreciation | 82,353 | 75,735 |
Net Book Value | 10,151 | 18,077 |
Estimated Useful Lives | 5 years | |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 1,580,640 | 1,556,497 |
Accumulated Depreciation | 1,528,418 | 1,477,801 |
Net Book Value | 52,222 | 78,696 |
Estimated Useful Lives | 3 years | |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Cost | 113,365 | 114,373 |
Accumulated Depreciation | 105,048 | 99,555 |
Net Book Value | $8,317 | $14,818 |
Estimated Useful Lives | 5 years |
Note_6_Intangible_Assets_at_Co2
Note 6 - Intangible Assets, at Cost (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Disclosure Text Block [Abstract] | ||
Amortization of Intangible Assets | $45,433 | $7,720 |
Note_6_Intangible_Assets_at_Co3
Note 6 - Intangible Assets, at Cost (Details) - Intangible Assets (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Finite-Lived Intangible Assets [Line Items] | ||
Cost | $1,646,603 | $1,670,711 |
Accumulated Amortization | 1,442,682 | 1,400,469 |
Net Book value | 203,921 | 270,242 |
eClinical Customer List [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 1,392,701 | 1,392,701 |
Accumulated Amortization | 1,392,701 | 1,392,701 |
Net Book value | 0 | 0 |
Estimated Useful Lives | 3 years | |
Promasys B.V. Customer List [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 120,305 | 136,253 |
Accumulated Amortization | 9,357 | 1,514 |
Net Book value | 110,948 | 134,739 |
Estimated Useful Lives | 15 years | |
Promasys B.V. Software Code [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 72,837 | 72,943 |
Accumulated Amortization | 16,995 | 2,431 |
Net Book value | 55,842 | 70,512 |
Estimated Useful Lives | 5 years | |
Promasys B.V. URLs/Website [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Cost | 60,760 | 68,814 |
Accumulated Amortization | 23,629 | 3,823 |
Net Book value | $37,131 | $64,991 |
Estimated Useful Lives | 3 years |
Note_6_Intangible_Assets_at_Co4
Note 6 - Intangible Assets, at Cost (Details) - Intangible Assets, Future Amortization Expense (USD $) | Dec. 31, 2014 |
Intangible Assets, Future Amortization Expense [Abstract] | |
2015 | $42,841 |
2016 | 39,466 |
2017 | 22,588 |
2018 | 20,160 |
2019 | 8,020 |
Thereafter | 70,846 |
Total | $203,921 |
Note_7_Accounts_Payable_and_Ac2
Note 7 - Accounts Payable and Accrued Expenses (Details) - Accounts Payable and Accrued Expenses (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Accounts Payable and Accrued Expenses [Abstract] | ||
Accounts payable | $613,584 | $724,421 |
Accrued payroll and related costs | 319,629 | 260,072 |
Other accrued expenses | 85,248 | 88,292 |
Accrued interest | 875,724 | 1,468,171 |
Total accounts payable and accrued expenses | $1,894,185 | $2,540,956 |
Note_8_Promasys_BV_Acquisition2
Note 8 - Promasys B.V. Acquisition (Details) | Dec. 31, 2014 | Dec. 31, 2013 | Nov. 11, 2013 | Nov. 11, 2013 | Oct. 31, 2013 | Nov. 11, 2013 | Nov. 11, 2013 |
Promasys B.V. [Member] | Promasys B.V. [Member] | Promasys B.V. [Member] | Promasys B.V. [Member] | Promasys B.V. [Member] | |||
Shareholder1 [Member] | Shareholder1 [Member] | Dr Adam F Cohen [Member] | |||||
USD ($) | EUR (€) | ||||||
Note 8 - Promasys B.V. Acquisition (Details) [Line Items] | |||||||
Sale of Stock, Percentage of Ownership after Transaction | 100.00% | ||||||
Payments to Acquire Businesses, Gross | $593,000 | € 435,998 | |||||
Common Stock, Shares, Issued | 91,561,802 | 90,104,659 | 790,000 | 2,270,000 | |||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 10.00% |
Note_8_Promasys_BV_Acquisition3
Note 8 - Promasys B.V. Acquisition (Details) - Net Assets Acquired in Acquisition (USD $) | Dec. 31, 2014 | Dec. 31, 2013 | Nov. 11, 2013 |
Note 8 - Promasys B.V. Acquisition (Details) - Net Assets Acquired in Acquisition [Line Items] | |||
Goodwill | $596,620 | $675,710 | |
Promasys B.V. [Member] | |||
Note 8 - Promasys B.V. Acquisition (Details) - Net Assets Acquired in Acquisition [Line Items] | |||
Cash | 215,571 | ||
Receivables | 216,287 | ||
Property and equipment | 2,178 | ||
Identifiable intangibles | 276,356 | ||
Goodwill | 671,689 | ||
Total assets acquired | 1,382,081 | ||
Accounts payable | -170,339 | ||
Deferred revenue | -229,353 | ||
Net assets acquired | $982,389 |
Note_8_Promasys_BV_Acquisition4
Note 8 - Promasys B.V. Acquisition (Details) - Pro Forma Information (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Pro Forma Information [Abstract] | |
Gross revenues | $15,119,861 |
Total expenses | 18,145,210 |
Net income/(loss) before taxes | -3,025,349 |
Weighted average number of shares outstanding (in Dollars per share) | ($0.04) |
Basic and diluted | $89,866,051 |
Note_9_Line_of_Credit_and_Note2
Note 9 - Line of Credit and Notes Payable (Details) (USD $) | 0 Months Ended | ||||||||||||||||
Jan. 01, 2013 | Jan. 02, 2014 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 18, 2013 | Mar. 18, 2013 | Jan. 02, 2013 | Jan. 31, 2015 | Feb. 03, 2015 | Dec. 01, 2014 | Apr. 04, 2014 | Feb. 01, 2013 | Mar. 05, 2013 | Apr. 01, 2013 | Jan. 01, 2014 | Dec. 17, 2014 | Dec. 23, 2014 | |
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $4,000,000 | $2,000,000 | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.00% | ||||||||||||||||
Long-term Line of Credit | 4,000,000 | ||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 2.25% | ||||||||||||||||
Unsecured Debt | 7,081,500 | 5,667,865 | |||||||||||||||
Notes Payable | 7,081,500 | 5,667,865 | |||||||||||||||
Subsequent Event [Member] | Note Payable 23 [Member] | Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Debt Instrument, Face Amount | 2,860,000 | ||||||||||||||||
Subsequent Event [Member] | Note Payable 23 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Subsequent Event [Member] | Note Payable 12 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Face Amount | 1,600,000 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | ||||||||||||||||
Subsequent Event [Member] | Note Payable 24 [Member] | Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Debt Instrument, Face Amount | 529,000 | ||||||||||||||||
Subsequent Event [Member] | Note Payable 24 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Debt Instrument, Face Amount | 529,000 | ||||||||||||||||
Subsequent Event [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 5,000,000 | ||||||||||||||||
Note Payable 4 [Member] | Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Debt Instrument, Face Amount | 529,000 | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 2,116,000 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | ||||||||||||||||
Interest Payable | 529,000 | ||||||||||||||||
Derivative Liability | 400,141 | ||||||||||||||||
Notes Payable | 128,859 | ||||||||||||||||
Debt Instrument, Convertible, Remaining Discount Amortization Period | 36 months | ||||||||||||||||
Note Payable 4 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | |||||||||||||||
Notes Payable | 529,000 | 529,000 | |||||||||||||||
Note Payable 5 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | 10.00% | |||||||||||||||
Debt Instrument, Face Amount | 308,561 | ||||||||||||||||
Notes Payable | 308,561 | ||||||||||||||||
Debt Instrument, Repurchase Amount | 8,561 | ||||||||||||||||
Debt Instrument, Repurchased Face Amount | 308,561 | ||||||||||||||||
Note Payable 16 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | 10.00% | |||||||||||||||
Debt Instrument, Face Amount | 300,000 | ||||||||||||||||
Notes Payable | 300,000 | ||||||||||||||||
Note Payable 6 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | 10.00% | |||||||||||||||
Debt Instrument, Face Amount | 123,425 | ||||||||||||||||
Notes Payable | 123,425 | ||||||||||||||||
Debt Instrument, Repurchase Amount | 3,425 | ||||||||||||||||
Debt Instrument, Repurchased Face Amount | 123,425 | ||||||||||||||||
Note Payable 15 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | 10.00% | |||||||||||||||
Debt Instrument, Face Amount | 120,000 | ||||||||||||||||
Notes Payable | 120,000 | ||||||||||||||||
Note Payable 7 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | |||||||||||||||
Debt Instrument, Face Amount | 45,000 | ||||||||||||||||
Notes Payable | 45,000 | ||||||||||||||||
Note Payable 13 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | |||||||||||||||
Debt Instrument, Face Amount | 45,000 | ||||||||||||||||
Notes Payable | 45,000 | ||||||||||||||||
Note Payable 8 [Member] | Board of Directors Chairman [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Debt Instrument, Face Amount | 20,000 | ||||||||||||||||
Note Payable 8 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | |||||||||||||||
Notes Payable | 20,000 | 20,000 | |||||||||||||||
Note Payable 9 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | |||||||||||||||
Debt Instrument, Face Amount | 137,500 | ||||||||||||||||
Notes Payable | 137,500 | ||||||||||||||||
Note Payable 14 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | |||||||||||||||
Debt Instrument, Face Amount | 137,500 | ||||||||||||||||
Notes Payable | 137,500 | ||||||||||||||||
Note Payable 10 [Member] | Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Debt Instrument, Face Amount | 2,866,879 | ||||||||||||||||
Debt Instrument, Repurchase Amount | 6,879 | ||||||||||||||||
Note Payable 10 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | |||||||||||||||
Notes Payable | 2,860,000 | 2,866,879 | |||||||||||||||
Note Payable 11 [Member] | Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Debt Instrument, Face Amount | 980,000 | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 3,920,000 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | ||||||||||||||||
Interest Payable | 980,000 | ||||||||||||||||
Derivative Liability | 628,086 | ||||||||||||||||
Note Payable 11 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Notes Payable | 980,000 | ||||||||||||||||
Net of Warrants [Member] | Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Notes Payable | 351,914 | ||||||||||||||||
Note Payable 12 [Member] | Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Face Amount | 1,600,000 | ||||||||||||||||
Note Payable 12 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Notes Payable | 1,600,000 | ||||||||||||||||
Note Payable 18 [Member] | Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Note Payable 18 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Debt Instrument, Face Amount | 100,000 | ||||||||||||||||
Notes Payable | 100,000 | ||||||||||||||||
Note Payable 17 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | |||||||||||||||
Debt Instrument, Face Amount | 90,000 | ||||||||||||||||
Notes Payable | 90,000 | ||||||||||||||||
Note Payable 21 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | |||||||||||||||
Debt Instrument, Face Amount | 20,000 | ||||||||||||||||
Notes Payable | 20,000 | ||||||||||||||||
Note Payable 22 [Member] | Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Debt Instrument, Face Amount | 280,000 | ||||||||||||||||
Note Payable 22 [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||
Notes Payable | $280,000 | ||||||||||||||||
Chief Executive Officer [Member] | |||||||||||||||||
Note 9 - Line of Credit and Notes Payable (Details) [Line Items] | |||||||||||||||||
Debt Instrument, Convertible, Remaining Discount Amortization Period | 39 months |
Note_9_Line_of_Credit_and_Note3
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable (USD $) | 12 Months Ended | |||||||
Dec. 31, 2014 | Dec. 31, 2013 | Jan. 02, 2013 | Apr. 04, 2014 | Dec. 01, 2014 | Dec. 17, 2014 | Jan. 01, 2013 | Mar. 05, 2013 | |
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Interest rate | 2.00% | |||||||
Ending principal | $7,081,500 | $5,667,865 | ||||||
Short-term Debt [Member] | Note Payable 4 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Short-term Debt [Member] | Note Payable 4 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Short-term Debt [Member] | Note Payable 8 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Short-term Debt [Member] | Note Payable 8 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Short-term Debt [Member] | Note Payable 10 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Short-term Debt [Member] | Note Payable 10 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Short-term Debt [Member] | Note Payable 11 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 11 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 12 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 12 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 13 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 13 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 14 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 14 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 15 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 15 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 16 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 16 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 17 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 17 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 18 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 18 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 21 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 21 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 22 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 22 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 1 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 1 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 2 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 17,500 | |||||||
Short-term Debt [Member] | Note Payable 2 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 3 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 20,000 | |||||||
Short-term Debt [Member] | Note Payable 3 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 5 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 5 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 6 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 6 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 7 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 7 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 9 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Note Payable 9 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Short-term Debt [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 37,500 | ||||||
Discount on note payable | 0 | 0 | ||||||
Short-term Debt [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Discount on note payable | 0 | 0 | ||||||
Long-term Debt [Member] | Note Payable 4 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Long-term Debt [Member] | Note Payable 4 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 529,000 | 529,000 | ||||||
Long-term Debt [Member] | Note Payable 8 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Long-term Debt [Member] | Note Payable 8 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 20,000 | 20,000 | ||||||
Long-term Debt [Member] | Note Payable 10 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | 0 | ||||||
Long-term Debt [Member] | Note Payable 10 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 2,860,000 | 2,866,879 | ||||||
Long-term Debt [Member] | Note Payable 11 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 11 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 980,000 | |||||||
Long-term Debt [Member] | Note Payable 12 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 12 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 1,600,000 | |||||||
Long-term Debt [Member] | Note Payable 13 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 45,000 | |||||||
Long-term Debt [Member] | Note Payable 13 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 14 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 137,500 | |||||||
Long-term Debt [Member] | Note Payable 14 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 15 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 120,000 | |||||||
Long-term Debt [Member] | Note Payable 15 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 16 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 300,000 | |||||||
Long-term Debt [Member] | Note Payable 16 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 17 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 90,000 | |||||||
Long-term Debt [Member] | Note Payable 17 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 18 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 100,000 | |||||||
Long-term Debt [Member] | Note Payable 18 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 21 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 20,000 | |||||||
Long-term Debt [Member] | Note Payable 21 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 22 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 22 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 280,000 | |||||||
Long-term Debt [Member] | Note Payable 1 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 1 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 1,600,000 | |||||||
Long-term Debt [Member] | Note Payable 2 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 2 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 3 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 3 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 5 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 308,561 | |||||||
Long-term Debt [Member] | Note Payable 5 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 6 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 123,425 | |||||||
Long-term Debt [Member] | Note Payable 6 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 7 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 45,000 | |||||||
Long-term Debt [Member] | Note Payable 7 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Note Payable 9 [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 137,500 | |||||||
Long-term Debt [Member] | Note Payable 9 [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 0 | |||||||
Long-term Debt [Member] | Non-Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 812,500 | 614,486 | ||||||
Discount on note payable | 0 | 0 | ||||||
Long-term Debt [Member] | Related Party [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Ending principal | 5,700,791 | 4,568,213 | ||||||
Discount on note payable | -568,209 | -447,666 | ||||||
Note Payable 4 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Jan-16 | 1-Jan-16 | ||||||
Interest rate | 12.00% | 12.00% | ||||||
Ending principal | 529,000 | 529,000 | ||||||
Note Payable 8 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Jan-16 | 1-Jan-16 | ||||||
Interest rate | 12.00% | 12.00% | ||||||
Ending principal | 20,000 | 20,000 | ||||||
Note Payable 10 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 31-Mar-16 | 31-Mar-16 | ||||||
Interest rate | 12.00% | 12.00% | ||||||
Ending principal | 2,860,000 | 2,866,879 | ||||||
Note Payable 11 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Apr-17 | |||||||
Interest rate | 12.00% | |||||||
Ending principal | 980,000 | |||||||
Note Payable 12 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Apr-17 | |||||||
Interest rate | 12.00% | |||||||
Ending principal | 1,600,000 | |||||||
Note Payable 13 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Apr-17 | |||||||
Interest rate | 12.00% | 12.00% | ||||||
Ending principal | 45,000 | |||||||
Note Payable 14 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Apr-17 | |||||||
Interest rate | 12.00% | 12.00% | ||||||
Ending principal | 137,500 | |||||||
Note Payable 15 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Apr-17 | |||||||
Interest rate | 10.00% | 10.00% | ||||||
Ending principal | 120,000 | |||||||
Note Payable 16 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Apr-17 | |||||||
Interest rate | 10.00% | 10.00% | ||||||
Ending principal | 300,000 | |||||||
Note Payable 17 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Apr-17 | |||||||
Interest rate | 12.00% | 12.00% | ||||||
Ending principal | 90,000 | |||||||
Note Payable 18 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Apr-17 | |||||||
Interest rate | 12.00% | |||||||
Ending principal | 100,000 | |||||||
Note Payable 21 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Jan-16 | |||||||
Interest rate | 12.00% | 12.00% | ||||||
Ending principal | 20,000 | |||||||
Note Payable 22 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Apr-17 | |||||||
Interest rate | 12.00% | |||||||
Ending principal | 280,000 | |||||||
Note Payable 1 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Jan-15 | |||||||
Interest rate | 12.00% | |||||||
Ending principal | 1,600,000 | |||||||
Note Payable 2 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Jan-14 | |||||||
Interest rate | 12.00% | |||||||
Ending principal | 17,500 | |||||||
Note Payable 3 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 16-Dec-14 | |||||||
Interest rate | 12.00% | |||||||
Ending principal | 20,000 | |||||||
Note Payable 5 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Jan-15 | |||||||
Interest rate | 10.00% | 10.00% | ||||||
Ending principal | 308,561 | |||||||
Note Payable 6 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Jan-15 | |||||||
Interest rate | 10.00% | 10.00% | ||||||
Ending principal | 123,425 | |||||||
Note Payable 7 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Jan-15 | |||||||
Interest rate | 12.00% | 12.00% | ||||||
Ending principal | 45,000 | |||||||
Note Payable 9 [Member] | ||||||||
Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items] | ||||||||
Maturity date | 1-Jan-15 | |||||||
Interest rate | 12.00% | 12.00% | ||||||
Ending principal | $137,500 |
Note_10_Convertible_Notes_Paya2
Note 10 - Convertible Notes Payable (Details) (USD $) | 12 Months Ended | 0 Months Ended | 12 Months Ended | 1 Months Ended | 9 Months Ended | |||||||||||||||||||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 16, 2008 | Dec. 31, 1999 | Mar. 30, 2011 | Sep. 30, 2009 | Jan. 02, 2013 | Jan. 31, 2015 | Feb. 22, 2013 | Sep. 30, 2011 | Feb. 29, 2008 | Dec. 31, 2009 | Dec. 23, 2014 | Jan. 01, 2014 | Jan. 01, 2013 | Dec. 31, 2011 | Mar. 31, 2011 | Feb. 27, 2013 | Mar. 12, 2013 | Mar. 06, 2013 | Jun. 30, 2004 | Jul. 31, 2014 | Jul. 30, 2014 | Aug. 29, 2008 | |
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.00% | |||||||||||||||||||||||
Repayments of Notes Payable | $36,365 | $0 | ||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Convertible Debenture Initiated in February 2008 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||
Convertible Notes Payable | 4,475,000 | |||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Aggregated Convertible Debt October -December 31, 2009 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||
Convertible Notes Payable | 1,440,000 | |||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 3,800,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | |||||||||||||||||||||||
Chief Executive Officer [Member] | Extended Maturity [Member] | Convertible Debentures [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 1,490,000 | |||||||||||||||||||||||
Chief Executive Officer [Member] | Extended Maturity [Member] | Convertible Debentures 4 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 1,440,000 | |||||||||||||||||||||||
Chief Executive Officer [Member] | Convertible Debentures 2 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 4,475,000 | |||||||||||||||||||||||
Chief Executive Officer [Member] | Convertible Debenture Initiated in February 2008 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 4,350,000 | 4,475,000 | 4,200,000 | |||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.50 | |||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 4,350,000 | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 8,700,000 | |||||||||||||||||||||||
Chief Executive Officer [Member] | Aggregated Convertible Debt October -December 31, 2009 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||
Convertible Notes Payable | 1,440,000 | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 5,760,000 | |||||||||||||||||||||||
Chief Executive Officer [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | 12.00% | 12.00% | 12.00% | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 3,920,000 | 2,116,000 | 6,400,000 | 11,467,517 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | $0.25 | $0.25 | $0.25 | ||||||||||||||||||||
Chief Financial Officer [Member] | Convertible Debentures 2 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 25,000 | |||||||||||||||||||||||
Chief Technology Officer1 [Member] | Convertible Debentures 2 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 5,000 | |||||||||||||||||||||||
Former Director Mathew Veatech [Member] | Extended Maturity [Member] | Convertible Debentures 2 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 15,000 | |||||||||||||||||||||||
Extended Maturity [Member] | Secured Convertible Debenture [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 1,200,000 | 1,200,000 | ||||||||||||||||||||||
Extended Maturity [Member] | Convertible Debentures [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 1,920,000 | 150,000 | ||||||||||||||||||||||
Extended Maturity [Member] | Convertible Debentures 2 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 4,980,000 | 4,505,000 | 100,000 | 200,000 | ||||||||||||||||||||
Extended Maturity [Member] | Convertible Debentures 3 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 360,000 | |||||||||||||||||||||||
Extended Maturity [Member] | Convertible Debentures 4 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 1,490,000 | |||||||||||||||||||||||
Convertible Notes 10% [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | |||||||||||||||||||||||
Convertible Notes Payable | 862,500 | |||||||||||||||||||||||
Debt Issuance Cost | 119,625 | |||||||||||||||||||||||
Proceeds from Issuance of Debt | 742,875 | |||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $1.25 | |||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 787,500 | |||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 1,495,179 | |||||||||||||||||||||||
Long-term Debt, Gross | 75,000 | |||||||||||||||||||||||
Interest Payable | 117,248 | |||||||||||||||||||||||
Secured Convertible Debenture [Member] | Director [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 1,100,000 | 1,100,000 | ||||||||||||||||||||||
Secured Convertible Debenture [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||
Convertible Notes Payable | 1,400,000 | |||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.25 | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 5,600,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | |||||||||||||||||||||||
Proceeds from Issuance of Secured Debt | 1,400,000 | |||||||||||||||||||||||
Repayments of Notes Payable | 200,000 | |||||||||||||||||||||||
Convertible Debentures [Member] | Chief Executive Officer [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 1,770,000 | |||||||||||||||||||||||
Convertible Debentures [Member] | Non-Related Party [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Convertible Notes Payable | 150,000 | 160,000 | ||||||||||||||||||||||
Convertible Debentures [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 10.00% | ||||||||||||||||||||||
Convertible Notes Payable | 5,075,000 | 2,270,000 | ||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.50 | $0.50 | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 10,150,000 | 4,540,000 | ||||||||||||||||||||||
Convertible Debentures 4 [Member] | ||||||||||||||||||||||||
Note 10 - Convertible Notes Payable (Details) [Line Items] | ||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||
Convertible Notes Payable | $1,490,000 | |||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.25 | |||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 5,960,000 | |||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 |
Note_10_Convertible_Notes_Paya3
Note 10 - Convertible Notes Payable (Details) - Convertible Debt (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Jan. 02, 2013 | |
Debt Instrument [Line Items] | |||
Interest Rate | 2.00% | ||
Short Term Related | $75,000 | $75,000 | |
Short Term Non Related | 75,000 | 75,000 | |
Long Term Related | 775,000 | 465,000 | |
Long Term Non Related | 775,000 | 465,000 | |
Convertible Note Payable 10% $862,500 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | 0 | |
Short Term Non Related | 0 | 0 | |
Long Term Related | 0 | 150,000 | |
Long Term Non Related | 0 | 150,000 | |
Convertible Note Payable 10% $862,500 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 75,000 | 0 | |
Short Term Non Related | 75,000 | 0 | |
Long Term Related | 0 | 0 | |
Long Term Non Related | 0 | 0 | |
Convertible Note Payable 10% $862,500 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 30-Jun-04 | 1-Jan-15 | |
Interest Rate | 10.00% | 10.00% | |
Original Principal | 862,500 | 150,000 | |
Principal at Period End | 75,000 | 150,000 | |
Allocated Discount | 0 | 135,600 | |
Amortized Discount | 0 | 135,600 | |
Discount at Period End | 0 | 0 | |
Carrying Amount at Period End | 75,000 | 150,000 | |
Convertible Notes Payable 10% $2,120,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | 0 | |
Short Term Non Related | 0 | 0 | |
Long Term Related | 1,770,000 | 1,770,000 | |
Long Term Non Related | 1,770,000 | 1,770,000 | |
Convertible Notes Payable 10% $2,120,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | 0 | |
Short Term Non Related | 0 | 0 | |
Long Term Related | 0 | 0 | |
Long Term Non Related | 0 | 0 | |
Convertible Notes Payable 10% $2,120,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | 1-Jan-16 | |
Interest Rate | 10.00% | 10.00% | |
Original Principal | 2,120,000 | 2,120,000 | |
Principal at Period End | 1,770,000 | 1,770,000 | |
Allocated Discount | 1,916,480 | 1,916,480 | |
Amortized Discount | 1,916,480 | 1,916,480 | |
Discount at Period End | 0 | 0 | |
Carrying Amount at Period End | 1,770,000 | 1,770,000 | |
Convertible Notes Payable 10% $150,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Notes Payable 10% $150,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 150,000 | ||
Long Term Non Related | 150,000 | ||
Convertible Notes Payable 10% $150,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Apr-16 | ||
Interest Rate | 10.00% | ||
Original Principal | 150,000 | ||
Principal at Period End | 150,000 | ||
Allocated Discount | 135,600 | ||
Amortized Discount | 135,600 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 150,000 | ||
Convertible Notes Payable 12% $160,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | 0 | |
Short Term Non Related | 0 | 0 | |
Long Term Related | 0 | 160,000 | |
Long Term Non Related | 0 | 160,000 | |
Convertible Notes Payable 12% $160,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | 0 | |
Short Term Non Related | 0 | 0 | |
Long Term Related | 375,000 | 0 | |
Long Term Non Related | 375,000 | 0 | |
Convertible Notes Payable 12% $160,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | 1-Jan-16 | |
Interest Rate | 12.00% | 12.00% | |
Original Principal | 375,000 | 160,000 | |
Principal at Period End | 375,000 | 160,000 | |
Allocated Discount | 101,250 | 44,024 | |
Amortized Discount | 101,250 | 44,024 | |
Discount at Period End | 0 | 0 | |
Carrying Amount at Period End | 375,000 | 160,000 | |
Convertible Notes Payable 12% $4,600,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 4,505,000 | ||
Long Term Non Related | 4,505,000 | ||
Convertible Notes Payable 12% $4,600,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Notes Payable 12% $4,600,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | ||
Interest Rate | 12.00% | ||
Original Principal | 4,600,000 | ||
Principal at Period End | 4,505,000 | ||
Allocated Discount | 1,242,000 | ||
Amortized Discount | 1,242,000 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 4,505,000 | ||
Convertible Note Payable 12% $100,000 Issued on 12/16/2008 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Note Payable 12% $100,000 Issued on 12/16/2008 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 100,000 | ||
Long Term Non Related | 100,000 | ||
Convertible Note Payable 12% $100,000 Issued on 12/16/2008 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Apr-16 | ||
Interest Rate | 12.00% | ||
Original Principal | 100,000 | ||
Principal at Period End | 100,000 | ||
Allocated Discount | 27,515 | ||
Amortized Discount | 27,515 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 100,000 | ||
Convertible Notes Payable 12% $100,000 Issued 09/30/2009 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Notes Payable 12% $100,000 Issued 09/30/2009 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 100,000 | ||
Long Term Non Related | 100,000 | ||
Convertible Notes Payable 12% $100,000 Issued 09/30/2009 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | ||
Interest Rate | 12.00% | ||
Original Principal | 100,000 | ||
Principal at Period End | 100,000 | ||
Allocated Discount | 37,600 | ||
Amortized Discount | 37,600 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 100,000 | ||
Convertible Notes Payable 12% 1,300,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 1,100,000 | ||
Long Term Non Related | 1,100,000 | ||
Convertible Notes Payable 12% 1,300,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Notes Payable 12% 1,300,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | ||
Interest Rate | 12.00% | ||
Original Principal | 1,300,000 | ||
Principal at Period End | 1,100,000 | ||
Allocated Discount | 488,800 | ||
Amortized Discount | 488,800 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 1,100,000 | ||
Convertible Notes Payable 12% $50,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Notes Payable 12% $50,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 50,000 | ||
Long Term Non Related | 50,000 | ||
Convertible Notes Payable 12% $50,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | ||
Interest Rate | 12.00% | ||
Original Principal | 50,000 | ||
Principal at Period End | 50,000 | ||
Allocated Discount | 31,400 | ||
Amortized Discount | 31,400 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 50,000 | ||
Convertible Notes Payable 12% $1,400,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | 0 | |
Short Term Non Related | 0 | 0 | |
Long Term Related | 1,440,000 | 1,100,000 | |
Long Term Non Related | 1,440,000 | 1,100,000 | |
Convertible Notes Payable 12% $1,400,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | 0 | |
Short Term Non Related | 0 | 0 | |
Long Term Related | 0 | 100,000 | |
Long Term Non Related | 0 | 100,000 | |
Convertible Notes Payable 12% $1,400,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | 1-Jan-16 | |
Interest Rate | 12.00% | 12.00% | |
Original Principal | 1,440,000 | 1,400,000 | |
Principal at Period End | 1,440,000 | 1,200,000 | |
Allocated Discount | 904,320 | 526,400 | |
Amortized Discount | 904,320 | 526,400 | |
Discount at Period End | 0 | 0 | |
Carrying Amount at Period End | 1,440,000 | 1,200,000 | |
Total [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | 0 | |
Short Term Non Related | 0 | 0 | |
Long Term Related | 8,815,000 | 9,125,000 | |
Long Term Non Related | 8,815,000 | 9,125,000 | |
Total [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 75,000 | 75,000 | |
Short Term Non Related | 75,000 | 75,000 | |
Long Term Related | 775,000 | 465,000 | |
Long Term Non Related | 775,000 | 465,000 | |
Total [Member] | |||
Debt Instrument [Line Items] | |||
Original Principal | 11,097,500 | 11,097,500 | |
Principal at Period End | 9,665,000 | 9,665,000 | |
Allocated Discount | 4,884,450 | 4,884,450 | |
Amortized Discount | 4,884,450 | 4,884,450 | |
Discount at Period End | 0 | 0 | |
Carrying Amount at Period End | 9,665,000 | 9,665,000 | |
Convertible Notes Payable 10% $862,500 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Notes Payable 10% $862,500 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 75,000 | ||
Short Term Non Related | 75,000 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Notes Payable 10% $862,500 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 30-Jun-04 | ||
Interest Rate | 10.00% | ||
Original Principal | 862,500 | ||
Principal at Period End | 75,000 | ||
Allocated Discount | 0 | ||
Amortized Discount | 0 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 75,000 | ||
Convertible Notes Payable 12% $100,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Notes Payable 12% $100,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 100,000 | ||
Long Term Non Related | 100,000 | ||
Convertible Notes Payable 12% $100,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-15 | ||
Interest Rate | 12.00% | ||
Original Principal | 100,000 | ||
Principal at Period End | 100,000 | ||
Allocated Discount | 27,515 | ||
Amortized Discount | 27,515 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 100,000 | ||
Convertible Notes Payable 12% $200,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 0 | ||
Long Term Non Related | 0 | ||
Convertible Notes Payable 12% $200,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 200,000 | ||
Long Term Non Related | 200,000 | ||
Convertible Notes Payable 12% $200,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | ||
Interest Rate | 12.00% | ||
Original Principal | 200,000 | ||
Principal at Period End | 200,000 | ||
Allocated Discount | 55,030 | ||
Amortized Discount | 55,030 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 200,000 | ||
Convertible Notes Payable 12% $4,615,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 4,505,000 | ||
Long Term Non Related | 4,505,000 | ||
Convertible Notes Payable 12% $4,615,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 15,000 | ||
Long Term Non Related | 15,000 | ||
Convertible Notes Payable 12% $4,615,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | ||
Interest Rate | 12.00% | ||
Original Principal | 4,615,000 | ||
Principal at Period End | 4,520,000 | ||
Allocated Discount | 1,243,681 | ||
Amortized Discount | 1,243,681 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | 4,520,000 | ||
Convertible Notes Payable 12% $1,490,000 [Member] | Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 1,440,000 | ||
Long Term Non Related | 1,440,000 | ||
Convertible Notes Payable 12% $1,490,000 [Member] | Non-Related Party [Member] | |||
Debt Instrument [Line Items] | |||
Short Term Related | 0 | ||
Short Term Non Related | 0 | ||
Long Term Related | 50,000 | ||
Long Term Non Related | 50,000 | ||
Convertible Notes Payable 12% $1,490,000 [Member] | |||
Debt Instrument [Line Items] | |||
Maturity Date | 1-Jan-16 | ||
Interest Rate | 12.00% | ||
Original Principal | 1,490,000 | ||
Principal at Period End | 1,490,000 | ||
Allocated Discount | 935,720 | ||
Amortized Discount | 935,720 | ||
Discount at Period End | 0 | ||
Carrying Amount at Period End | $1,490,000 |
Note_10_Convertible_Notes_Paya4
Note 10 - Convertible Notes Payable (Details) - Convertible Debt Maturity Payments (Convertible Debt [Member], USD $) | Dec. 31, 2014 |
Convertible Debt [Member] | |
Note 10 - Convertible Notes Payable (Details) - Convertible Debt Maturity Payments [Line Items] | |
2015 | $75,000 |
2016 | 9,590,000 |
Total | $9,665,000 |
Note_11_Fair_Value_Measurement2
Note 11 - Fair Value Measurement (Details) | 12 Months Ended |
Dec. 31, 2014 | |
Minimum [Member] | |
Note 11 - Fair Value Measurement (Details) [Line Items] | |
Finite-Lived Intangible Asset, Useful Life | 3 years |
Maximum [Member] | |
Note 11 - Fair Value Measurement (Details) [Line Items] | |
Finite-Lived Intangible Asset, Useful Life | 15 years |
Note_11_Fair_Value_Measurement3
Note 11 - Fair Value Measurement (Details) - Fair Value of Liabilities Measured on a Recurring Basis (USD $) | Dec. 31, 2014 | Dec. 31, 2013 | ||
Derivatives: (1) (2) | ||||
Derivative liability fair value | $9,639,462 | [1],[2] | $9,070,183 | [1] |
Conversion Feature Liability [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 0 | [1],[2] | 0 | [1] |
Conversion Feature Liability [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 0 | [1],[2] | 0 | [1] |
Conversion Feature Liability [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 2,944,402 | [1],[2] | 3,126,206 | [1] |
Conversion Feature Liability [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 2,944,402 | [1],[2] | 3,126,206 | [1] |
Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 0 | [1],[2] | 0 | [1] |
Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 0 | [1],[2] | 0 | [1] |
Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 6,695,060 | [1],[2] | 5,943,977 | [1] |
Warrant Liability [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 6,695,060 | [1],[2] | 5,943,977 | [1] |
Fair Value, Inputs, Level 1 [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 0 | [1],[2] | 0 | [1] |
Fair Value, Inputs, Level 2 [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | 0 | [1],[2] | 0 | [1] |
Fair Value, Inputs, Level 3 [Member] | ||||
Derivatives: (1) (2) | ||||
Derivative liability fair value | $9,639,462 | [1],[2] | $9,070,183 | [1] |
[1] | The fair value at the measurement date is equal to their carrying value on the balance sheet | |||
[2] | The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2014 |
Note_11_Fair_Value_Measurement4
Note 11 - Fair Value Measurement (Details) - Fair Value Assumptions | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Risk free interest rate | 0.13% | |
Dividend yield | 0.00% | 0.00% |
Conversion Feature Liability [Member] | Minimum [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Conversion feature liability | 1 year | 1 year |
Conversion Feature Liability [Member] | Maximum [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Conversion feature liability | 1 year 3 months | 2 years |
Warrant Liability [Member] | Minimum [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Conversion feature liability | 1 year | 1 year |
Warrant Liability [Member] | Maximum [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Conversion feature liability | 2 years 3 months | 2 years 3 months |
Minimum [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Risk free interest rate | 0.12% | |
Expected volatility | 119.80% | 166.70% |
Maximum [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Risk free interest rate | 0.13% | |
Expected volatility | 155.70% | 217.10% |
Note_11_Fair_Value_Measurement5
Note 11 - Fair Value Measurement (Details) - Fair Value of Assets Aquired on Non-recurring Basis (Fair Value, Measurements, Nonrecurring [Member], USD $) | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |||
Acquired assets (3) | ||||||
Promasys B.V. customer lists (4) | $110,948 | [1],[2] | $134,739 | [1],[2] | $0 | [1],[2] |
Promasys B.V. software code (4) | 55,842 | [1],[2] | 70,512 | [1],[2] | 0 | [1],[2] |
Promasys B.V. URLs/website (4) | 37,131 | [1],[2] | 64,991 | [1],[2] | 0 | [1],[2] |
Total | 203,921 | [1] | 270,242 | [1] | 0 | [1] |
Fair Value, Inputs, Level 1 [Member] | ||||||
Acquired assets (3) | ||||||
Promasys B.V. customer lists (4) | 0 | [1],[2] | 0 | [1],[2] | ||
Promasys B.V. software code (4) | 0 | [1],[2] | 0 | [1],[2] | ||
Promasys B.V. URLs/website (4) | 0 | [1],[2] | 0 | [1],[2] | ||
Total | 0 | [1] | 0 | [1] | ||
Fair Value, Inputs, Level 2 [Member] | ||||||
Acquired assets (3) | ||||||
Promasys B.V. customer lists (4) | 0 | [1],[2] | 0 | [1],[2] | ||
Promasys B.V. software code (4) | 0 | [1],[2] | 0 | [1],[2] | ||
Promasys B.V. URLs/website (4) | 0 | [1],[2] | 0 | [1],[2] | ||
Total | 0 | [1] | 0 | [1] | ||
Fair Value, Inputs, Level 3 [Member] | ||||||
Acquired assets (3) | ||||||
Promasys B.V. customer lists (4) | 136,253 | [1],[2] | 136,253 | [1],[2] | ||
Promasys B.V. software code (4) | 72,943 | [1],[2] | 72,943 | [1],[2] | ||
Promasys B.V. URLs/website (4) | 68,814 | [1],[2] | 68,814 | [1],[2] | ||
Total | $278,010 | [1] | $278,010 | [1] | ||
[1] | The fair value of the acquired assets was estimated using the Income Approach with a discounted cash flow valuation methodology applied. | |||||
[2] | The acquired Promasys B.V. software code, customer list and URLs/website are not measured on a recurring basis since their initial fair value has been deemed tohave a finite life and is being amortized periodically. Instead the Company performs an impairment analysis on a quarterly basis in order to determine whether thecarrying value of the assets reflects the fair value of the assets in a market based transaction. |
Note_11_Fair_Value_Measurement6
Note 11 - Fair Value Measurement (Details) - Fair Value of Goodwill (USD $) | Dec. 31, 2014 | Dec. 31, 2013 | Nov. 11, 2013 |
Goodwill [Line Items] | |||
Goodwill | $596,620 | $675,710 | |
Fair Value, Inputs, Level 3 [Member] | Promasys B.V. [Member] | |||
Goodwill [Line Items] | |||
Goodwill | 596,620 | 675,710 | |
Promasys B.V. [Member] | |||
Goodwill [Line Items] | |||
Goodwill | $671,689 |
Note_11_Fair_Value_Measurement7
Note 11 - Fair Value Measurement (Details) - Unrealized Gain or Loss Included in Earnings (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Unrealized Gain or Loss Included in Earnings [Abstract] | ||
The net amount of gains/(losses) for the period included in earnings attributable to the unrealized gain/(loss) from changes in derivative liabilities at the reporting date | $58,807 | ($95,121) |
Total unrealized gains/(losses) included in earnings | $58,807 | ($95,121) |
Note_11_Fair_Value_Measurement8
Note 11 - Fair Value Measurement (Details) - Change in Level 3 Financial Liabilities Fair Value (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Derivatives: | ||
Balance, beginning of year | ($9,070,183) | ($8,574,921) |
Net realized gains/(losses) | 0 | 0 |
Net Unrealized (gains)/losses relating to instruments still held at the reporting date | 58,807 | -95,121 |
Net purchases, issuances and settlements | -628,086 | -400,141 |
Net transfers in and/or out of Level 3 | 0 | 0 |
Balance, end of period | -9,639,462 | -9,070,183 |
Conversion Feature Liability [Member] | ||
Derivatives: | ||
Balance, beginning of year | -3,126,206 | -2,287,323 |
Net realized gains/(losses) | 0 | 0 |
Net Unrealized (gains)/losses relating to instruments still held at the reporting date | 181,804 | -838,883 |
Net purchases, issuances and settlements | 0 | 0 |
Net transfers in and/or out of Level 3 | 0 | 0 |
Balance, end of period | -2,944,402 | -3,126,206 |
Warrant Liability [Member] | ||
Derivatives: | ||
Balance, beginning of year | -5,943,977 | -6,287,598 |
Net realized gains/(losses) | 0 | 0 |
Net Unrealized (gains)/losses relating to instruments still held at the reporting date | -122,997 | 743,762 |
Net purchases, issuances and settlements | -628,086 | -400,141 |
Net transfers in and/or out of Level 3 | 0 | 0 |
Balance, end of period | ($6,695,060) | ($5,943,977) |
Note_12_Commitments_and_Contin2
Note 12 - Commitments and Contingencies (Details) (USD $) | 1 Months Ended | 12 Months Ended | 66 Months Ended | |
Jun. 30, 2009 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2014 | |
Note 12 - Commitments and Contingencies (Details) [Line Items] | ||||
Operating Leases, Rent Expense | $889,880 | $894,121 | ||
Patent Royalty Percentage Obligation | 2.00% | |||
License Payments | 300,000 | 200,000 | ||
Other Expenses | 156,701 | 189,408 | ||
Fee As Percentage of Aggregate Consideration | 2.00% | |||
Chief Executive Officer [Member] | ||||
Note 12 - Commitments and Contingencies (Details) [Line Items] | ||||
Salaries, Wages and Officers' Compensation | 196,000 | |||
Chief Technology Officer [Member] | ||||
Note 12 - Commitments and Contingencies (Details) [Line Items] | ||||
Officers' Compensation | 310,500 | |||
Chief Operating Officer [Member] | ||||
Note 12 - Commitments and Contingencies (Details) [Line Items] | ||||
Officers' Compensation | $310,500 |
Note_12_Commitments_and_Contin3
Note 12 - Commitments and Contingencies (Details) - Future Minimum Lease Payments (USD $) | Dec. 31, 2014 |
Future Minimum Lease Payments [Abstract] | |
2015 | $654,134 |
2016 | 367,327 |
2017 | 50,266 |
2018 | 5,165 |
Total | $1,076,892 |
Note_12_Commitments_and_Contin4
Note 12 - Commitments and Contingencies (Details) - Minimum Royalty Payments Per Year (USD $) | Dec. 31, 2014 |
Minimum Royalty Payments Per Year [Abstract] | |
2015 | $450,000 |
2016 | 450,000 |
2017 | 450,000 |
Total | $1,350,000 |
Note_13_Related_Party_Transact1
Note 13 - Related Party Transactions (Details) (USD $) | 12 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | ||||||||||||||||||||||||||
Dec. 31, 2014 | Dec. 31, 2013 | Aug. 29, 2008 | Dec. 16, 2008 | Sep. 30, 2009 | Dec. 31, 2010 | Oct. 05, 2011 | Nov. 23, 2011 | Oct. 28, 2011 | 13-May-11 | Apr. 13, 2010 | Oct. 31, 2011 | Sep. 30, 2011 | Sep. 30, 2010 | Jun. 29, 2010 | Dec. 31, 2011 | Feb. 03, 2015 | Dec. 18, 2013 | Mar. 18, 2013 | Jan. 02, 2013 | Apr. 04, 2014 | Feb. 01, 2013 | Feb. 22, 2013 | Apr. 21, 2014 | Dec. 05, 2013 | Jan. 31, 2015 | Jan. 01, 2015 | Oct. 06, 2012 | Jun. 30, 2008 | Feb. 29, 2008 | Dec. 31, 2009 | Dec. 23, 2014 | Jan. 01, 2014 | Jan. 01, 2013 | Mar. 31, 2011 | Jul. 31, 2014 | |
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.00% | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 24,620,000 | |||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $4,000,000 | $2,000,000 | ||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 4,000,000 | |||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 2.25% | |||||||||||||||||||||||||||||||||||
Interest Expense, Related Party | 2,389,786 | 2,339,702 | ||||||||||||||||||||||||||||||||||
Chief Technology Officer [Member] | Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Notes Payable, Related Parties | 20,000 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||
Chief Technology Officer [Member] | Convertible Debentures [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 5,000 | |||||||||||||||||||||||||||||||||||
Director [Member] | Convertible Debentures [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | 12.00% | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 150,000 | 150,000 | 160,000 | |||||||||||||||||||||||||||||||||
Chief Operating Officer [Member] | Convertible Debentures [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 25,000 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Convertible Debenture Inititated in June 2008 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,770,000 | 1,770,000 | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Convertible Debenture Initiated in February 2008 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 4,475,000 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Aggregated Convertible Debt July - September 30, 2009 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,100,000 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Aggregated Convertible Debt October -December 31, 2009 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,440,000 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 3,800,000 | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Purchased From Chief Financial Officer [Member] | Convertible Debenture Initiated in February 2008 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 125,000 | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 250,000 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Convertible Debenture Inititated in June 2008 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,260,000 | 1,770,000 | 1,770,000 | 510,000 | ||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 510,000 | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 3,540,000 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.50 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Convertible Debenture Initiated in February 2008 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Notes Payable, Related Parties | 150,000 | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 4,350,000 | 4,475,000 | 4,200,000 | |||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 4,350,000 | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 8,700,000 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.50 | |||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Rate | 12.00% | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Aggregated Convertible Debt July - September 30, 2009 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,100,000 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 4,400,000 | |||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | 4,400,000 | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Aggregated Convertible Debt October -December 31, 2009 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,440,000 | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 5,760,000 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Issued December 31, 2010 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 1,197,500 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Issued December 31, 2010 2 [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 409,379 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Chief Operating Officer [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase (Decrease), Net | -6,879 | |||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Notes Payable, Related Parties | 1,600,000 | 280,000 | 980,000 | 529,000 | 2,866,879 | |||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | 12.00% | 12.00% | 12.00% | |||||||||||||||||||||||||||||||
Due to Related Parties | 15,034,000 | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 6,400,000 | 3,920,000 | 2,116,000 | 11,467,517 | ||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | $0.25 | $0.25 | $0.25 | ||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 130,000 | 60,000 | 123,000 | 96,000 | 450,000 | 82,000 | 342,000 | 695,000 | 115,000 | 767,000 | ||||||||||||||||||||||||||
Subsequent Event [Member] | The Northern Trust Company [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 5,000,000 | |||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate During Period | 2.00% | |||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 5,000,000 | |||||||||||||||||||||||||||||||||||
Convertible Debentures [Member] | Former Director [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 160,000 | |||||||||||||||||||||||||||||||||||
Convertible Debentures [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | 12.00% | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 2,270,000 | 5,075,000 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 4,540,000 | 10,150,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $0.50 | $0.50 | ||||||||||||||||||||||||||||||||||
Convertible Debentures 10% [Member] | Former Director [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 150,000 | |||||||||||||||||||||||||||||||||||
The Northern Trust Company [Member] | ||||||||||||||||||||||||||||||||||||
Note 13 - Related Party Transactions (Details) [Line Items] | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 4,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||
Long-term Line of Credit | $4,000,000 | |||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 2.25% |
Note_14_Stockholders_Deficit_D
Note 14 - Stockholders' (Deficit) (Details) (USD $) | 6 Months Ended | 12 Months Ended | 1 Months Ended | |||||||
Jun. 30, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 1999 | Oct. 31, 2014 | Nov. 30, 2013 | Dec. 31, 2012 | Feb. 07, 2002 | Aug. 31, 2001 | Nov. 11, 2013 | |
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Common Stock, Shares Authorized | 250,000,000 | 250,000,000 | ||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $0.00 | $0.00 | ||||||||
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 | ||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $0.00 | $0.00 | ||||||||
Preferred Stock, Dividend Rate, Percentage | 5.00% | |||||||||
Common Stock, Shares, Issued | 91,561,802 | 90,104,659 | ||||||||
Class of Warrant or Right, Outstanding | 48,463,517 | 44,728,873 | 43,412,873 | |||||||
Convertible Debt (in Dollars) | $9,665,000 | |||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 24,620,000 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 11,000 | 150,000 | 100,000 | |||||||
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars) | 4,668,680 | 4,462,419 | ||||||||
Conversion of Stock, Shares Converted | 337,150 | |||||||||
Series A Preferred Stock [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 | 5,000,000 | |||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $0.00 | $0.00 | ||||||||
Preferred Stock, Dividend Rate, Percentage | 5.00% | |||||||||
Preferred Stock, Shares Issued | 4,125,224 | 4,125,224 | ||||||||
Preferred Stock, Shares Outstanding | 4,125,224 | 4,125,224 | ||||||||
Convertible Preferred Stock, Conversion Price (in Dollars per share) | $1.50 | |||||||||
Convertible Preferred Stock Conversion Term | 1 year | |||||||||
Convertible Preferred Stock Stock Price Trigger (in Dollars per share) | $3 | |||||||||
Convertible Preferred Stock Threshold Consecutive Trading Days | 20 days | |||||||||
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | $1 | |||||||||
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars) | 2,586,700 | 2,380,439 | ||||||||
Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears (in Dollars per share) | $0.63 | $0.58 | ||||||||
Conversion of Stock, Shares Converted | 235,000 | |||||||||
Series B Preferred Stock [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Preferred Stock, Shares Authorized | 230,000 | 230,000 | 230,000 | 200,000 | ||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $0.00 | $0.00 | ||||||||
Preferred Stock, Dividend Rate, Percentage | 8.00% | |||||||||
Preferred Stock, Shares Issued | 0 | 0 | ||||||||
Preferred Stock, Shares Outstanding | 0 | 0 | ||||||||
Convertible Preferred Stock Stock Price Trigger (in Dollars per share) | $0.50 | |||||||||
Convertible Preferred Stock Threshold Consecutive Trading Days | 20 days | |||||||||
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | $10 | |||||||||
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars) | 609,887 | 609,887 | ||||||||
Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears (in Dollars per share) | $3.05 | $3.05 | ||||||||
Conversion of Stock, Shares Converted | 200,000 | |||||||||
Share Price (in Dollars per share) | $10 | |||||||||
Convertible Preferred Stock Public Offering Proceeds Threshold (in Dollars) | 25,000,000 | |||||||||
Series C Preferred Stock [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Preferred Stock, Shares Authorized | 747,500 | 747,500 | ||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $0.00 | $0.00 | ||||||||
Preferred Stock, Dividend Rate, Percentage | 8.00% | |||||||||
Preferred Stock, Shares Issued | 0 | 0 | ||||||||
Preferred Stock, Shares Outstanding | 0 | 0 | ||||||||
Convertible Preferred Stock Threshold Consecutive Trading Days | 20 years | |||||||||
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | $10 | |||||||||
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars) | 1,472,093 | 1,472,093 | ||||||||
Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears (in Dollars per share) | $4.37 | $4.37 | ||||||||
Share Price (in Dollars per share) | $0.25 | |||||||||
Convertible Preferred Stock Public Offering Proceeds Threshold (in Dollars) | 25,000,000 | |||||||||
Preferred Stock, Redemption Price Per Share (in Dollars per share) | $10 | |||||||||
Convertible Preferred Stock Offering Price Threshold Ratio | 2.5 | |||||||||
Series D Preferred Stock [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Preferred Stock, Shares Authorized | 250,000 | 250,000 | ||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $0.00 | $0.00 | ||||||||
Preferred Stock, Shares Issued | 250,000 | 250,000 | ||||||||
Preferred Stock, Shares Outstanding | 250,000 | 250,000 | ||||||||
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | $0.00 | |||||||||
Preferred Stock, Voting Rights | 400 | |||||||||
Convertible Series B Preferred Stock [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Share Price (in Dollars per share) | $0.75 | |||||||||
Common Stock [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 57,143 | 11,000 | ||||||||
Stock Issued During Period, Shares, Acquisitions | 2,270,000 | |||||||||
Share Price (in Dollars per share) | $0.25 | |||||||||
Restricted Stock [Member] | Senior Management And Board Of Directors [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 1,225,000 | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 3 years | 3 years | ||||||||
Allocated Share-based Compensation Expense (in Dollars) | 33,055 | |||||||||
Restricted Stock [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Allocated Share-based Compensation Expense (in Dollars) | $74,167 | $53,125 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 57,143 | |||||||||
Promasys B.V. [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Common Stock, Shares, Issued | 2,270,000 | |||||||||
Stock Issued During Period, Shares, Acquisitions | 2,270,000 | |||||||||
Senior Management And Board Of Directors [Member] | ||||||||||
Note 14 - Stockholders' (Deficit) (Details) [Line Items] | ||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 1,400,000 |
Note_14_Stockholders_Deficit_D1
Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends [Line Items] | ||
Preferred Stock, Dividend, Cumulative Arrearage | $4,668,680 | $4,462,419 |
Series A Preferred Stock [Member] | ||
Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends [Line Items] | ||
Preferred Stock, Dividend, Cumulative Arrearage | 2,586,700 | 2,380,439 |
Preferred Stock, Dividend, Cumulative Arrearage Per Share (in Dollars per share) | $0.63 | $0.58 |
Series B Preferred Stock [Member] | ||
Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends [Line Items] | ||
Preferred Stock, Dividend, Cumulative Arrearage | 609,887 | 609,887 |
Preferred Stock, Dividend, Cumulative Arrearage Per Share (in Dollars per share) | $3.05 | $3.05 |
Series C Preferred Stock [Member] | ||
Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends [Line Items] | ||
Preferred Stock, Dividend, Cumulative Arrearage | $1,472,093 | $1,472,093 |
Preferred Stock, Dividend, Cumulative Arrearage Per Share (in Dollars per share) | $4.37 | $4.37 |
Note_14_Stockholders_Deficit_D2
Note 14 - Stockholders' (Deficit) (Details) - Dividends Payable (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Series A Preferred Stock [Member] | ||
Dividends Payable [Line Items] | ||
Dividends accreted | $206,261 | $206,261 |
Divideds accreted per share | $0.05 | $0.05 |
Series B Preferred Stock [Member] | ||
Dividends Payable [Line Items] | ||
Dividends accreted | 0 | 0 |
Divideds accreted per share | $0 | $0 |
Series C Preferred Stock [Member] | ||
Dividends Payable [Line Items] | ||
Dividends accreted | $0 | $0 |
Divideds accreted per share | $0 | $0 |
Note_14_Stockholders_Deficit_D3
Note 14 - Stockholders' (Deficit) (Details) - Warrants (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Class of Warrant or Right [Line Items] | |||
Number of Warrants Outstanding (in Shares) | 48,463,517 | 44,728,873 | 43,412,873 |
Number of Warrants Exercisable (in Shares) | 48,463,517 | ||
Exercise Price Range $0.25 to $0.60 [Member] | Minimum [Member] | |||
Class of Warrant or Right [Line Items] | |||
Range of Exercise Price - Minimum | $0.25 | $0.25 | |
Exercise Price Range $0.25 to $0.60 [Member] | Maximum [Member] | |||
Class of Warrant or Right [Line Items] | |||
Range of Exercise Price - Minimum | $0.60 | $0.60 | |
Exercise Price Range $0.25 to $0.60 [Member] | |||
Class of Warrant or Right [Line Items] | |||
Number of Warrants Outstanding (in Shares) | 48,463,517 | 44,728,873 | |
Weighted Average Remaining Contractual Life | 1 year 62 days | 2 years 18 days | |
Weighted Average Exercise Price | $0.35 | $0.36 | |
Number of Warrants Exercisable (in Shares) | 48,463,517 | 44,728,873 | |
Weighted Average Exercise Price | $0.35 | $0.36 |
Note_14_Stockholders_Deficit_D4
Note 14 - Stockholders' (Deficit) (Details) - Warrants Activity (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Warrants Activity [Abstract] | |||
Balance at December 31, | 48,463,517 | 44,728,873 | 43,412,873 |
Warrants exercisable at December 31, 2014 | 48,463,517 | ||
Weighted average fair value of warrants granted (in Dollars) | $0.15 | $0.19 | |
Issued (in Dollars) | $3,920,000 | $2,116,000 | |
Exercised | 0 | 0 | |
Expired/forfeited | -185,356 | -800,000 |
Note_14_Stockholders_Deficit_D5
Note 14 - Stockholders' (Deficit) (Details) - Accumulated Other Comprehensive Gain (Loss) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Accumulated Other Comprehensive Gain (Loss) [Abstract] | ||
Foreign Currency Translation | ($87,604) | ($69,092) |
Accumulated other comprehensive income (loss) | -87,604 | -69,092 |
Foreign Currency Translation | -156,223 | -18,512 |
Accumulated other comprehensive income (loss) | -156,223 | -18,512 |
Foreign Currency Translation | -243,827 | -87,604 |
Accumulated other comprehensive income (loss) | ($243,827) | ($87,604) |
Note_15_Employee_Equity_Incent2
Note 15 - Employee Equity Incentive Plans (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Note 15 - Employee Equity Incentive Plans (Details) [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 3,130,000 | 5,745,000 | 10,452,500 |
Proceeds from Stock Options Exercised (in Dollars) | $0 | $0 | |
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense (in Dollars) | 0 | 0 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $0.16 | $0.17 | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | $29,825 | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 25 days | ||
Restricted Stock [Member] | |||
Note 15 - Employee Equity Incentive Plans (Details) [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number | 2,625,000 | ||
Maximum [Member] | Equity Incentive Plan 2009 [Member] | |||
Note 15 - Employee Equity Incentive Plans (Details) [Line Items] | |||
Stock Option Grant Term | 10 years | ||
Equity Incentive Plan 2009 [Member] | |||
Note 15 - Employee Equity Incentive Plans (Details) [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 7,500,000 | ||
Stock Option Expiration Term | 5 years | ||
Vesting Percentage Year 1 | 50.00% | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 2,680,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 2,195,000 | ||
Stock Incentive Plan 1998 [Member] | |||
Note 15 - Employee Equity Incentive Plans (Details) [Line Items] | |||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 12,500,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 450,000 |
Note_15_Employee_Equity_Incent3
Note 15 - Employee Equity Incentive Plans (Details) - Stock Option Activity (USD $) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | |
Stock Option Activity [Abstract] | ||||
Number of shares | 3,130,000 | 5,745,000 | 10,452,500 | |
Weighted average exercise price (per share) | $0.20 | $0.29 | $0.36 | |
Weighted average remaining contractual term (in years) | 1 year 215 days | 1 year 255 days | 1 year 248 days | |
Aggregate intrinsic value | $364,900 | $93,945 | $149,598 | |
Vested and exercisable at December 31, 2014 | 2,855,000 | |||
Vested and exercisable at December 31, 2014 | $0.21 | |||
Vested and exercisable at December 31, 2014 | 1 year 127 days | |||
Vested and exercisable at December 31, 2014 | $332,850 | |||
Number of shares | 150,000 | 350,000 | ||
Weighted average exercise price (per share) | $0.16 | $0.17 | ||
Number of shares | -11,000 | -150,000 | -100,000 | |
Weighted average exercise price (per share) | $0.13 | $0.18 | ||
Number of shares | -2,615,000 | -4,957,500 | ||
Weighted average exercise price (per share) | $0.40 | $0.42 |
Note_15_Employee_Equity_Incent4
Note 15 - Employee Equity Incentive Plans (Details) - Vested Shares (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Vested Shares [Abstract] | ||
Number of options vested | 695,834 | 768,833 |
Fair value of options vested | $84,450 | $81,391 |
Note_15_Employee_Equity_Incent5
Note 15 - Employee Equity Incentive Plans (Details) - Stock Options Oustanding (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Strike Price Range Lower Limit | $0.05 | |
Strike Price Range Upper Limit | $0.50 | |
Strike Price Range 0.00 to 0.20 [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Strike Price Range Lower Limit | $0 | $0 |
Strike Price Range Upper Limit | $0.20 | $0.20 |
Outstanding Stock Options (in Shares) | 2,080,000 | 3,251,000 |
Weighted Average Remaining Contractual Life | 1 year 357 days | 2 years 58 days |
Weighted Average Outstanding Strike Price | $0.13 | $0.15 |
Vested Stock Options (in Shares) | 1,855,000 | 2,530,166 |
Weighted Average Remianing Vested Life | 1 year 262 days | 1 year 313 days |
Weighted Average Vested Strike Price | $0.12 | $0.16 |
Strike Price Range 0.21 to 0.29 [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Strike Price Range Lower Limit | $0.21 | $0.21 |
Strike Price Range Upper Limit | $0.29 | $0.29 |
Outstanding Stock Options (in Shares) | 600,000 | 750,000 |
Weighted Average Remaining Contractual Life | 335 days | 1 year 233 days |
Weighted Average Outstanding Strike Price | $0.24 | $0.25 |
Vested Stock Options (in Shares) | 550,000 | 650,000 |
Weighted Average Remianing Vested Life | 251 days | 1 year 73 days |
Weighted Average Vested Strike Price | $0.25 | $0.25 |
Strike Price Range 0.30 to 0.49 [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Strike Price Range Lower Limit | $0.30 | $0.30 |
Strike Price Range Upper Limit | $0.49 | $0.49 |
Outstanding Stock Options (in Shares) | 0 | 110,000 |
Weighted Average Remaining Contractual Life | 0 years | 357 days |
Weighted Average Outstanding Strike Price | $0 | $0.38 |
Vested Stock Options (in Shares) | 0 | 110,000 |
Weighted Average Remianing Vested Life | 0 years | 357 days |
Weighted Average Vested Strike Price | $0 | $0.38 |
Strike Price Range 0.50 to 0.70 [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Strike Price Range Lower Limit | $0.50 | $0.50 |
Strike Price Range Upper Limit | $0.70 | $0.70 |
Outstanding Stock Options (in Shares) | 450,000 | 1,634,000 |
Weighted Average Remaining Contractual Life | 248 days | 317 days |
Weighted Average Outstanding Strike Price | $0.50 | $0.59 |
Vested Stock Options (in Shares) | 450,000 | 1,634,000 |
Weighted Average Remianing Vested Life | 248 days | 317 days |
Weighted Average Vested Strike Price | $0.50 | $0.59 |
Strike Price Range 0.00 to 0.70 [Member] | ||
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] | ||
Strike Price Range Lower Limit | $0 | $0 |
Strike Price Range Upper Limit | $0.70 | $0.70 |
Outstanding Stock Options (in Shares) | 3,130,000 | 5,745,000 |
Weighted Average Remaining Contractual Life | 1 year 215 days | 1 year 255 days |
Weighted Average Outstanding Strike Price | $0.20 | $0.29 |
Vested Stock Options (in Shares) | 2,855,000 | 4,924,166 |
Weighted Average Remianing Vested Life | 1 year 127 days | 1 year 153 days |
Weighted Average Vested Strike Price | $0.21 | $0.32 |
Note_15_Employee_Equity_Incent6
Note 15 - Employee Equity Incentive Plans (Details) - Fair Value Assumptions of Share-Based Payments | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Fair Value Assumptions of Share-Based Payments [Abstract] | ||
Risk-free interest rate | 0.93% | 0.58% |
Expected dividend yield | 0.00% | 0.00% |
Expected volatility | 199.00% | 202.70% |
Expected life of options (in years) | 5 years | 5 years |
Note_15_Employee_Equity_Incent7
Note 15 - Employee Equity Incentive Plans (Details) - Weighted Average Grant Date Fair Value Activity (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Weighted Average Grant Date Fair Value Activity [Abstract] | ||
Stock options granted during the year ended December 31, | $0.16 | $0.17 |
Stock options vested during the year ended December 31, | $0.12 | $0.11 |
Stock options forfeited during the year ended December 31, | $0.31 | $0.29 |
Note_15_Employee_Equity_Incent8
Note 15 - Employee Equity Incentive Plans (Details) - Status of Non-Vested Shares (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Status of Non-Vested Shares [Abstract] | ||
Nonvested shares at January 1, 2014 | 275,000 | 820,834 |
Nonvested shares at January 1, 2014 | $0.17 | $0.13 |
Nonvested shares at December 31, 2014 | 275,000 | 820,834 |
Nonvested shares at December 31, 2014 | $0.17 | $0.13 |
Note_16_Income_Taxes_Details
Note 16 - Income Taxes (Details) (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Income Tax Disclosure [Abstract] | |
Operating Loss Carryforwards | $54,497,491 |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $1,422,676 |
Note_16_Income_Taxes_Details_R
Note 16 - Income Taxes (Details) - Reconciliation of Income Tax Expense (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Reconciliation of Income Tax Expense [Abstract] | ||
Federal statutory rate applied to (loss) before income taxes | ($1,685,418) | ($1,154,195) |
Current tax expense/(benefit) | -19,537 | 94,122 |
Non deductible expenses | 198,295 | 296,783 |
Change in deferred assets | 64,449 | 71,274 |
Change in valuation allowance | 1,422,674 | 786,138 |
Income tax expense/(benefit) | ($19,537) | $94,122 |
Note_16_Income_Taxes_Details_T
Note 16 - Income Taxes (Details) - The Components of Income Tax Expense (Benefit) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Note 16 - Income Taxes (Details) - The Components of Income Tax Expense (Benefit) [Line Items] | ||
Current tax expense/(benefit): | ($19,537) | $94,122 |
Deferred tax expense/(benefit): | ||
Deferred tax expense (benefit) | -1,442,211 | -692,016 |
Valuation allowance | 1,422,674 | 786,138 |
Total tax expense/(benefit) | -19,537 | 94,122 |
Bad Debt Allowance [Member] | ||
Deferred tax expense/(benefit): | ||
Deferred tax expense (benefit) | -45,407 | 7,100 |
Operating Loss Carryforward [Member] | ||
Deferred tax expense/(benefit): | ||
Deferred tax expense (benefit) | -1,441,716 | -864,512 |
Amortization of Intangibles [Member] | ||
Deferred tax expense/(benefit): | ||
Deferred tax expense (benefit) | 5,482 | 0 |
Patent Litigation Settlement [Member] | ||
Deferred tax expense/(benefit): | ||
Deferred tax expense (benefit) | $58,967 | $71,274 |
Note_16_Income_Taxes_Details_D
Note 16 - Income Taxes (Details) - Deferred Taxes Assets and Liabilities (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Deferred Taxes Assets and Liabilities [Abstract] | ||
Amortization of intangibles | $278,216 | $283,698 |
Bad debt allowance | 69,022 | 23,615 |
Patent litigation liability accrual | 256,441 | 315,408 |
Operating loss carryforwards | 19,662,198 | 18,220,482 |
Gross deferred tax assets | 20,265,877 | 18,843,203 |
Valuation allowance | -20,265,877 | -18,843,203 |
Net deferred tax liability/(asset) | $0 | $0 |
Note_17_Subsequent_Events_Deta
Note 17 - Subsequent Events (Details) (USD $) | 6 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 3 Months Ended | ||||||||||||||||||||||||
Jun. 30, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Jan. 31, 2015 | Oct. 05, 2011 | Nov. 23, 2011 | Oct. 28, 2011 | 13-May-11 | Apr. 13, 2010 | Oct. 31, 2011 | Sep. 30, 2011 | Sep. 30, 2010 | Jun. 29, 2010 | Dec. 31, 2011 | Mar. 20, 2015 | Oct. 31, 2014 | Mar. 23, 2015 | Mar. 30, 2015 | Dec. 18, 2013 | Mar. 18, 2013 | Jan. 02, 2013 | Jan. 01, 2015 | Sep. 30, 2009 | Feb. 22, 2013 | Aug. 29, 2008 | Jun. 30, 2008 | Dec. 16, 2008 | Feb. 29, 2008 | Dec. 31, 2009 | Dec. 23, 2014 | Jan. 01, 2014 | Jan. 01, 2013 | Mar. 31, 2011 | Feb. 03, 2015 | Apr. 04, 2014 | |
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.00% | ||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $4,000,000 | $2,000,000 | |||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) | 11,000 | 150,000 | 100,000 | ||||||||||||||||||||||||||||||||
Proceeds from Lines of Credit | 500,000 | 3,500,000 | |||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Note Payable 25 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Notes Payable, Related Parties | 950,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Note Payable 22 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 280,000 | ||||||||||||||||||||||||||||||||||
Interest Payable | 670,000 | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Note Payable 23 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 2,860,000 | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Aggregated Convertible Debt July - September 30, 2009 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,100,000 | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Convertible Debenture Inititated in June 2008 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,770,000 | 1,770,000 | |||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Convertible Debenture Initiated in February 2008 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 4,475,000 | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | Aggregated Convertible Debt October -December 31, 2009 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,440,000 | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Subsequent Event [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 3,800,000 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Aggregated Convertible Debt July - September 30, 2009 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,100,000 | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Convertible Debenture Inititated in June 2008 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 3,540,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,770,000 | 1,770,000 | 1,260,000 | 510,000 | |||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Convertible Debenture Initiated in February 2008 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Notes Payable, Related Parties | 150,000 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 8,700,000 | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 4,350,000 | 4,475,000 | 4,200,000 | ||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | Aggregated Convertible Debt October -December 31, 2009 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 5,760,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 1,440,000 | ||||||||||||||||||||||||||||||||||
Chief Executive Officer [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Notes Payable, Related Parties | 1,600,000 | 280,000 | 980,000 | 529,000 | 2,866,879 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | 6,400,000 | 3,920,000 | 2,116,000 | 11,467,517 | |||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 130,000 | 60,000 | 123,000 | 96,000 | 450,000 | 82,000 | 342,000 | 695,000 | 115,000 | 767,000 | |||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | 12.00% | 12.00% | 12.00% | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | $0.25 | $0.25 | $0.25 | |||||||||||||||||||||||||||||||
Restricted Stock [Member] | Subsequent Event [Member] | Chief Technology Officer [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | 275,000 | ||||||||||||||||||||||||||||||||||
Restricted Stock [Member] | Subsequent Event [Member] | Chief Executive Officer [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | 175,000 | ||||||||||||||||||||||||||||||||||
Restricted Stock [Member] | Subsequent Event [Member] | Chief Operating Officer [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | 115,000 | ||||||||||||||||||||||||||||||||||
Restricted Stock [Member] | Subsequent Event [Member] | Chief Financial Officer [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | 100,000 | ||||||||||||||||||||||||||||||||||
Restricted Stock [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) | 57,143 | ||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Note Payable 23 [Member] | Chief Executive Officer [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 2,860,000 | ||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Note Payable 23 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Note Payable 24 [Member] | Chief Executive Officer [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 529,000 | ||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Note Payable 24 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 529,000 | ||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Note Payable 12 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $0.25 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 1,600,000 | ||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | The Northern Trust Company [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 5,000,000 | ||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Former Employee [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) | 7,500 | ||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | 5,000,000 | ||||||||||||||||||||||||||||||||||
Proceeds from Lines of Credit | 750,000 | ||||||||||||||||||||||||||||||||||
Note Payable 22 [Member] | Chief Executive Officer [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 280,000 | ||||||||||||||||||||||||||||||||||
Note Payable 22 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||||||||||||||||||||||||||||||||
Note Payable 12 [Member] | Chief Executive Officer [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $1,600,000 | ||||||||||||||||||||||||||||||||||
Note Payable 12 [Member] | |||||||||||||||||||||||||||||||||||
Note 17 - Subsequent Events (Details) [Line Items] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% |